 EXHIBIT 2.1      

  



  

Exhibit 2.1

  

 _ _

  

 _EXECUTION COPY_

  



  

  



  

    



  

AGREEMENT AND PLAN OF MERGER

  



  

by and among 
 

  



  

Scilex Holding Company,

  



  

Sigma Merger Sub, Inc.,

  



  

Semnur Pharmaceuticals, Inc.,

  



  

Fortis Advisors LLC, solely as the Equityholders' Representative

  



  

and, solely with respect to Section 1.8(a), Section 3.11 and Article X, 
  
 Sorrento Therapeutics, Inc.

  



  



  

  

  



  

Dated as of March 18, 2019

  



  



  



  

    

  



  



    



 



    



  

Table of Contents

  



  

  



       |

Page

    
---|--- 
     | 
   Article I DESCRIPTION OF TRANSACTION  | 2 
     |   | 
   Section 1.1  | Merger of Merger Sub into the Company  | 2 
   Section 1.2  | Effect of the Merger  | 2 
   Section 1.3  | Closing; Effective Time  | 2 
   Section 1.4  | Certificate of Incorporation and Bylaws; Directors and
Officers  | 2 
   Section 1.5  | Conversion of Shares  | 3 
   Section 1.6  | Unaccredited Investors  | 6 
   Section 1.7  | Closing of the Company's Transfer Books  | 6 
   Section 1.8  | Exchange of Certificates; Payment of Merger
Consideration  | 7 
   Section 1.9  | Calculation of Consideration  | 8 
   Section 1.10  | Escrow and Expense Fund  | 9 
   Section 1.11  | Appraisal Rights  | 11 
   Section 1.12  | Stock Options  | 12 
   Section 1.13  | Milestone Payments  | 13 
   Section 1.14  | Further Action  | 17 
   Section 1.15  | Definitions  | 17 
     |   | 
   Article II Representations and Warranties of the COMPANY  | 17 
     |   | 
   Section 2.1  | Organization and Good Standing  | 18 
   Section 2.2  | Capitalization  | 18 
   Section 2.3  | Subsidiaries  | 20 
   Section 2.4  | Authority, No Conflict; Required Filings and Consents  |
21 
   Section 2.5  | Company Financial Statements; Books and Records  | 22 
   Section 2.6  | No Undisclosed Liabilities; Indebtedness  | 23 
   Section 2.7  | No Company Material Adverse Effect; Absence of Certain
Changes or Events  | 23 
   Section 2.8  | Taxes  | 27 
   Section 2.9  | Real Property  | 30 
   Section 2.10  | Personal Property  | 30 
   Section 2.11  | Intellectual Property  | 31 
   Section 2.12  | Agreements  | 34 
   Section 2.13  | Litigation  | 37 
   Section 2.14  | Environmental Matters  | 38 
   Section 2.15  | Employee Matters  | 39 
   Section 2.16  | Employee Benefit Plans  | 41 
   Section 2.17  | Compliance With Laws; Governmental Authorizations  | 44 
   Section 2.18  | Insurance  | 45 
   Section 2.19  | Brokerage and Finders  | 45 
   Section 2.20  | Title to Tangible Assets  | 45 
   Section 2.21  | Bank Accounts  | 45 
   Section 2.22  | Related Party Transactions  | 46 
   Section 2.23  | Customers and Suppliers  | 46 
  



    

-i-

 



    



  

Table of Contents

  

(continued)

  



       |   | Page 
---|---|--- 
     |   | 
   Section 2.24  | Import/Export Control  | 46 
   Section 2.25  | Certain Payments  | 46 
   Section 2.26  | Personal Information and Privacy  | 47 
   Section 2.27  | Manufacturing  | 48 
   Section 2.28  | Regulatory Filings  | 48 
   Section 2.29  | Product Candidates  | 48 
   Section 2.30  | OFAC  | 49 
   Section 2.31  | Independent Investigations  | 50 
     |   | 
   Article III Representations and Warranties of PARENT PARTIES  | 50 
     |   | 
   Section 3.1  | Organization and Good Standing  | 50 
   Section 3.2  | Authority, No Conflict; Required Filings and Consents;
Compliance with Laws  | 51 
   Section 3.3  | [Intentionally omitted].  | 52 
   Section 3.4  | Capitalization  | 52 
   Section 3.5  | Cash Resources of Parent  | 53 
   Section 3.6  | Independent Investigations  | 53 
   Section 3.7  | Parent Shares  | 53 
   Section 3.8  | Litigation  | 54 
   Section 3.9  | Voting Agreement  | 54 
   Section 3.10  | Affiliate Transactions  | 54 
   Section 3.11  | Sorrento Representations  | 54 
     |   | 
   Article IV CERTAIN COVENANTS AND AGREEMENTS  | 55 
     |   | 
   Section 4.1  | Tax Matters  | 55 
   Section 4.2  | Legends  | 57 
   Section 4.3  | Stockholder Approvals; Notice to Stockholders  | 58 
   Section 4.4  | Director and Officer Indemnification  | 58 
   Section 4.5  | Spreadsheets  | 59 
     |   | 
   Article V COMPANY CLOSING DELIVERABLES  | 60 
     |   | 
   Section 5.1  | Ancillary Agreements and Deliveries  | 60 
     |   | 
   Article VI Parent Closing Deliverables  | 62 
     |   | 
   Section 6.1  | Ancillary Agreements and Deliveries  | 62 
     |   | 
   Article VII TERMINATION  | 63 
     |   | 
   Section 7.1  | Termination Events  | 63 
     |   | 
   Article VIII Indemnification  | 63 
     |   | 
   Section 8.1  | Indemnification Obligations of the Equityholders  | 63 
  



    

-ii-

 



    



  

Table of Contents

  

(continued)

  



       |   | Page 
---|---|--- 
     |   | 
   Section 8.2  | Limitations on Indemnification  | 64 
   Section 8.3  | Indemnification Procedure  | 67 
   Section 8.4  | Satisfaction of Losses  | 69 
   Section 8.5  | Survival and Claims Periods  | 69 
   Section 8.6  | Set-Off  | 70 
   Section 8.7  | Characterization of Indemnification Payments  | 71 
     |   | 
   Article IX EquityHOLDERS' REPRESENTATIVE  | 71 
     |   | 
   Section 9.1  | Equityholders' Representative  | 71 
     |   | 
   Article X Miscellaneous Provisions  | 75 
     |   | 
   Section 10.1  | Fees and Expenses  | 75 
   Section 10.2  | Waiver; Amendment  | 75 
   Section 10.3  | Entire Agreement  | 75 
   Section 10.4  | Execution of Agreement; Counterparts; Electronic
Signatures  | 75 
   Section 10.5  | Governing Law; Arbitration; Venue  | 76 
   Section 10.6  | WAIVER OF JURY TRIAL  | 77 
   Section 10.7  | Assignment and Successors  | 77 
   Section 10.8  | Parties in Interest  | 77 
   Section 10.9  | Notices  | 78 
   Section 10.10  | Construction; Usage  | 79 
   Section 10.11  | Enforcement of Agreement  | 81 
   Section 10.12  | Severability  | 81 
   Section 10.13  | Time of Essence  | 81 
   Section 10.14  | Privileged Communications  | 81 
  



    

-iii-

 



    



  

EXHIBITS

  



     Exhibit A  | -  | Definitions 
---|---|--- 
   Exhibit B   | -  | Stockholder Written Consent 
   Exhibit C  | -  | Charter Amendment 
   Exhibit D  | -  | Certificate of Merger 
   Exhibit E  | -  | Escrow Agreement 
   Exhibit F  | -  | Joinder Agreement 
   Exhibit G  | -  | Voting Agreement 
   Exhibit H  | -  | Exchange Agreement 
   Exhibit I  | -  | Contribution and Loan Agreement 
  



    

-iv-

 



    



  

AGREEMENT AND PLAN OF MERGER

  



  

This AGREEMENT AND PLAN OF MERGER is made and entered into as of March 18,
2019, by and among Scilex Holding Company, a Delaware corporation (" _Parent_
"), Sigma Merger Sub, Inc., a Delaware corporation and a wholly-owned
subsidiary of Parent (" _Merger Sub_ "), Semnur Pharmaceuticals, Inc., a
Delaware corporation (the " _Company_ "), Fortis Advisors LLC, a Delaware
limited liability company, solely in its capacity as representative of the
Equityholders (the " _Equityholders ' Representative_"), and, solely with
respect to Section 1.8(a), Section 3.11 and Article X (collectively, the "
_Specified Sections_ "), Sorrento Therapeutics, Inc., a Delaware corporation
(" _Sorrento_ ").

  



  

RECITALS

  



  

Whereas, Parent, Merger Sub and the Company intend to effect a merger of
Merger Sub with and into the Company (the " _Merger_ ") in accordance with
this Agreement and the General Corporation Law of the State of Delaware (the "
_DGCL_ ") and, to the extent applicable, the California Corporations Code
(the " _CCC_ "). Upon consummation of the Merger, Merger Sub will cease to
exist, and the Company will become a wholly-owned subsidiary of Parent;

  



  

Whereas, the respective boards of directors of Parent, Merger Sub and the
Company have approved, adopted and declared advisable this Agreement and the
Merger;

  



  

Whereas, the respective boards of directors of Merger Sub and the Company
have each determined that the Merger is advisable and in the best interests
of the holders of their respective capital stock, and such boards of directors
have approved the Merger, upon the terms and subject to the conditions set
forth in this Agreement;

  



  

Whereas, concurrently with the execution and delivery of this Agreement and
as a material inducement to the willingness of Parent and Merger Sub to enter
into this Agreement, certain Stockholders have each entered into a non-
competition agreement with Parent (each, a " _Non-Competition Agreement_ "),
in each case to be effective at or following the Closing in accordance with
their respective terms;

  



  

Whereas concurrently with the execution and delivery of this Agreement and as
a material inducement to the parties' willingness to enter into this
Agreement, (i) certain Stockholders have executed and delivered a joinder
agreement in substantially the form attached hereto as Exhibit F (the "
_Joinder Agreement_ "), an accredited investor questionnaire, in a form
reasonably satisfactory to Parent, certifying, among other things, as to such
Person's status as an "accredited investor" as defined in Rule 501(a) of
Regulation D promulgated under the Securities Act (the " _Investor
Questionnaire_ ") and a "bad actor" questionnaire relating to Rule 506(d) of
the Securities Act, in form reasonably satisfactory to Parent, executed
by each Stockholder that is an officer, director or promoter of Parent or a
beneficial owner of 20% or more of the Parent Shares (the " _Disqualification
Questionnaire_ ") and (ii) Scilex Pharmaceuticals, Inc., a Delaware
corporation (" _Scilex_ "), on the one hand, and each of Sorrento and the
other holders of shares of Scilex capital stock (collectively, the "
_Scilex Stockholders_ "), on the other hand, have executed and delivered a
contribution and loan agreement in substantially the form attached hereto as
Exhibit I (the " _Contribution and Loan Agreement_ "); and

  



    



 



    



  

Whereas, immediately following the execution and delivery of this Agreement
by the parties hereto, the Company will deliver the written consent, in the
form attached hereto as Exhibit B (each, a " _Stockholder Written Consent_ ")
from the Stockholders constituting the Required Company Stockholder Vote.

  



  

Now, Therefore, in consideration of the respective covenants, agreements and
representations and warranties set forth in this Agreement, the parties to
this Agreement, intending to be legally bound, agree as follows:

  



  

Article I 
 DESCRIPTION OF TRANSACTION

  



  

Section 1.1 _Merger of Merger Sub into the Company_. Upon the
terms and subject to the conditions set forth in this Agreement, at the
Effective Time, Merger Sub shall be merged with and into the Company, and the
separate existence of Merger Sub shall cease. The Company will continue as
the surviving corporation in the Merger (the " _Surviving Corporation_ ").

  



  

Section 1.2 _Effect of the Merger_. The Merger shall have the
effects set forth in this Agreement and in the applicable provisions of the
DGCL and, to the extent applicable, the CCC.

  



  

Section 1.3 _Closing; Effective Time_. The consummation of the
transactions contemplated by this Agreement (the " _Closing_ ") shall take
place at the offices of Paul Hastings LLP, 1117 S. California Avenue, Palo
Alto, California 94304, on the date of delivery of the Stockholder Written
Consent by the Company as contemplated by this Agreement. The date on which
the Closing actually takes place is referred to in this Agreement as the "
_Closing Date_ _._ " Contemporaneously with or as promptly as practicable
after the Closing, an amendment to the certificate of incorporation of the
Company in substantially the form attached hereto as Exhibit C (the "
_Charter Amendment_ ") duly executed by the Company shall be filed with the
Secretary of State of the State of Delaware and, immediately following
acceptance thereof, a certificate of merger in substantially the form
attached hereto as Exhibit D hereto (the " _Certificate of Merger_ ") duly
executed by the Company shall be filed with the Secretary of State of the
State of Delaware. The Merger shall become effective upon the date and time of
the filing of the Certificate of Merger with the Secretary of State of the
State of Delaware or such other date and time as Parent and the Company may
mutually agree and include in the Certificate of Merger (the " _Effective
Time_ ").

  



  

Section 1.4 _Certificate of Incorporation and Bylaws; Directors
and Officers_. Unless otherwise determined by Parent and the Company prior to
the Effective Time:

  



  

(a) The certificate of incorporation of the Surviving Corporation shall
be amended and restated as of the Effective Time to conform to the
certificate of incorporation of Merger Sub as in effect immediately prior to
the Effective Time (except that the name of the Surviving Corporation shall
be such name as Parent may designate).

  



    

 | -2-| 
---|---|--- 

 



    



  

(b) The bylaws of the Surviving Corporation shall be amended and
restated as of the Effective Time to conform to the bylaws of Merger Sub as
in effect immediately prior to the Effective Time (except that all references
to Merger Sub shall refer to the name of the Surviving Corporation designated
by Parent).

  



  

(c) From and after the Effective Time, until their successors are duly
elected or appointed and qualified in accordance with applicable Law, the
directors of the Surviving Corporation immediately after the Effective Time
shall be the individuals who are the directors of Merger Sub immediately
prior to the Effective Time, together with such additional individuals as
Parent may designate.

  



  

(d) From and after the Effective Time, until their successors are duly
elected or appointed and qualified in accordance with applicable Law, the
officers of the Surviving Corporation immediately after the Effective Time
shall be the individuals who are the officers of Merger Sub immediately prior
to the Effective Time, together with such additional individuals as Parent may
designate.

  



  

Section 1.5 _Conversion of Shares_. At the Effective Time, by
virtue of the Merger and without any further action on the part of Parent,
Merger Sub, the Company or any Stockholder:

  



  

(a) any Company Shares then held by the Company (or held in the
Company's treasury) shall be canceled and retired and shall cease to exist,
and no consideration shall be delivered in exchange therefor;

  



  

(b) any Company Shares then held by Parent, Merger Sub or any other
Subsidiary of Parent shall be canceled and retired and shall cease to exist,
and no consideration shall be delivered in exchange therefor;

  



  

(c) except as provided in clauses (a) and (b) above, subject to Section
1.8, Section 1.9, Section 1.10 and Section 8.6, as applicable, each Company
Preferred Share (excluding for these purposes Dissenting Shares and Restricted
Shares) issued and outstanding immediately prior to the Effective Time shall
be canceled and automatically converted into the right of the holder to
receive the following:

  



   | (i)| the Per Share Cash Preference;  
---|---|--- 
  



   | (ii)| the Per Share Stock Preference;  
---|---|--- 
  



   | (iii)| the Per Share Cash Participation;  
---|---|--- 
  



   | (iv)| the Per Share Stock Participation;  
---|---|--- 
  



   | (v)| the Contingent Per Share Participation Cash; and  
---|---|--- 
  



   | (vi)| the Contingent Per Share Cash.  
---|---|--- 
  



    

 | -3-| 
---|---|--- 

 



    



  

(d) except as provided in clauses (a) and (b) above, subject to Section
1.8, Section 1.9, Section 1.10 and Section 8.6, as applicable, each Company
Common Share (excluding for these purposes Dissenting Shares) issued and
outstanding immediately prior to the Effective Time shall be canceled and
automatically converted into the right of the holder to receive the following:

  



   | (i)| the Per Share Cash Participation;  
---|---|--- 
  



   | (ii)| the Per Share Stock Participation;  
---|---|--- 
  



   | (iii)| the Contingent Per Share Participation Cash;  
---|---|--- 
  



   | (iv)| the Contingent Per Common Share Cash; and  
---|---|--- 
  



   | (v)| the Contingent Per Share Cash.  
---|---|--- 
  



  

(e) each share of the common stock, par value $0.00001 per share, of
Merger Sub outstanding immediately prior to the Effective Time shall be
converted into one share of common stock of the Surviving Corporation, such
that immediately following the Effective Time, Parent shall become the sole
and exclusive owner of all of the issued and outstanding capital stock of the
Company as the Surviving Corporation; and

  



  

(f) each Restricted Share that is issued and outstanding immediately
prior to the Effective Time shall vest in full and all
restrictions, forfeiture conditions and repurchase rights with respect
thereto shall lapse, and each Restricted Share shall be converted into the
right to receive the consideration specified in Section 1.5(d) for Company
Common Shares.

  



  

For purposes of this Agreement:

  



  

" _Aggregate Adjustment Amount_ " means the amount by which (a) the Aggregate
Negative Adjustment Amount (expressed as an absolute value) exceeds (b) the
amount of Aggregate Closing Cash in excess of $1,500,000 (if any).

  



  

" _Aggregate Available Parent Shares_ " a number of Parent Shares equal to
the quotient obtained by _dividing_ (a) the Initial Stock Amount _by_ (b) the
Parent Stock Price.

  



  

" _Aggregate Closing Cash_ " means the sum of the cash, cash equivalents and
marketable securities of the Company as of the date of this Agreement.

  



  

" _Aggregate Negative Adjustment Amount_ " means the sum of (a) the Closing
Indebtedness _plus_ (b) the Closing Transaction Expenses, each expressed as
an absolute value.

  



  

" _Closing Aggregate Exercise Price_ " means the aggregate exercise price of
all Company Options that are outstanding as of immediately prior to the
Closing.

  



    

 | -4-| 
---|---|--- 

 



    



  

" _Closing Indebtedness_ " means the aggregate unpaid principal amount of,
and accrued and unpaid interest on, the outstanding Indebtedness for borrowed
money of the Company as of immediately prior to the Closing.

  



  

" _Closing Transaction Expenses_ " means the aggregate amount of the
Transaction Expenses that remain outstanding and unpaid as of immediately
prior to the Closing.

  



  

" _Contingent Per Common Share Cash_ " means an amount, with respect to each
Milestone Payment, General Escrow Property, Designated Escrow Property and
the Expense Fund, payable with respect to each Company Common Share pursuant
to Section 1.13(b)(ii).

  



  

" _Contingent Per Share Cash_ " means an amount, with respect to each
Milestone Payment, General Escrow Property, Designated Escrow Property and
the Expense Fund, payable with respect to each Company Share pursuant to
Section 1.13(b)(iii).

  



  

" _Contingent Per Share Participation Cash_ " means an amount, with respect
to each Milestone Payment, General Escrow Property, Designated Escrow
Property and the Expense Fund, payable with respect to each Company Share
pursuant to Section 1.13(b)(i).

  



  

" _Fully Diluted Capital Number_ " means the sum (without duplication) of (a)
the aggregate number of Company Preferred Shares that are issued and
outstanding immediately prior to the Effective Time, calculated on an as-
converted to Company Common Shares basis and after giving effect to the
exercise, exchange or conversion of any other securities or rights that are
convertible into, exercisable for or exchangeable for, Company Preferred
Shares that are issued and outstanding immediately prior to the
Effective Time, _plus_ (b) the Fully Diluted Common Number.

  



  

" _Fully Diluted Common Number_ " means the sum (without duplication) of (a)
the aggregate number of Company Common Shares that are issued and outstanding
immediately prior to the Effective Time, _plus_ (b) the aggregate number of
Company Common Shares that are issuable upon full exercise, exchange or
conversion of all Company Options and any other securities (other than
Company Preferred Shares) or rights (in each such case whether vested or
unvested) that are convertible into, exercisable for or exchangeable for,
Company Common Shares that are issued and outstanding immediately prior to the
Effective Time.

  



  

" _Initial Cash Amount_ " means an amount equal to the sum of (a) the Initial
Merger Consideration _minus_ (b) the Initial Stock Amount _minus_ (c) the
Aggregate Adjustment Amount (if any).

  



  

" _Initial Escrow Shares_ " means the number of Parent Shares (rounded down
to the nearest whole share) equal the product obtained by _multiplying_ (a)
the Aggregate Available Parent Shares _by_ (b) ten percent (10%).

  



  

" _Initial Merger Consideration_ " means an amount equal to the sum of (a)
$70,000,000 _plus_ (c) the Closing Aggregate Exercise Price.

  



  

" _Initial Stock Amount_ " means the product obtained by _multiplying_ (a)
the Initial Merger Consideration _by_ (b) quotient obtained by _dividing_ (i)
fifty-five (55) _by_ (ii) seventy (70).

  



    

 | -5-| 
---|---|--- 

 



    



  

" _Participation Cash Amount_ " means an amount equal the sum of (a) the
Initial Cash Amount _less_ (b) the Preference Cash Amount  _less_ (c) the
Expense Fund; _provided_ , _however_ , in no event shall such amount be less
than zero.

  



  

" _Participation Stock Amount_ " means a number of Parent Shares equal to the
sum of (a) the Aggregate Available Parent Shares _minus _ (b) the Preference
Stock Amount _minus_ (c) the Initial Escrow Shares.

  



  

" _Per Share Cash Participation_ " means the quotient obtained by _dividing_
(a) the Participation Cash Amount _by_ (b) the Fully Diluted Capital Number.

  



  

" _Per Share Cash Preference_ " means an amount equal to the product obtained
by _multiplying_ (a) $0.95455 _by_ (b) the quotient obtained by _dividing_
(i) the Initial Cash Amount _by_ (ii) the sum of (A) the Initial Cash Amount
plus (B) the Initial Stock Amount.

  



  

" _Per Share Stock Participation_ " means a number of Parent Shares equal to
the quotient obtained by _dividing_ (a) the Participation Stock Amount _by_
(b) the Fully Diluted Capital Number.

  



  

" _Per Share Stock Preference_ " means a number of Parent Shares equal to the
quotient obtained by _dividing_ (a) the sum of (i) $0.95455 _minus_ (ii) the
Per Share Cash Preference _by_ (b) the Parent Stock Price.

  



  

" _Preference Cash Amount_ " means the aggregate amount of cash payable
pursuant to Section 1.5(c)(i).

  



  

" _Preference Stock Amount_ " means the aggregate number of Parent Shares
issuable pursuant to Section 1.5(c)(ii).

  



  

Section 1.6 _Unaccredited Investors_. Notwithstanding any
provisions of this Agreement to the contrary, in the event Parent believes in
its reasonable discretion that an Equityholder is not an "accredited
investor" as defined in Rule 501(a) of Regulation D promulgated under the
Securities Act, Parent may determine in its discretion, to be exercised in
good faith, to pay (and in such case Sorrento shall pay or cause to be paid)
the portion of the Merger Consideration that would otherwise be due under this
Agreement to such Equityholder (or, in the case of contributions to or
distributions from the General Escrow Fund, be contributed on such
Equityholder's behalf or released to such Equityholder) in the form of cash
only, and not in the form of Parent Shares, with the amount of cash to be
paid in lieu of any such Parent Shares or deposited with the Escrow Agent
pursuant to Section 1.10 with respect thereto to be calculated based on the
Parent Stock Price.

  



  

Section 1.7 _Closing of the Company 's Transfer Books_. At the
Effective Time: (a) all Company Shares outstanding immediately prior to
the Effective Time shall automatically be canceled and retired and shall
cease to exist, and all holders of certificates representing Company Shares
that were outstanding immediately prior to the Effective Time shall cease to
have any rights as stockholders of the Company, and each certificate
representing any such Company Shares (each, a " _Company Share Certificate_
") shall thereafter represent the right to receive the consideration referred
to in Section 1.5; and (b) the stock transfer books of the Company shall be
closed with respect to all Company Shares outstanding immediately prior to the
Effective Time. No further transfer of any such Company Share shall be made
on such stock transfer books after the Effective Time. If, after the
Effective Time, a Company Share Certificate is presented to the Surviving
Corporation or Parent, such Company Share Certificate shall be canceled and
shall be exchanged as provided in Section 1.8.

  



    

 | -6-| 
---|---|--- 

 



    



  

Section 1.8 _Exchange of Certificates; Payment of Merger
Consideration_.

  



  

(a) Promptly following the Effective Time (but on the Closing Date or,
if confirmation of the filing of the Certificate of Merger has not
been obtained prior to 1PM Pacific Time on the Closing Date, then on the
first business day after the Closing Date), Sorrento shall (or shall cause
Parent to) deposit cash in an amount equal to the Initial Cash Amount with
Wilmington Trust N.A. (the " _Paying Agent_ "), as contemplated by that
certain paying agent agreement entered into by the Paying Agent with Parent
concurrently with the execution and delivery of this Agreement..

  



  

(b) Within five (5) Business Days following the Effective Time, Parent
will send or cause to be sent to the holders of Company Share
Certificates previously representing Company Shares through email (unless
requested by the Company in writing on behalf of each such holder prior to
the Closing): (i) a letter of transmittal in customary form reasonably agreed
to by Parent and the Company (" _Letters of Transmittal_ ") (other than those
holders that have already duly completed and delivered a Letter of
Transmittal to the Paying Agent), and (ii) instructions for use in effecting
the surrender of Company Share Certificates in exchange for the applicable
portion of the Merger Consideration.

  



  

(c) As soon as reasonably practicable following surrender of a Company
Share Certificate to Parent at Closing, or the Paying Agent thereafter, by a
Stockholder that does not perfect his, her or its appraisal rights in
accordance with Section 1.11 and is otherwise entitled to receive the
applicable portion of the Merger Consideration (a " _Non-Dissenting
Stockholder_ ") for exchange, together with a duly executed Letter of
Transmittal and such other documents as may be reasonably required by Parent,
all in accordance with the instructions therein, (i) Parent shall cause the
Paying Agent to deliver to such Non-Dissenting Stockholder, by check or wire
transfer of immediately available funds, such amount of cash that such Non-
Dissenting Stockholder is entitled to pursuant to Section 1.5 in respect of
the Company Common Shares or Company Preferred Shares, as
applicable, represented by such Company Share Certificate and (ii) Parent
shall issue or caused to be issued (which may be in book entry form) to such
Non-Dissenting Stockholder the Parent Shares such Non-Dissenting Stockholder
is then entitled to receive pursuant to Section 1.5 in respect of the Company
Common Shares or Company Preferred Shares, as applicable, represented by such
Company Share Certificate. Parent shall pay (or cause to be paid) the Merger
Consideration payable to the holders of Company Options pursuant to Section
1.12(a)(i) and Section 1.12(a)(ii), as soon as reasonably practicable when
such obligations become payable.

  



  

(d) Until surrendered in accordance with Section 1.8(c), after the
Effective Time, the Company Shares held by any Stockholder immediately prior
to the Effective Time shall, for all corporate purposes, evidence only the
ownership of the right to the consideration set forth in Section 1.5 such
Company Shares shall have been converted pursuant to the terms of this
Agreement.

  



    

 | -7-| 
---|---|--- 

 



    



  

(e) In the event any Company Share Certificate representing Company
Shares converted in connection with the Merger pursuant to Section 1.5 shall
have been lost, stolen, mutilated or destroyed, Parent may, in its discretion
or as required by the Paying Agent and as a condition precedent to the
payment of any Merger Consideration with respect to the Company Shares
previously represented by such Company Share Certificate, require the owner
of such lost, stolen, mutilated or destroyed Company Share Certificate to
provide an appropriate affidavit and to deliver a bond (in such amount, form
and with such surety as the Paying Agent customarily requires) as indemnity
against any claim that may be made against Parent, the Surviving Corporation
or any affiliated party with respect to such Company Share Certificate.

  



  

(f) No dividends or other distributions declared or made with respect
to Parent Shares with a record date after the Effective Time shall be paid to
the holder of any unsurrendered Company Share Certificate with respect to the
Company Shares represented thereby, until such holder surrenders such Company
Share Certificate, as applicable, in accordance with this Section 1.8 (at
which time such holder shall be entitled to receive all such dividends and
distributions).

  



  

(g) Parent, the Surviving Corporation, the Paying Agent and the Escrow
Agent shall be entitled to deduct and withhold from any amounts payable or
otherwise deliverable pursuant to this Agreement such amounts as may be
required to be deducted or withheld therefrom under the Code or under any
provision of state, local or foreign tax law. To the extent such amounts are
so deducted or withheld and paid to the appropriate Governmental Body, such
amounts shall be treated for all purposes under this Agreement as having been
paid to the Person to whom such amounts would otherwise have been paid.

  



  

(h) None of Parent, the Surviving Corporation or the Paying Agent shall
be liable to any holder or former holder of Company Shares for any Parent
Shares (or dividends or distributions with respect thereto), or for any cash
amounts, delivered to any public official pursuant to any applicable
abandoned property, escheat or similar law.

  



  

(i) As soon as commercially practicable after the Effective Time (but
on the Closing Date), on behalf of the Company, Parent shall pay an amount
equal to the Closing Indebtedness to such accounts and in the amounts
specified in the Closing Indebtedness Statement.

  



  

(j) As soon as commercially practicable after the Effective Time (but
no later than one (1) Business Day after the Closing Date), on behalf of the
Company, Parent shall pay an amount equal to the Closing Transaction Expenses
to such accounts and in the amounts specified in the Closing Transaction
Expenses Statement.

  



  

Section 1.9 _Calculation of Consideration_. For purposes of
calculating the aggregate amount of cash payable and Parent Shares issuable to
each Equityholder under this Agreement, including for purposes of calculating
their respective portions of distributions from amounts placed in escrow
under this Agreement and the Expense Fund (i) the consideration payable in
respect of Company Shares held by each such Non-Dissenting Stockholder shall
be calculated on a certificate-by-certificate basis, (ii) the consideration
payable in respect of Company Options shall be calculated on a grant-by-grant
basis, (iii) the amount of cash to be paid shall be rounded down to the
nearest whole cent on an Equityholder-by-Equityholder basis, and (iv) the
number of Parent Shares to be issued shall be rounded down to the nearest
whole number on an Equityholder-by-Equityholder basis. In lieu of any
fractional shares to which such Non-Dissenting Stockholder would otherwise be
entitled, after combining any fractional interests of such Non-Dissenting
Stockholder into as many whole shares as is possible, such Non-Dissenting
Stockholder shall be paid in cash an amount equal to the dollar amount
(rounded to the nearest whole cent) determined by multiplying the Parent
Stock Price by the fraction of a Parent Share that would otherwise be
deliverable to such Non-Dissenting Stockholder under this Section 1.9.

  



    

 | -8-| 
---|---|--- 

 



    



  

Section 1.10 _Escrow and Expense Fund_.

  



  

(a) As soon as reasonably practicable following the Effective Time,
Parent shall issue, or shall cause the issuance of (which may be in book
entry form) the Initial Escrow Shares in the name of Wilmington Trust N.A., as
escrow agent (the " _Escrow Agent_ ") to be held by the Escrow Agent as
collateral to secure the rights of the Indemnified Parties under Article VIII
(such escrow fund, the " _General Escrow Fund_ "). If any Milestone Payment
becomes due and payable (A) prior to the expiration of the First Escrow
Period, an amount equal to ten percent (10%) of such Milestone Payment or (B)
following the expiration of the First Escrow Period and prior to the date
that is twelve months following the Closing Date, an amount equal to five
percent (5%) of such Milestone Payment, shall not be paid to the
Equityholders and shall instead be deposited with the Escrow Agent in the
General Escrow Fund (such amounts, the " _Milestone General Escrow Property_
"), which amount shall be held by the Escrow Agent pursuant to the Escrow
Agreement (and such deposited amount shall constitute a portion of the
General Escrow Property). Parent shall deposit the Milestone General Escrow
Property with the Escrow Agent at the same time that Parent is required to
deliver the related Milestone Payment to the Paying Agent pursuant to Section
1.13. The Parent Shares deposited in the General Escrow Fund pursuant to this
Section 1.10(a), together with the Milestone General Escrow Property, is
referred to, collectively, as the " _General Escrow Property_."

  



  

(b) In accordance with Article IX, Parent shall withhold from the
Initial Cash Amount $100,000 (the " _Expense Fund_ ") and, within five (5)
Business Days following the Effective Time, Parent shall deposit the Expense
Fund with the Equityholders' Representative, _provided_ , that the
Equityholders' Representative has provided written instructions to Parent on
or prior to the Closing with respect to such deposit.

  



  

(c) If any Milestone Payment becomes due and payable prior to the
Designated Survival Date, an amount equal to ten percent (10%) of such
Milestone Payment (the " _Designated Escrow Property_ "), shall not be paid to
the Equityholders and shall instead be deposited with the Escrow Agent. The
Designated Escrow Property shall be held by the Escrow Agent in a
separate escrow account from the General Escrow Fund and shall be held as
collateral to secure the rights of the Indemnified Parties under Article VIII
with respect to the Designated Indemnification Matters (such escrow fund, the
" _Designated Escrow Fund_ "). Parent shall deposit the Designated Escrow
Property with the Escrow Agent at the same time that Parent is required to
deliver the related Milestone Payment to the Paying Agent.

  



    

 | -9-| 
---|---|--- 

 



    



  

(d) Subject to any reduction pursuant to Section 8.4, the General
Escrow Property and the Designated Escrow Property shall each be held
in segregated accounts by the Escrow Agent pursuant to the provisions of an
escrow agreement which each of Parent, the Escrow Agent and the
Equityholders' Representative shall enter into on or prior to the Closing Date
substantially in the form of Exhibit E hereto (the " _Escrow Agreement_ ").

  



  

(e) Fifty percent (50%) of the General Escrow Property (the " _First-
Half Escrow Property_ "), less the amount of the First-Half Escrow Property
distributed by the Escrow Agent to Parent, Sorrento or other Indemnified
Parties pursuant to the Escrow Agreement on or prior to the date that is six
(6) months after the Closing Date (the " _First Escrow Period_ "), shall be
released and paid to the Equityholders by the Escrow Agent in accordance with
the allocations provided in Section 1.13(b), on the fifth (5th) Business Day
following the end of the First Escrow Period (the " _First Escrow Release
Date_ ");  _provided_ , _however_ , that in the event any Indemnified Party
has made any claims for indemnification prior to the expiration of the First
Escrow Period in accordance with Section 8.3 that are unresolved or resolved
but yet to be satisfied (each, an " _Unresolved Claim_ " and each such claim
to the extent made with respect to a Designated Indemnification Matter, an "
_Unresolved Designated Claim_ "), to the extent funds are available in the
General Escrow Fund to satisfy such Unresolved Claim as of the end of the
First Escrow Period, then, in accordance with and subject to the terms and
conditions of the Escrow Agreement, the Escrow Agent will, pursuant to
written instructions delivered by Parent to the Escrow Agent, with a copy
delivered to the Equityholders' Representative, prior to the First Escrow
Release Date, continue to hold an amount of the remaining First-Half Escrow
Property that Parent reasonably expects to be necessary to satisfy such
Unresolved Claims.

  



  

(f) As promptly as reasonably practicable following the date that is
twelve (12) months after the Closing Date (such twelve (12) month period
after the Closing Date, the " _Final Escrow Period_ "), any General Escrow
Property not previously released by the Escrow Agent as of such date shall be
released and paid to the Equityholders by the Escrow Agent in accordance with
the allocations provided in Section 1.13(b) on the fifth (5th) Business Day
following the end of the Final Escrow Period (the " _Final Escrow Release
Date_ "); _provided_ , _however_ , that in the event any Indemnified
Party has made any Unresolved Claims as of the end of the Final Escrow
Period, then, in accordance with and subject to the terms and conditions of
the Escrow Agreement, the Escrow Agent will, pursuant to written instructions
delivered by Parent to the Escrow Agent, with a copy delivered to the
Equityholders' Representative, prior to the Final Escrow Release Date,
continue to hold an amount of General Escrow Property that Parent reasonably
expects to be necessary to satisfy such Unresolved Claims.

  



  

(g) As promptly as reasonably practicable following the date that is
twelve (12) months after the date on which Parent is required to deposit an
applicable portion of the Designated Escrow Property with the Escrow Agent
pursuant to this Section 1.10 (such twelve (12) month period after such date,
a " _Designated Escrow Period_ "), any such Designated Escrow Property not
previously released by the Escrow Agent as of such date shall be released and
paid to the Equityholders by the Escrow Agent in accordance with the
allocations provided in Section 1.13(b) on the fifth (5th) Business Day
following the end of the applicable Designated Escrow Period (a " _Designated
Escrow Release Date_ "); _provided_ , _however_ , that in the event any
Indemnified Party has made any Unresolved Designated Claim as of the end of
such Designated Escrow Period, then, in accordance with and subject to the
terms and conditions of the Escrow Agreement, the Escrow Agent will, pursuant
to written instructions delivered by Parent to the Escrow Agent, with a copy
delivered to the Equityholders' Representative, prior to the applicable
Designated Escrow Release Date, continue to hold an amount of Designated
Escrow Property that Parent reasonably expects to be necessary to satisfy
such Unresolved Designated Claims. For purposes of this Section 1.10, payments
and distributions made from the Designated Escrow Fund shall be deemed to be
made from the earliest available despot of the Designated Escrow
Property into the Designated Escrow Fund.

  



    

 | -10-| 
---|---|--- 

 



    



  

(h) In the event that this Agreement and the Merger are adopted and
approved by the Stockholders constituting the Required Company
Stockholder Vote, then all Equityholders shall, without any further act of
any Stockholder, be deemed to have consented to and approved (i) the use of
the General Escrow Property as collateral to secure the indemnification rights
of the Indemnified Parties under Article VIII and the use of the Designated
Escrow Property as collateral to secure the rights of the Indemnified Parties
under Article VIII with respect to the Designated Indemnification Matters, in
each case, in the manner set forth herein and in the Escrow Agreement and
(ii) the application of the Expense Fund for use by the Equityholders'
Representative in accordance with Section 9.1(h).

  



  

Section 1.11 _Appraisal Rights_.

  



  

(a) Notwithstanding any provisions of this Agreement to the contrary,
Company Shares held by a holder who has demanded and perfected such demand
for appraisal of such holder's Company Shares in accordance with Section 262
of the DGCL and/or, if applicable by virtue of Section 2115 of the CCC,
Chapter 1300 _et. seq._ of the CCC, and as of the Closing has neither
effectively withdrawn nor lost such holder's right to such appraisal (the "
_Dissenting Shares_ ") shall not be converted into the applicable portion of
the Merger Consideration, in accordance with Section 1.5, but shall be
entitled to only such rights as are granted by the DGCL or the CCC. Parent
shall be entitled to retain any Merger Consideration not paid on account of
such Dissenting Shares pending resolution of the claims of such holders, and
the holder of any Dissenting Shares shall not be entitled to any
portion thereof.

  



  

(b) Notwithstanding the provisions of Section 1.11(a), if any holder of
Company Shares who demands appraisal of such holder's shares under the DGCL
or the CCC, as applicable, shall effectively withdraw or lose (through the
failure to perfect or otherwise) such holder's right to appraisal, then, as
of the Closing or the occurrence of such event, whichever later occurs, such
holder's Company Shares shall automatically be converted into the right to
receive, promptly following the surrender of the certificate or
certificates representing such Company Shares, the applicable portion of the
Merger Consideration, as provided in Section 1.5.

  



  

(c) The Company shall give Parent: (i) prompt written notice of any
demands for appraisal of Company Shares received by the Company,
withdrawals of any demands, and any other instruments served pursuant to the
DGCL or the CCC, as applicable, and received by the Company; and (ii) the
opportunity and right to direct all negotiations, petitions and proceedings
with respect to any such demands for appraisal. The Company shall not, except
with the prior written consent of Parent (which may be given or withheld in
Parent's sole discretion), make any payment with respect to any demands for
appraisal of Company Shares or offer to settle any such demands, or agree to
do any of the foregoing, other than by operation of law or pursuant to a
final order of a court of competent jurisdiction.

  



    

 | -11-| 
---|---|--- 

 



    



  

Section 1.12 _Stock Options_.

  



  

(a) Subject to the terms of this Agreement, at the Effective Time, each
Company Option that is outstanding as of immediately prior to the
Effective Time, whether vested or unvested, and that has not been exercised
prior to the Effective Time shall be cancelled and the holder thereof shall
be entitled to receive in full satisfaction of the rights of such holder with
respect thereto:

  



  

(i) a number of Parent Shares equal to the product obtained by
_multiplying_ (i) the aggregate number of Company Common Shares subject to
such Company Option as of immediately prior to the Effective Time (the "
_Underlying Company Shares_ ")  _by_ (ii) the sum of (A) the Per Share Stock
Participation _less_ (B) the quotient obtained by _dividing_ (I) the exercise
price per Underlying Company Share (the " _Option Exercise Price_ ") by (II)
the Parent Stock Price;  _provided_ , _however_ , in no event shall such
number of Parent Shares be less than zero (0); _provided, further,_ that the
Option Exercise Price shall be reduced by application of this Section
1.12(a)(i) by the cash value of the Per Share Stock Participation (as
determined based on the Parent Stock Price), with any positive remainder of
the Option Exercise Price after such reduction being referred to herein as
the " _Remaining Exercise Price_ ";

  



  

(ii) an amount in cash equal to the product obtained by _multiplying_
(i) the Underlying Company Shares by (ii) the sum of (A) the Per Share Cash
Participation _less_ (B) the Remaining Exercise Price per Underlying Company
Share (if any) following the application of Section 1.12(a)(i); and

  



  

(iii) an amount of cash equal to the product obtained by _multiplying_
(i) the Underlying Company Shares _by_ (ii) the sum of (A) the Contingent Per
Share Participation Cash _plus_ (B) the Contingent Per Common Share Cash
_plus_ (C) the Contingent Per Share Cash, if and when payable (such amount,
an " _Option Contingent Payment_ "). The parties agree that any payment of
the Option Contingent Payment, if any, payable with respect to Company Options
will be treated and reported for all tax purposes as being subject to a
substantial risk of forfeiture within the meaning of Treasury
Regulation Section 1.409A-1(b)(4) until such amounts become due and payable
under the Agreement and shall be paid to the holders of Company Options
entitled to such payments within the short-term deferral period within the
meaning of Treasury Regulation Section 1.409A-1(b)(4).

  



  

(b) At or prior to the Effective Time, the Company's board of directors
shall adopt appropriate resolutions, and take all other actions necessary
(including, but not limited to, obtaining the written consent of each Company
Optionholder regarding the treatment of Company Options set forth in this
Section 1.12), to effectuate the provisions of this Section 1.12. As a
condition to the right of a holder of Company Options to receive the
consideration set forth in this Section 1.12, such holder shall have executed
and delivered to Parent (i) a consent in a form reasonably requested by
Parent, consenting to and acknowledging the treatment of the Company Options
as set forth in Section 1.12 (the " _Company Option Consent_ "), (ii) with
respect to any holder of Company Options holding greater than one-fourth of
one percent (0.25%) of the Fully Diluted Capital Number, a Joinder Agreement,
(iii) a copy of, or joinder agreement in a form reasonably satisfactory to
Sorrento to, the Exchange Agreement and (iv) an Investor Questionnaire.

  



    

 | -12-| 
---|---|--- 

 



    



  

Section 1.13 _Milestone Payments_.

  



  

(a) Following the occurrence (or deemed occurrence pursuant to the
definitions in Annex A) of any of the events set forth in Annex A under
"Milestone Event" (each a " _Milestone_ "), whether achieved by or on behalf
of Parent or any of its Affiliates or Sublicensees or any Milestone Obligor,
Parent shall, within thirty (30) Business Days following each such event,
deposit or cause to be deposited the amount of cash in U.S. dollars set forth
in Annex A under "Milestone Payment" opposite such Milestone (each, a "
_Milestone Payment_ ") to an account designated in writing by the Paying
Agent. The Equityholders Representative shall cause the Paying Agent to pay
such amount to the Equityholders in accordance with Section 1.5 and Section
1.12, in each case subject to any right of set-off pursuant to Section 8.6 and
less (i) any withholding on such amount by Parent pursuant to Section 1.8(g)
and (ii) the portion of such amount, if any, that would otherwise be paid
with respect to Dissenting Shares; _provided_ , _however_ , that the Milestone
Payments shall be subject to withholding for the escrow provisions set forth
in Section 1.10. Each of the Milestone Payments shall be payable one (1)
time only on the initial achievement of the applicable Milestone. The maximum
aggregate amount of Milestone Payments that may be payable by Parent is
$280,000,000. Once a Milestone Payment has been paid as directed by the
Equityholders' Representative pursuant to this Section 1.13(a), Parent shall
have no further obligations to any Person, including, without limitation, the
Equityholders, with respect to the portion of the Milestone Payment so paid,
other than to reasonably cooperate with the Equityholders' Representative to
process and pay, through its or its Affiliate's payroll system, any portion of
such Milestone Payment that constitutes an Option Contingent Payment payable
to Company Optionholders who are current or former employees and subject to
Tax withholding, and to perform its obligations pursuant to Section 8.6.

  



  

(b) Each Milestone Payment as well as each distribution to the
Equityholders from the General Escrow Fund and Designated Escrow Fund,
and from the Expense Fund, shall be allocated under Section 1.5 (after taking
into account any amounts previously made pursuant to Section 1.5(c)(i),
Section 1.5(c)(ii), Section 1.5(c)(iii), Section 1.5(c)(iv), Section 1.5(d)(i)
and Section 1.5(d)(ii)) among the Equityholders as follows:

  



  

(i) first, to the Equityholders allocated on a pro rata basis among the
Equityholders based their owned Company Securities as of immediately prior to
the Effective Time until each holder of Company Preferred Stock outstanding as
of immediately prior to the Effective Time has received pursuant to Section
1.5 (without allocating to the Equityholders any amounts deposited in the
General Escrow Fund or the Designated Escrow Fund or the Expense Fund) an
amount equal to $2.86 per share of Company Preferred Stock (the "
_Preferred Cap_ ");

  



    

 | -13-| 
---|---|--- 

 



    



  

(ii) second, once the Preferred Cap has been satisfied, to the holders
of Company Common Shares and Company Optionholders outstanding as
of immediately prior to the Effective Time allocated on a pro rata basis
among such holders based on their owned Company Common Shares and Company
Options as of immediately prior to the Effective Time until each holder of
Company Common Shares issued and outstanding as of immediately prior to the
Effective Time has received pursuant to Section 1.5 (without allocating to the
Equityholders any amounts deposited in the General Escrow Fund or the
Designated Escrow Fund or the Expense Fund) an amount equal to $2.86 per
Company Common Shares (the " _Common Catch-Up_ "); and

  



  

(iii) third, once the Common Catch-Up has been satisfied, to the
Equityholders allocated on a pro rata basis among the Equityholders based
on their owned Company Securities as of immediately prior to the Effective
Time.

  



  

For the avoidance of doubt, if any portion of a Milestone Payment is subject
to a setoff pursuant to Section 8.6, then the foregoing shall apply to the
portion of the Milestone Payment as they are paid to the Equityholders.

  



  

(c) Parent shall (i) on the first (1st) Business Day following the
Closing, make an amount of cash available to the Surviving Corporation equal
to $3,500,000 and (ii) following the Closing, use its Diligent Efforts to
assist the Surviving Corporation in obtaining funding necessary to enable the
Surviving Corporation to cause the Milestones to occur. " _Diligent Efforts_ "
shall mean the level of efforts required to carry out such obligation in a
sustained manner consistent with the efforts a similarly
situated biopharmaceutical company typically devotes to products of similar
market potential, project potential or strategic value, based on conditions
then prevailing.

  



  

(d) The right of the Equityholders to receive the Milestone Payments
(i) is solely a contractual right and will not be evidenced by a
certificate, does not constitute a security, or other instrument, (ii) may
not be sold, assigned, transferred, pledged, encumbered or in any other
manner transferred or disposed of, in whole or in part, except by will or
intestacy, by operation of law, (iii) does not represent any equity or
ownership interest in Parent or in any constituent company to the Merger or
any of their respective Affiliates, (iv) does not give the Equityholders any
right to receive interest payments and (v) shall (together with any Milestone
Payments actually made) be treated by the parties as consideration in respect
of Company Shares or Company Options, as applicable, for applicable income
tax purposes, except for any amount required by Law to be treated as interest.
Without limiting the obligations of Parent under this Section 1.13 (including
the obligations to pay the Milestone Payments when due), there is no guaranty
or other assurance of any kind that any Milestone Payments will become
payable hereunder (regardless of any projections, models forecasts or any
other financial data generated by, or provided to, the Company, the
Equityholders, Parent or their respective representatives).

  



  

(e) Commencing upon the Closing, Parent shall, and shall cause the
Surviving Corporation and their respective Affiliates and each Milestone
Obligor to use Diligent Efforts to cause each Milestone to be achieved.

  



    

 | -14-| 
---|---|--- 

 



    



  

(f) Following the Closing, for so long as a Milestone Payment may
become payable hereunder, Parent shall cause to be delivered a status
update to the Equityholders' Representative within thirty (30) days following
each anniversary of the Closing Date (each such report, an " _Update Report_
"). Parent shall cause each Update Report to include a reasonably detailed
outline of the status of efforts to cause the occurrence of each outstanding
Milestone during the period covered by such Update Report and, commencing
upon the first commercial sale of the first Company Product, the cumulative
Net Sales of each Company Product.

  



  

(i) All information contained in any Update Report, or conveyed to the
Equityholders' Representative in any meeting or other communication regarding
an Update Report, shall be subject to a confidentiality agreement to be
entered into by Parent and the Equityholders' Representative in customary
form as reasonably agreed to by Parent and the Equityholders' Representative.
The Equityholders' Representative shall not disclose any information included
in any such Update Report except as permitted in such
confidentiality agreement and except to Equityholders and any limited
partners of such Equityholders who have executed a confidentiality
agreement containing confidentiality provisions with respect to any
information provided with respect hereto that are no less protective than the
provisions contained in the confidentiality agreement referred to in the
preceding sentence, and the Equityholders' Representative shall cause Parent
to be named as third-party beneficiaries of such provisions with the right to
enforce such provisions.

  



  

(ii) Within thirty (30) days after delivery of an Update Report, if the
Equityholders' Representative in good faith requests a meeting with
representatives of Parent to discuss such report, Parent shall make reasonably
available during normal business hours for such a meeting at least one (1)
employee with operating responsibility for the activities (whether at Parent
or the Surviving Corporation) and related to the development, regulatory and
other activities for the Company Product(s). The Equityholders'
Representative may not request more than one (1) such meeting in respect of
any Update Report.

  



  

(g) Without limiting the foregoing, during the period commencing on the
first sale of a Company Product anywhere in the world and continuing until
the earlier of (i) receipt by the Equityholders of all Milestone Payments, and
(ii) the third anniversary of the cessation of all sales of all Company
Products, Parent and its Affiliates (each, an " _Audited Party_ ") shall,
once during any fiscal year, permit an accountant appointed by the
Equityholders' Representative, and reasonably acceptable to Parent, at
reasonable times during normal business hours and upon reasonable notice, to
examine such books and records as may be necessary for the purpose of
verifying the calculation of the Net Sales of Company Products during the
period covered by the applicable audit. The accountant shall disclose to the
Equityholders' Representative and to Parent, based on its inspection of the
applicable records, whether such Net Sales have been accurately calculated,
and if not, the amount and nature of any discrepancy discovered. The
accountant shall disclose no other information revealed in such audit, and
Parent may require such accountant to enter into a reasonable and customary
confidentiality agreement with respect to the records examined by such
accountant. The Equityholders' Representative (on behalf of the
Equityholders) shall pay for any such audit pursuant to Section 9.1(d).

  



    

 | -15-| 
---|---|--- 

 



    



  

(h) Prior to any Milestone Obligor obtaining any rights to develop,
seek Marketing Approval for and/or commercialize any, Company
Product (collectively, a " _Milestone Right_ "), Parent shall (and shall
cause the Surviving Corporation and their affiliates to) comply with this
Section 1.13(h).

  



  

(i) _Significant Pharmaceutical Companies_.

  



  

(1) Prior, and as a condition to, transferring any Milestone Rights to
a Milestone Obligor that is a Significant Pharmaceutical Company,
Parent shall (A) enter into a written agreement with such Milestone Obligor
expressly providing as follows (such agreement, an " _Assumption Agreement_
"): (w) that the Significant Pharmaceutical Company assumes and agrees to be
bound by and perform all of the obligations of Parent and the Surviving
Corporation under this Agreement that apply to, relate to or with respect to,
the Milestones and Milestone Payments set forth in Sections 1.5, Section
1.13, Article X and Annex A hereto (collectively, the "
_Milestone Provisions_ ") and provides that all references to Parent, Merger
Sub and Surviving Corporation set forth in the Milestone Provisions that
apply to, relate to or are with respect to the Milestones or Milestone
Payments shall be deemed to be references to such Significant Pharmaceutical
Company, (x) specifically provides that upon the execution of the Assumption
Agreement, the Significant Pharmaceutical Company will obtain all of the
right, title and interest of Parent, the Surviving Corporation,
each Milestone Obligor and their Affiliates to develop, seek Marketing
Approval for and/or commercialize the Company Products (collectively, the "
_Total Milestone Rights_ "), (y) provides that any Net Sales previously made
by Parent, a Sublicensee or other Milestone Obligor shall be included in the
Net Sales made by such Significant Pharmaceutical Company for purposes of
calculating the Milestones related to Net Sales, and (z) provides that the
Equityholders' Representative, on behalf of the Equityholders, will be an
express third party beneficiary of such Assumption Agreement and that the
Equityholders' Representative will be able to enforce, and seek claims
against the Significant Pharmaceutical Company with respect to the Milestones
and Milestone Payments to the same extent the Equityholders' Representative
could against Parent and the Surviving Corporation under this Agreement, and
(B) provide the Equityholders' Representative (on no less than ten (10)
Business Days' notice) the opportunity to review and countersign the
Assumption Agreement (it being understood that if the Equityholders'
Representative determines not to countersign the Assumption Agreement, it
will still have the rights required to be set forth in the Assumption
Agreement pursuant to the foregoing).

  



  

(2) If Parent complies with the terms of this Section 1.13(h) and the
Significant Pharmaceutical Company and Parent enter into an
Assumption Agreement (and the assignment and assumption contemplated thereby
is consummated) that complies with the terms in Section
1.13(h)(i)(1) (including that all of the Total Milestone Rights are assigned
and transferred to the Significant Pharmaceutical Company), then Parent and
the Surviving Corporation shall be fully and forever released with respect to,
and the Equityholders shall look solely to such Significant Pharmaceutical
Company for the performance of, the obligations of Parent to achieve the
Milestones and make the Milestone Payments pursuant to the Milestone
Provisions that were not payable at such time; _provided_ , _however_  that
(i) Parent shall reasonably cooperate with the Equityholders' Representative
to process and pay, through its or its Affiliate's payroll system, any
portion of the Milestone Payments that constitute an Option Contingent Payment
payable to the Company Optionholders who are current or former employees and
subject to Tax withholding; (ii) Parent shall continue to be responsible for
any Milestone Payments owed prior to such transfer; and (iii) Parent and the
Surviving Corporation shall not be so released if a Significant
Pharmaceutical Company fails to be bound by and obligated to perform all of
the Milestone Provisions (other than as a result of bankruptcy) due to the
invalidity or failure of such Assumption Agreement or the assignment and
assumption contemplated thereby (as determined at the time of the applicable
assignment and assumption).

  



    

 | -16-| 
---|---|--- 

 



    



  

(ii) _Other Milestone Obligors_. If Parent wishes to transfer any
Milestone Rights to a Milestone Obligor in a manner that does not comply with
all of the terms of Section 1.13(h)(i)(1), Parent shall remain responsible for
the performance of all obligations set forth in this Section 1.13, including
any obligation assigned to and assumed by such Milestone Obligor, unless
otherwise expressly agreed in writing by the Equityholders' Representative on
behalf of the Equityholders.

  



  

(i) For the avoidance of doubt, the only obligations of Parent, the
Surviving Corporation and their Affiliates, and the only rights of the
Equityholders' Representative for the benefit of Equityholders, and any other
Persons, in each case, with respect to the funding of the Surviving
Corporation and the efforts required to cause the Milestones to be achieved,
are as expressly provided solely in the Milestone Provisions and no other
provisions of this Agreement shall be applicable thereto unless referenced in
the Milestone Provisions.

  



  

Section 1.14 _Further Action_. If, at any time after the Effective
Time, any further action is determined by Parent to be necessary or
desirable to carry out the purposes of this Agreement and any agreement
entered into in connection herewith or to vest the Surviving Corporation or
Parent with full right, title and possession of and to all rights and property
of Merger Sub and the Company, the officers and directors of the Surviving
Corporation and Parent shall be fully authorized (in the name of Merger Sub,
in the name of the Company and otherwise) to take such lawful and necessary
action.

  



  

Section 1.15 _Definitions_. Capitalized terms used in this
Agreement but not otherwise defined in this Agreement shall have the meanings
set forth in Exhibit A hereto.

  



  

Article II 
 Representations and Warranties of the COMPANY

  



  

Except as set forth on the Disclosure Schedule, the Company represents and
warrants to each of Parent and Merger Sub and for the benefit of the
Indemnified Parties, as of the date of this Agreement and as of the Closing
Date, as set forth below (it being understood and hereby agreed that (i) the
information set forth in the Disclosure Schedule shall be disclosed under
separate section and subsection references that correspond to the sections
and subsections of this Article II to which such information relates, and (ii)
the information set forth in each section and subsection of the Disclosure
Schedule shall qualify (A) the representations and warranties set forth in
the corresponding section or subsection of this Article II, and (B) any other
representations and warranties set forth in this Article II to the extent
that it is reasonably apparent on the face of such disclosure that such
disclosure applies to such other representations and warranties).

  



    

 | -17-| 
---|---|--- 

 



    



  

Section 2.1 _Organization and Good Standing_.

  



  

(a) The Company is a corporation duly incorporated, validly existing
and in good standing under the laws of the State of Delaware, has all
requisite and necessary power and authority to own, lease, use and operate its
properties and assets, to carry on and conduct its business as now being
conducted, and is duly qualified or registered to do business and is in good
standing as a foreign corporation (or equivalent status in the relevant
jurisdiction) in each jurisdiction in which the character of the properties it
owns, operates or leases or the nature of its activities makes such
qualification necessary or advisable, except for those jurisdictions
where the failure to be so qualified would not reasonably be expected to
have, individually or in the aggregate, a Material Adverse Effect.

  



  

(b) The Company has not conducted any business under or otherwise used,
for any purpose or in any jurisdiction, any fictitious name, assumed name,
trade name or other name other than the name under which the Company is
currently incorporated.

  



  

(c) Section 2.1(c) of the Disclosure Schedule sets forth, as of the
date of this Agreement, (i) the names of the members of the board of
directors of the Company, (ii) the names of the members of each committee of
the board of directors of the Company, and (iii) the names and titles of the
officers of the Company.

  



  

(d) The Company has provided to Parent true, correct and complete
copies of: (i) the Organizational Documents of the Company, as in effect on
the date of this Agreement, and such copies reflect all amendments made
thereto at any time prior to the date of this Agreement, (ii) the stock
records of the Company, (iii) the minutes and other records of the meetings
and other proceedings (including any actions taken by written consent or
otherwise without a meeting) of the stockholders of the Company, the board of
directors of the Company and all committees of the board of directors of the
Company (clauses (i), (ii) and (iii), collectively, the "
_Company Constituent Documents_ "). The Company is not in default under or in
violation of any provision of its Organizational Documents. The books and
records of the Company are up to date, true, correct and complete in all
material respects. All the records of the Company have been maintained in
accordance with applicable Laws and prudent business practices and are in the
actual possession and direct control of the Company.

  



  

Section 2.2 _Capitalization_.

  



  

(a) The authorized capital stock of the Company consists of forty-two
million one hundred thousand (42,100,000) Company Common Shares, of which
nine million two hundred ten thousand three hundred ninety-nine (9,210,399)
shares have been issued and are outstanding as of the date of this Agreement
and thirty-one million five hundred seven thousand one hundred forty-four
(31,507,144) Company Preferred Shares, of which thirty-one million four
hundred twenty-eight thousand five hundred seventy-two (31,428,572) shares
are outstanding as of the date of this Agreement. All of the outstanding
Company Shares have been duly authorized and validly issued, and are fully
paid and non-assessable. All of the outstanding Company Shares have been
issued and granted in compliance with (i) all applicable securities laws and
other applicable Laws, and (ii) all requirements set forth in the
Organizational Documents of the Company and applicable Contracts. None of the
issued Company Shares were issued in violation of any preemptive rights or
other rights to subscribe for or purchase securities of the Company. Section
2.2(a) of the Disclosure Schedule accurately sets forth with respect to each
Company Share outstanding as of the date of this Agreement: (A) the name of
the holder of such Company Share; and (B) the date on which such Company
Share was issued.

  



    

 | -18-| 
---|---|--- 

 



    



  

(b) The Company has reserved three million seventy-six thousand one
hundred ninety (3,076,190) Company Common Shares for issuance under the
Company Stock Option Plan, of which options to purchase eight hundred sixty-
six thousand forty-eight (866,048) Company Common Shares are outstanding and
options to purchase one million eight hundred ten thousand three hundred
ninety-nine (1,810,399) Company Common Shares have been exercised, in each
case as of the date of this Agreement. Section 2.2(b) of the Disclosure
Schedule accurately sets forth, with respect to each Company Option
outstanding as of the date of this Agreement (whether vested or unvested): (i)
the name of the holder of such Company Option, (ii) the total number of
Company Common Shares that are subject to such Company Option and the number
of Company Common Shares with respect to which such Company Option is
immediately exercisable, (iii) the date on which such Company Option was
granted and the term of such Company Option, (iv) the vesting schedule for
such Company Option, (v) the exercise price per Company Common Share
purchasable under such Company Option, and (vi) whether (and to what extent)
the vesting of such Company Option will be accelerated in any way by the
transactions contemplated by this Agreement or by the termination of
employment or engagement or change in position of any holder thereof following
consummation of the transactions contemplated by this Agreement. The terms of
the Company Stock Option Plan permits the treatment of Company Options as
provided herein, without notice to, or the consent or approval of, the
holders of the Company Options, the Company Stockholders or otherwise.

  



  

(c) Except for Company Options granted pursuant to the Company Stock
Option Plan and set forth on Section 2.2(c) of the Disclosure Schedule, there
is no: (i) outstanding subscription, option, call, warrant or right (whether
or not currently exercisable) to acquire any capital stock or other
securities of the Company, (ii) outstanding security, instrument or obligation
that is or may become convertible into or exchangeable for any capital stock
or other securities of the Company, or (iii) Contract under which the Company
is or may become obligated to sell or otherwise issue any of its capital
stock or any other securities of the Company, or (iv) condition or
circumstance that may give rise to or provide a basis for the assertion of a
claim by any Person to the effect that such Person is entitled to acquire or
receive any capital stock or other securities of the Company from the Company
or, to the Company's Knowledge, any other Person (clauses (i) through (iv),
collectively, " _Company Rights_ "). The Company does not have any
outstanding stock appreciation rights, phantom stock, performance based stock,
restricted stock units or equity rights or similar stock or equity rights or
obligations. The Company has not issued any debt securities which grant the
holder thereof any right to vote on, or veto, any actions by the Company.

  



    

 | -19-| 
---|---|--- 

 



    



  

(d) Section 2.2(d) of the Disclosure Schedule sets forth all issued and
outstanding Company Shares that, as of the date of this Agreement, constitute
restricted shares or are otherwise subject to a repurchase or redemption right
or right of first refusal in favor of the Company (" _Restricted Shares_ "),
indicating the name of the applicable stockholder, the class of any such
shares, the lapsing schedule for any such shares, including the extent to
which any such repurchase or redemption right or right of first refusal has
lapsed as of the date of this Agreement, whether (and to what extent) the
lapsing will be accelerated in any way by the transactions contemplated by
this Agreement or by termination of employment or change in position following
consummation of the transactions contemplated by this Agreement, and whether
such holder has the sole power to vote and dispose of such shares.

  



  

(e) The Company is not a party to or bound by any, and to the Knowledge
of the Company, there are no, agreements or understandings with respect to
the voting (including pooling agreements, voting trusts and proxies) or sale
or transfer (including agreements imposing transfer restrictions) of any
capital stock or other equity interests of the Company.

  



  

(f) None of the outstanding capital stock of the Company is subject to
any purchase option, call option, right of first refusal, preemptive right,
right of participation, subscription right or any similar right (whether
pursuant to (i) the Company Constituent Documents, (ii) any Contract to which
the Company is a party or, to the Company's Knowledge, any Contract to which
the Company is not a party or (iii) any statute to which the Company is
subject) and the Company is not a party to any Contract that provides the
holders of capital stock of the Company with information rights, the right to
receive financial statements of the Company, or otherwise relates to the
voting or registration of, or the restricting of any Person from purchasing,
selling, pledging, transferring or otherwise disposing of (or granting any
option or similar right with respect to), any of the Company's capital
stock. The Company is not under any obligation, or bound by any Contract
pursuant to which it may become obligated (i) to repurchase, redeem or
otherwise acquire any outstanding capital stock of the Company, or (ii) make
any investment (in the form of a loan or capital contribution) in any other
Entity.

  



  

(g) The Company has never repurchased, redeemed or otherwise reacquired
any of its capital stock or other securities except repurchases of Company
Common Shares issued or held by employees, officers, directors or consultants
of the Company upon termination of their employment or services pursuant to
agreements providing for the right of said repurchase (" _Permitted
Repurchases_ ").

  



  

Section 2.3 _Subsidiaries_.

  



  

(a) The Company has no Subsidiaries and has never had any Subsidiaries.
The Company does not own, and has never owned, beneficially or otherwise, any
shares or other securities of, or any direct or indirect equity or other
financial interest in, any other Entity.

  



  

(b) The Company has not agreed and is not obligated to make any future
investment in or capital contribution to any Entity. The Company has not
guaranteed and is not responsible or liable for any obligation of any other
Entity.

  



    

 | -20-| 
---|---|--- 

 



    



  

Section 2.4 _Authority, No Conflict; Required Filings and
Consents_.

  



  

(a) (i) The Company has all requisite corporate power and authority to
enter into this Agreement and any Stockholder Related Agreement to which it
is a party, perform its obligations under this Agreement and any Stockholder
Related Agreement to which it is a party and to consummate the Merger and the
other transactions contemplated by this Agreement and any Stockholder Related
Agreement to which it is a party, subject to the approval and adoption of the
Merger and this Agreement by the Required Company Stockholder Vote; (ii) the
affirmative vote of (A) the holders of at least a majority of the Company
Common Shares and (B) the holders of more than sixty percent (60%) of the
Company Preferred Shares (the " _Required Company Stockholder Vote_ ") is the
only vote of the holders of the Company Shares necessary to approve or adopt
the Merger or this Agreement or consummate the Merger; and (iii) the
execution, delivery and performance of this Agreement and any Stockholder
Related Agreement to which it is a party and the consummation of the Merger
and the other transactions contemplated by this Agreement and any Stockholder
Related Agreement to which it is a party by the Company have been duly
authorized by all necessary corporate action on the part of the Company, and
no other corporate action or proceeding on the part of the Company or its
board of directors is necessary to authorize the execution, delivery or
performance of this Agreement, any Stockholder Related Agreement to which it
is a party or the consummation of the Merger or any of the other transactions
contemplated by this Agreement or any such Stockholder Related Agreement;
_provided_ ,  _however_ that the Merger is subject to the approval and
adoption of the Merger and this Agreement by the Required Company Stockholder
Vote. This Agreement has been duly executed and delivered by the Company and
constitutes the legal, valid and binding obligation of the Company,
enforceable against the Company in accordance with its terms, except as such
enforceability may be limited by (i) bankruptcy, insolvency, reorganization,
moratorium or other similar laws affecting or relating to creditors'
rights generally, and (ii) the availability of injunctive relief and other
equitable remedies.

  



  

(b) Assuming (i) the receipt of approval and adoption of this Agreement
by the Required Company Stockholder Vote and (ii) the receipt or making of
the consents, waivers, approvals, orders, authorizations, registrations,
declarations and filings specified in Section 2.4(c) of the Disclosure
Schedule, neither the execution, delivery or performance by the Company of
this Agreement or any of the Stockholder Related Agreements, nor the
consummation of the Merger or any of the other transactions contemplated by
this Agreement or any of the Stockholder Related Agreements, will directly or
indirectly (with or without notice or lapse of time, or both): (A)
contravene, conflict with, or result in any violation or breach of, any
Company Organizational Document, (B) contravene, conflict with, or result in
any violation or breach of, or constitute (with or without notice or lapse of
time, or both) a default (or give rise to a right of modification,
termination, cancellation or acceleration of any obligation or loss of any
material benefit) under, require notice to any Person or a consent or waiver,
constitute a change in control under, require the payment of a fee or
penalty under or result in the creation or imposition of any Lien upon or
with respect to any asset owned or used by the Company under, any of the
terms, conditions or provisions of any Material Contracts, (C) contravene,
conflict with or violate, or give any Person the right to challenge any of
the transactions contemplated by this Agreement or any of the Stockholder
Related Agreements or to exercise any remedy or obtain any relief under, any
Law or any order, writ, injunction, judgment or decree to which the
Company or any of its assets is subject, or (D) contravene, conflict with or
result in a violation of any of the terms or requirements of, or give any
Governmental Body the right to revoke, withdraw, suspend, cancel, terminate or
modify, any Governmental Authorization that is held by the Company or that
otherwise relates to the business of the Company or to any of the assets
owned, used or controlled by the Company other than, in the case of clauses
(B), (C) and (D), above, for such contraventions, conflicts, violations or
rights that would not be material to the Company.

  



    

 | -21-| 
---|---|--- 

 



    



  

(c) No Governmental Authorization, or registration, declaration, notice
or filing with, any Governmental Body is required by or with respect to the
Company: (i) in connection with the execution and delivery of this Agreement
or any of the Stockholder Related Agreements by the Company or the
consummation by the Company of the Merger and the other transactions
contemplated by this Agreement or any of the Stockholder Related Agreements,
or (ii) necessary for the Company to operate its business immediately after
the Closing in the same manner as operated immediately prior to the Closing
after giving effect to the consummation of the Merger and the
other transactions contemplated by this Agreement and the Stockholder Related
Agreements, except in each case for (A) the filing of the Charter Amendment
and the Certificate of Merger with the Secretary of State of the State of
Delaware, and (B) any filings required by applicable securities Laws.

  



  

(d) The Company is not now, nor has it ever been, required to file any
periodic or other reports, or any registration statement, with any applicable
securities regulatory authority, including the United States Securities and
Exchange Commission (the " _SEC_ "), pursuant to any securities legislation,
regulations or rules or policies promulgated thereunder, including the
Securities Act and the rules and regulations promulgated thereunder, or the
Securities Exchange Act of 1934 (the " _Exchange Act_ "), as amended, and the
rules and regulations promulgated thereunder.

  



  

Section 2.5 _Company Financial Statements; Books and Records_.

  



  

(a) The Company has made available to Parent the following financial
statements and notes thereto (collectively, the " _Company Financial
Statements_ "):

  



  

(i) The audited consolidated balance sheets of the Company as of
December 31, 2017 and December 31, 2016, and the related audited consolidated
statements of operations, convertible preferred stock and stockholders'
deficit and cash flows for the periods then ended; and

  



  

(ii) the unaudited consolidated balance sheet of the Company as of
December 31, 2018 (the " _Interim Balance Sheet_ ") and the related unaudited
consolidated statements of profit and loss and cash flows for the twelve
months then ended.

  



  

(b) Each Company Financial Statement: (i) is true, correct and complete
in all material respects and has been prepared in conformity with GAAP
consistently applied throughout the periods covered thereby (except as may be
indicated in the notes to such Company Financial Statement); (ii) fairly
presents the financial position of the Company as of such dates and the
results of operations, changes in stockholders' equity and cash flow, as
applicable, of the Company for the periods then ended, subject in the case of
unaudited financial statements to (y) normal recurring year-end audit
adjustments, none of which would individually or in the aggregate be
material, and (z) the absence of footnote disclosures, none of which would,
alone or in the aggregate, would have a Company Material Adverse Effect; and
(iii) contains and reflects adequate reserves, in accordance with GAAP, for
all reasonably anticipated losses, costs and expenses. No financial statement
of any Person (other than the Company) is required by GAAP to be included in
the Company Financial Statements.

  



    

 | -22-| 
---|---|--- 

 



    



  

(c) The Company Financial Statements were prepared from, and are
consistent with, the books, records and accounts of the Company, which books,
records and accounts have been maintained in accordance with all applicable
Laws and accounting requirements. The Company maintains accurate books and
records reflecting its assets and liabilities and maintains proper and
adequate internal accounting controls which provide assurance (A) that
transactions are executed in accordance with management's authorization (B)
that transactions are recorded as necessary to permit preparation of the
financial statements in conformity with GAAP and to maintain accountability
for the Company's assets and (C) regarding prevention or timely detection of
unauthorized acquisition, use or disposition of the assets of the Company.

  



  

Section 2.6 _No Undisclosed Liabilities; Indebtedness_.

  



  

(a) As of the date of this Agreement, the Company has no obligations or
liabilities (whether or not absolute, accrued, contingent,
determined, determinable, unliquidated or otherwise, whether known or
unknown, whether due or to become due or whether or not required to
be reflected in financial statements prepared in accordance with GAAP, except
for: (i) liabilities that are reflected or provided for in the Company
Financial Statements, (ii) liabilities incurred in the ordinary course of
business consistent with past practice since the date of the Interim Balance
Sheet, (iii) Transaction Expenses, (iv) those expressly permitted or required
to be incurred under the terms of this Agreement or (v) liabilities or
obligations that would not, individually or in the aggregate, reasonably be
expected to be material to the Company.

  



  

(b) Section 2.6(b) of the Disclosure Schedule sets forth a true,
correct and complete list of all loan or credit agreements, notes,
bonds, mortgages, indentures and other agreements and instruments pursuant to
which any Indebtedness is outstanding and the respective principal amounts
outstanding thereunder as of the date of this Agreement. All of the
outstanding Indebtedness may be prepaid by the Company at any time without
the consent or approval of, or prior notice to, any other Person, and without
payment of any premium or penalty.

  



  

Section 2.7 _No Company Material Adverse Effect; Absence of
Certain Changes or Events_. Since December 31, 2017 through the date of this
Agreement, the Company has conducted its business only in the ordinary course
of business consistent with past practice, except in connection with the
authorization, preparation, negotiation or execution of this Agreement, and,
since such date:

  



  

(a) there has not been any event, occurrence, development or state of
circumstances or facts that has had a Company Material Adverse Effect,

  



  

(b) the Company has not taken any of the following actions and none of
the following events have occurred:

  



    

 | -23-| 
---|---|--- 

 



    



  

(i) (A) declare, accrue, set aside or pay any dividends on, or make any
other distributions (whether in cash, stock, shares or property) in respect
of, any of its capital stock or other equity or voting interests (except
Permitted Repurchases), (B) authorize for issuance or issue and deliver any
additional shares of its capital stock or securities convertible into or
exchangeable for shares of its capital stock, or grant any right, option or
other commitment for the issuance of shares of its capital stock or of such
securities (except that the Company shall be permitted to issue Company
Common Shares upon the valid exercise of Company Options outstanding as of
the date of this Agreement or upon conversion of Company Preferred Shares),
(C) split, combine or reclassify any of its shares of capital stock or other
equity or voting interests, or issue or authorize the issuance of any other
securities in respect of, in lieu of or in substitution for shares of its
capital stock or other equity or voting interests, (D) purchase, redeem or
otherwise acquire any of its capital stock, any other securities of the
Company or any Company Option (except Permitted Repurchases) or (E) take any
action that would result in any change of any term (including any conversion
price thereof) of any debt security of the Company;

  



  

(ii) amend or waive any of its rights under, or accelerate the vesting
under, any provision of the Company Stock Option Plan, any provision of any
Contract related to any Company Option or Restricted Shares as in effect as of
the date of this Agreement, or otherwise modify any of the terms of any
Company Option as in effect as of the date of this Agreement;

  



  

(iii) amend or permit the adoption of any amendment to the
Organizational Documents of the Company other than the Charter Amendment, or
effect, become a party to or authorize any Acquisition Transaction,
recapitalization, reclassification of shares, stock split, reverse stock
split or similar transaction;

  



  

(iv) except as required by applicable Laws, recognize any labor union
or adopt or enter into any collective bargaining agreement or other
labor union Contract applicable to the employees;

  



  

(v) adopt a plan of complete or partial liquidation or dissolution or
resolutions providing for or authorizing such a liquidation or a dissolution;

  



  

(vi) form any Subsidiary or acquire any equity interest or other
interest in any other Entity;

  



  

(vii) make any capital expenditure outside the ordinary course of
business or make any capital expenditures in excess of $25,000
individually or $50,000 in the aggregate;

  



  

(viii) other than in the ordinary course of business consistent with
past practice, enter into or become bound by, or permit any of the
assets owned or used by it to become bound by, any Material Contract or any
Contract, lease, agreement or instrument that would be required to be set
forth on Section 2.12(a) of the Disclosure Schedule if it were entered into on
or prior to the date of this Agreement, or amend or terminate, or waive or
exercise any material right or remedy under, any Material Contract or any
Contract, lease, agreement or instrument that would be required to be set
forth on Section 2.12(a) of the Disclosure Schedule if it were entered into on
or prior to the date of this Agreement;

  



    

 | -24-| 
---|---|--- 

 



    



  

(ix) acquire, lease or license any right or other asset from any other
Person or sell or otherwise dispose of, or lease, license or encumber, any
right or other asset to any other Person (except in each case for assets
acquired, leased, non-exclusively licensed, encumbered or disposed of by the
Company in the ordinary course of business consistent with past practice and
not having a value, or not requiring payments to be made or received, in
excess of $25,000 individually, or $50,000 in the aggregate), or waive or
relinquish any claim or right;

  



  

(x) incur any Indebtedness in excess of $25,000, or guarantee any
Indebtedness of another Person, guarantee any debt securities of
another Person, enter into any "keep well" or other agreement to maintain any
financial statement condition of another Person or enter into any arrangement
having the economic effect of any of the foregoing, other than trade credit
receivables incurred in the ordinary course of business;

  



  

(xi) grant, create, incur or suffer to exist any Lien, other than
Permitted Liens, on the assets of the Company that did not exist on the
date of this Agreement or write down the value of any asset or investment on
the books or records of the Company, except for depreciation and amortization
in the ordinary course of business consistent with the Company's past
practice;

  



  

(xii) make any loans, advances or capital contributions to, or
investments in, any other Person;

  



  

(xiii) increase in any manner the compensation or benefits of, or pay
any bonus to, any Employee, officer, director, consultant or
independent contractor of the Company, except for (A) increases in the
ordinary course of business consistent with the Company's past practice
(other than executive officers or directors of the Company whose annualized
compensation is $150,000 or more or whose annual compensation for the
12-month period following the Closing Date is expected to be $150,000 or more)
that were communicated to such Employee, consultant or independent contractor
prior to the date of this Agreement, or (B) as required by Applicable
Benefit Laws;

  



  

(xiv) except as required to comply with applicable Laws or any Contract
or Employee Plan in effect on the date of this Agreement, (A) pay to any
Employee, officer, director, consultant or independent contractor of the
Company any benefit not provided for under any Contract or Employee Plan in
effect on the date of this Agreement, (B) grant any awards under any Employee
Plan, (C) take any action to fund or in any other way secure the payment of
compensation or benefits under any Contract or Employee Plan, (D) take any
action to accelerate the vesting or payment of any compensation or benefit
under any Contract or Employee Plan, (E) adopt, enter into or amend any
Employee Plan other than offer letters entered into with new Employees in the
ordinary course of business consistent with the Company's past practice in
order to fill a position vacated after the date of this Agreement that
provide, except as required by applicable Laws, for "at will employment" with
no severance benefits, or (F) make any material determination under any
Employee Plan that is inconsistent with the ordinary course of business or
inconsistent with the Company's past practice;

  



    

 | -25-| 
---|---|--- 

 



    



  

(xv) hire any new Employee at the level of vice president or above or
with an annual base salary in excess of $150,000, dismiss any
Employee, promote any Employee except in order to fill a position vacated
after the date of this Agreement, or engage any consultant or
independent contractor whose relationship may not be terminated by the
Company on seven days' notice or less;

  



  

(xvi) dismiss or otherwise terminate the employment of any of the
Employees other than for cause;

  



  

(xvii) except as required by GAAP or applicable Laws, make or change
any Tax election, change its fiscal year, revalue any of its material
assets or adopt or make any changes in financial or Tax accounting methods,
principles or practices;

  



  

(xviii) enter into any closing agreement or Tax ruling, settle or
compromise any Tax claim or assessment, consent to any extension or waiver of
the limitation period applicable to any Tax claim or assessment, make or
rescind any material Tax election, surrender any right to claim a Tax refund,
or file any amended Tax Return unless such Tax Return has been provided to
Parent for review within a reasonable period prior to the due date for filing
and Parent has consented to such filing;

  



  

(xix) commence, settle or compromise any Legal Proceedings related to
or in connection with the Company's business;

  



  

(xx) (A) dispose of or permit to lapse any ownership and/or right to
the use of, or fail to protect, defend and maintain the ownership, validity
and registration of, the Company Intellectual Property, other than Company
Intellectual Property that is not material to the business in the ordinary
course of business consistent with past practice, or (B) dispose of or
disclose to any Person any Confidential Information other than in the
ordinary course of business consistent with past practice and under binding
obligations of confidentiality;

  



  

(xxi) delay any normally scheduled maintenance of its assets; or

  



  

(xxii) authorize, agree, commit or enter into any Contract to take any
of the actions described in clauses (i) through (xxi) of this Section 2.7; or

  



  

(c) any event, occurrence, development or state of circumstances or
facts that has, or could reasonably be expected to have, the effect of
preventing, delaying, making illegal or otherwise interfering with the
transactions contemplated by this Agreement.

  



    

 | -26-| 
---|---|--- 

 



    



  

Section 2.8 _Taxes_.

  



  

(a) All Tax Returns required to have been filed by or on behalf of the
Company through the date of this Agreement have been timely filed in
accordance with all applicable Laws (pursuant to an extension of time or
otherwise) and are true, correct and complete in all material respects. The
Company has provided to Parent true, correct and complete copies of all Tax
Returns.

  



  

(b) No written claim has ever been made by a Governmental Body in a
jurisdiction where the Company does not file Tax Returns that it is or may be
subject to taxation or to a requirement to file Tax Returns in that
jurisdiction.

  



  

(c) All Taxes due and owing by or on behalf of the Company (whether or
not shown on any Tax Return) have been or will be timely paid in full through
the date of this Agreement.

  



  

(d) The Company has accrued on the Company Financial Statements in
accordance with GAAP all liabilities for unpaid Taxes through the date of the
applicable Company Financial Statements.

  



  

(e) The amount of any Taxes paid by the Company, together with all
amounts accrued as liabilities for Taxes (including Taxes accrued
as currently payable but excluding any accrual to reflect timing differences
between book and Tax income) on the books of the Company, are adequate based
on the tax rates and applicable Laws in effect to satisfy all accrued
liabilities for Taxes of the Company in any jurisdiction.

  



  

(f) The Company has withheld all amounts of Taxes required to be
withheld from its employees, agents, contractors, creditors,
stockholders, members or other equityholders and third parties and timely
remitted such amounts to the proper Governmental Body and filed all federal,
state, local and foreign Tax Returns and reports with respect to employee
income Tax withholding, social security, unemployment, and other similar
Taxes, all in compliance with the withholding provisions of the Code, or any
prior provision of the Code and other applicable Laws.

  



  

(g) The Company has collected all sales, value-added and use Taxes
required to be collected, and have remitted, or will remit on a timely basis,
such amounts to the appropriate Governmental Body (or have been furnished
properly completed exemption certificates and have maintained all such
records and supporting documents, in each case, in material compliance with
all applicable sales and use Tax statutes and regulations).

  



  

(h) No claims have been asserted and no proposals or deficiencies for
any Taxes of the Company have been asserted, proposed or, to the Knowledge of
the Company, threatened, and no Legal Proceeding, audit, examination or
investigation of any Tax Return of the Company is currently underway, pending
or, to the Knowledge of the Company, threatened. There have been no
examinations or audits of any Tax Return of the Company. The Company has
provided to Parent true, correct and complete copies of all audit reports,
correspondence with Tax authorities and similar documents (to which the
Company has access) relating to the Tax Returns of the Company.

  



    

 | -27-| 
---|---|--- 

 



    



  

(i) All Tax deficiencies asserted by a Governmental Body against the
Company have been paid in full, accrued on the books of the Company, as
applicable, or finally settled.

  



  

(j) There are no outstanding waivers or agreements between any
Governmental Body and the Company for the extension of time for the
assessment of any Taxes or deficiency thereof, nor are there any requests for
rulings, outstanding subpoenas or requests for information, notices of
proposed reassessment of any property owned or leased by the Company or any
other matter pending between the Company and any Governmental Body.

  



  

(k) There are no Liens (other than Permitted Liens) for Taxes with
respect to the Company or the assets or properties of the Company, nor is
there any Lien that is pending or, to the Knowledge of the Company,
threatened.

  



  

(l) The Company has not been a member of an "affiliated group" of
companies (within the meaning of Section 1504 of the Code) filing a
consolidated federal income tax return (other than a group, the common parent
of which was the Company).

  



  

(m) The Company (i) has never been a member of an affiliated group
filing a consolidated federal income Tax Return or any similar group for
deferral, state, local or foreign Tax purposes, (ii) does not have any
liability for the Taxes of any other Person under Treasury Regulation Section
1.1502-6 (or any similar provision of state, local or foreign Law), as a
transferee or successor, by written or oral contract (other than pursuant to
any contracts the primary purpose of which is not the sharing of or
indemnification for Taxes), whether express or implied, operation of Law or
otherwise and (iii) has never been a party to any joint venture,
partnership or other arrangement that is treated as a partnership for Tax
purposes.

  



  

(n) The Company is not a party to or bound by any Tax allocation, Tax
indemnification or Tax sharing agreement (other than any such agreement the
primary purpose of which is not the sharing of or indemnification for Taxes).

  



  

(o) The Company has not made any payments, is not obligated to make any
payments and is not a party to any Contract that would obligate it to make
any payments that will not be deductible under Section 280G of the Code (or
any similar provision of national, provincial, territorial, state, local or
foreign Law).

  



  

(p) The Company has not constituted either a "distributing corporation"
or a "controlled corporation" in a distribution of stock qualifying for tax
free treatment under Section 355 of the Code (i) in the two years prior to the
date of this Agreement, or (ii) in a distribution which would otherwise
constitute part of a "plan" or "series of related transactions" (within the
meaning of Section 355(e) of the Code) in connection with the transactions
contemplated by this Agreement.

  



  

(q) Section 2.8(q) of the Disclosure Schedule sets forth a reasonable
estimate of the amount of federal net operating loss carryovers of
the Company as of January 1, 2019.

  



    

 | -28-| 
---|---|--- 

 



    



  

(r) To the Knowledge of the Company, the Company has no net operating
losses or other tax attributes presently subject to limitation under Sections
382, 383, 384 of the Code or the federal consolidated return regulations (or
any corresponding or similar provision of state, local or foreign income Tax
law).

  



  

(s) The Company will not be required to include any item of income in,
or exclude any item of deduction from, taxable income for any Tax period
after the date of this Agreement as a result of any (i) adjustment in taxable
income for any tax period (or portion thereof) pursuant to Section 481 of the
Code or any comparable provision under state or foreign tax Laws as a result
of a change in a method of accounting occurring before the date of this
Agreement, (ii) "closing agreement" as described in Section 7121 of the Code
(or any corresponding or similar provision of national, provincial,
territorial, state, local or foreign income Tax Law) executed on or prior to
the date of this Agreement, (iii) installment sale or open transaction
disposition made on or prior to the date of this Agreement, (iv) prepaid
amount received on or prior to the date of this Agreement, (v) intercompany
transaction or excess loss account described in U.S. Treasury Regulations
under Section 1502 of the U.S. Tax Code (or any corresponding or similar
provision of state, local, or non-U.S. income Tax law), (vi) income inclusion
pursuant to Section 951 of the Code with respect to any interest held in a
"controlled foreign corporation" (as that term is defined in Section 957 of
the Code) on or before the Closing Date, (vii) any installment of the "net
tax liability" described in Section 965(h)(1) of the Code after December 31,
2017, or (viii) change in method of accounting for a Tax period ending on or
prior to the Closing Date.

  



  

(t) The Company has not, directly or indirectly, transferred property
to or acquired property from a Person with whom it was not dealing at arm's
length for consideration other than consideration equal to the fair market
value of the property at the time of the disposition or acquisition thereof
and has complied in all material respects with all material transfer pricing
rules and requirements, including any disclosure, reporting and other similar
requirements under Section 482 of the Code (or any corresponding provision of
any state, local or foreign Tax Law).

  



  

(u) The Company has not been a United States real property holding
corporation within the meaning of Section 897(c)(2) of the Code during the
applicable period specified in Section 897(c)(1)(A)(ii) of the Code.

  



  

(v) The Company (i) does not have a permanent establishment, office or
other fixed place of business, and (ii) has never filed or had any obligation
to file, and does not have any obligation to file, any Tax Return based on
income or otherwise, in each case in any jurisdiction other than the United
States.

  



  

(w) None of the Tax Returns described in Section 2.8(a) contains any
position which is or would reasonably be expected to be subject to penalties
under Section 6662 of the Code (or any similar provision of national,
provincial, territorial, state, local or foreign law) and the Treasury
Regulations issued thereunder.

  



  

(x) The Company is, and has at all times been, in compliance with the
provisions of Sections 6011, 6111 and 6112 of the Code relating to tax
shelter disclosure, registration and list maintenance and with the Treasury
Regulations thereunder.

  



    

 | -29-| 
---|---|--- 

 



    



  

(y) The Company has not at any time engaged in or entered into a
"reportable transaction" within the meaning of Treasury Regulation Sections
1.6011-4(b), and no IRS Form 8886 has been filed with respect to the Company,
nor has the Company entered into any tax shelter or listed transaction with
the sole or dominant purpose of the avoidance or reduction of a Tax liability
with respect to which there is a significant risk of challenge of such
transaction by a Governmental Body.

  



  

(z) Nothing in this Section 2.8 (other than Section 2.8(s)) or
otherwise in this Agreement shall be construed as a representation or
warranty with respect to any Tax position that any Person may take in or in
respect of a Tax period ending after the Closing Date.

  



  

(aa) No Stockholder has entered into any binding contract or arrangement to
sell any Parent Shares received by it as Merger Consideration following the
Closing in a manner which will cause the Contribution, together with the
Merger contemplated herein, to fail to qualify as a tax free transfer of
property pursuant to Section 351 of the Code.

  



  

Section 2.9 _Real Property_.

  



  

(a) The Company does not own, and has never owned, any real property,
and the Company is not obligated and does not have an option to acquire an
ownership interest in any real property.

  



  

(b) Section 2.9(b) of the Disclosure Schedule sets forth a true,
correct and complete list of the Leased Real Property and the leases
under which such Leased Real Property is leased, subleased or licensed,
including all amendments or modifications to such leases (the " _Leases_ ").
The Company has provided to Parent true, correct and complete copies of all
Leases. The Company is not a party to any lease, sublease, license,
assignment or similar arrangement under which it is a lessor, sublessor,
licensor or assignor of, or otherwise makes available for use by any third
party of, any portion of the Leased Real Property, and the Company is not in
violation of any zoning, building, safety or environmental ordinance,
acquisition or requirement or Law applicable to such Leased Real Property.
The Company does not owe any brokerage commissions or finder's fees with
respect to any such Lease which is not paid or accrued in full.

  



  

(c) No material damage or destruction has occurred with respect to any
of the Leased Real Property for which the Company may be liable.

  



  

(d) The premises leased pursuant to each Lease are supplied with
utilities and other services necessary for the operation of such premises.

  



  

Section 2.10 _Personal Property_.

  



  

(a) All items of equipment and other tangible personal property and
assets owned by or leased to the Company that are, in each case, material to
the Company's business: (i) are reasonably adequate for the uses to which they
are being put, (ii) are structurally sound, free of material defects and
deficiencies and in good operating condition, maintenance and repair, subject
to ordinary wear and tear, (iii) are adequate for the conduct of the business
of the Company in the manner in which such business is being conducted and
(iv) are located at the Leased Real Property.

  



    

 | -30-| 
---|---|--- 

 



    



  

(b) No Person other than the Company owns any equipment or other
tangible personal property or asset that is necessary to the operation of the
Company's business. Section 2.10(b) of the Disclosure Schedule sets forth all
assets that are material to the business of the Company and that are being
leased or licensed to the Company for which the annual rental payment for each
such assets exceeds $25,000.

  



  

Section 2.11 _Intellectual Property_.

  



  

(a) Section 2.11(a) of the Disclosure Schedule sets forth all Company
Registrations as of the date of this Agreement, in each case
enumerating specifically the applicable filing or registration number, title,
jurisdiction in which filing was made or from which registration was issued,
date of filing or issuance, and names of all current applicant(s) and
registered owners(s), as applicable. All assignments of Company Owned
Registrations to the Company have been properly executed and recorded. All
issued Company Owned Registrations are enforceable and, to the Knowledge of
the Company, all issued Company Registrations that are not Company Owned
Registrations are enforceable. To the Knowledge of the Company, all issued
Company Registrations are valid, and all pending patent applications included
in the Company Registrations if issued would be valid and enforceable. Except
with respect to the decision to not file for Patent Rights in any particular
country or region, all issuance, renewal, maintenance and other payments and
fees that are or have become due with respect to the Company Registrations
have been timely paid by or on behalf of the Company.

  



  

(b) There are and have been no challenges, opposition or nullity
proceedings or interferences declared or commenced or, to the Knowledge of
the Company, threatened, and to the Knowledge of the Company there is no fact
that is reasonably likely to result in a valid challenge, opposition or
nullity proceeding or interference, with respect to any Company Intellectual
Property (including, without limitation, with any inventor challenges,
oppositions, or proceedings with respect to Patent Rights included in the
Company Registrations). The Company has complied with its duty of candor and
disclosure to the United States Patent and Trademark Office and any
relevant foreign patent office with respect to all patent and trademark
applications filed by or on behalf of the Company and, to the knowledge of
the Company, has made no misrepresentation in such applications.

  



  

(c) The Company exclusively owns all right, title and interest in and
to the Company Owned Intellectual Property (other than with respect to the
Company Owned Intellectual Property set forth on Section 2.11(c) of the
Disclosure Schedule, which is jointly owned by the Company), free and clear
of any Liens other than Permitted Liens. The Company Intellectual Property
constitutes all Intellectual Property Rights used in or necessary to the
conduct of the Company's business as now conducted and as contemplated by
the Company to be conducted by the Company as of the Closing and by Parent
after the Closing, free and clear of any Liens, other than Permitted Liens.
The Company Intellectual Property constitutes all Intellectual Property Rights
controlled by the Company.

  



    

 | -31-| 
---|---|--- 

 



    



  

(d) The Company has taken commercially reasonable steps to maintain and
protect the proprietary nature of each item of Company Intellectual Property
(other than Company Intellectual Property that is non-exclusively licensed to
the Company), and to maintain in confidence all trade secrets and
Confidential Information comprising a part thereof. The Company has materially
complied with all applicable contractual and legal requirements pertaining to
data collection, use, privacy, protection and security. No written
complaint, nor to the Knowledge of the Company, any other complaint relating
to an improper use or disclosure of, or a breach in the security of, any such
information has been made to or, to the Knowledge of the Company, threatened
against the Company. There has been no: (i) unauthorized material disclosure
of any third-party proprietary or Confidential Information in the possession,
custody or control of the Company, or (ii) material breach of the Company's
security procedures wherein Confidential Information has been disclosed to a
third Person. Nothing in this Section 2.11(d) relates to privacy, data
protection or data security with respect to Personal Information, which is
addressed exclusively in Section 2.26.

  



  

(e) No product, product candidate or service marketed or sold (or
proposed to be marketed or sold) by the Company or the conduct of
the business of the Company, as it is currently conducted and as it is
contemplated by the Company to be conducted, infringes, violates or
constitutes a misappropriation, or will infringe, violate or constitute a
misappropriation, of any Intellectual Property Rights of any third-party. The
Company has not received any complaint, claim or notice (i) alleging any such
infringement, violation or misappropriation, or that, by conducting its
business, the Company would infringe, violate or misappropriate any
Intellectual Property Rights of any other Person, or (ii) advising that such
Person is challenging or threatening to challenge the ownership, use,
legality, validity or enforceability of any Company Intellectual Property.

  



  

(f) To the Knowledge of the Company, no Person (including any current
or former employee, independent contractor or consultant of the Company) has
infringed, violated or misappropriated, or is infringing, violating or
misappropriating, any of the Company Owned Intellectual Property and there
are no facts or circumstances that could reasonably be expected to result in
any valid claims against a third Person relating to the foregoing.

  



  

(g) Section 2.11(g) of the Disclosure Schedule sets forth each license,
covenant or other agreement pursuant to which the Company has
assigned, transferred, licensed, distributed or otherwise granted any right
to any Person, or covenanted not to assert any right, with respect to Company
Intellectual Property, other than (i) Excluded Agreements, and (ii) customary
powers of attorney granted to the Company's patent prosecution counsel solely
for purposes of representing the Company before the U.S. Patent and Trademark
Office or its foreign equivalents. The Company is not a member of or party to
any patent pool, industry standards body, trade association or other
organization pursuant to the rules of which it is obligated to license any
existing or future Intellectual Property Rights to any Person, and none of
the Company Owned Intellectual Property was developed in whole or in part
using any governmental funding or using any funding, facilities, or resources
of any university or research institution.

  



  

(h) [Intentionally omitted].

  



    

 | -32-| 
---|---|--- 

 



    



  

(i) The Company is not a party to any proceeding or outstanding decree,
order, judgment, agreement, or stipulation (i) restricting in any material
manner the use, transfer or licensing by the Company of any of the Company
Owned Intellectual Property or any material Company Licensed Intellectual
Property, or (ii) that may affect in any material respect the ability of the
Company to use or sell any product, product candidate, or service, or that
may affect in any material respect the validity, use or enforceability of
the Company Owned Intellectual Property, other than patent prosecution and
regulatory proceedings in the ordinary course of business.

  



  

(j) Each current and former employee of the Company and each current
and former independent contractor of or consultant to the Company
has executed a valid and binding written agreement, substantially in the form
or forms provided to Parent (each, an " _Assignment Agreement_ "), expressly
assigning to the Company all right, title and interest in any inventions and
works of authorship, whether or not patentable, invented, created, developed,
conceived and/or reduced to practice during the term of such
employee's employment or such independent contractor's or consultant's work
for the Company, and all Intellectual Property Rights therein, and has waived
all moral rights therein to the extent legally permissible. All Company Owned
Intellectual Property was developed by (i) an employee of the Company working
within the scope of his or her employment at the time of such development, or
(ii) agents, consultants, contractors, or other Persons who have executed
appropriate Assignment Agreements or substantially similar valid and binding
assignment agreements.

  



  

(k) The execution and delivery of this Agreement by the Company, the
consummation by the Company of the Merger and the other
transactions contemplated by this Agreement and the Stockholder Related
Agreements and the Company continuing to operate its business
immediately after the Closing in the same manner as operated immediately
prior to the Closing after giving effect to the consummation of the Merger
and the other transactions contemplated by this Agreement and the Stockholder
Related Agreements will not result in the breach of, or create on behalf of
any third-party the right to terminate or modify, any license, sublicense or
other agreement relating to any Company Intellectual Property.

  



  

(l) To the Knowledge of the Company, no current or former director,
officer, employee, independent contractor, or consultant of the Company (i)
is in violation of any employment agreement, invention assignment agreement,
nondisclosure agreement, non-competition agreement or any other Contract with
any other Person by virtue of such director's, officer's, employee's,
independent contractor's, or consultant's being employed by, performing
services for or serving on the board of directors of the Company, (ii) is
using or has used any trade secrets or Confidential Information of any third
Person in connection with performing any services for the Company or the
development or creation of any Company Owned Intellectual Property without the
permission of the Company and such third Person, or (iii) has developed or
created any Intellectual Property Rights for or on behalf of the Company that
are subject to any agreement under which such director, officer, employee,
independent contractor, or consultant has assigned or otherwise granted any
third party any rights in or to such Intellectual Property Rights without the
permission of the Company. To the Knowledge of the Company, no director,
agent, employee, independent contractor, or consultant of the Company is a
party to, or is otherwise bound by, any Contract, including any
confidentiality, non-competition or proprietary rights agreement, with any
other Person that in any way has or could adversely affected his or her
ability to assign to the Company rights to any Intellectual Property Rights.

  



    

 | -33-| 
---|---|--- 

 



    



  

(m) The Company owns, free and clear of all Liens other than Permitted
Liens, or has obtained and possesses valid licenses to use all of the
software that it owns or leases or that it has otherwise provided to its
employees for their use in connection with the Company's business. To the
Knowledge of Company, all software and systems owned or used by the Company
and material to the conduct of the Company's business (i) are free from any
material defect, bug, virus or programming, design or documentation error or
corruptant or other software routines or hardware components that permit
unauthorized access or the unauthorized disablement or erasure of such, (ii)
function, operate and run in a reasonably efficient manner, (iii) are
reasonably sufficient for the current needs of the business of the Company,
and (iv) have not had any material failures, breakdowns or outages since
January 1, 2013.

  



  

Section 2.12 _Agreements_.

  



  

(a) Except as set forth on Section 2.12(a) of the Disclosure Schedule,
and except for Excluded Agreements, as of the date of this Agreement, the
Company is not a party to or bound by any written or oral:

  



  

(i) pension, profit sharing, stock option, employee stock purchase,
bonus or other plan or arrangement providing for deferred or other
compensation to current or former employees, independent contractors or
consultants, or any other employee benefit plan or arrangement, or
any collective bargaining agreement or any other Contract with any labor
union, or severance agreements, programs, policies or arrangements, except,
in each case, as disclosed in Section 2.12(a) of the Disclosure Schedule;

  



  

(ii) contract for the employment of, or receipt of services from, any
officer, individual employee or other Person on a full-time, part-
time, consulting or other basis which involves consideration on its face in
excess of $25,000 annually and that are terminable at-will and do not provide
for severance or other separation payments, except for (A) contracts disclosed
in Section 2.12(a) of the Disclosure Schedule and (B) the Company's standard
form at-will employment agreement in the form provided to Parent;

  



  

(iii) Contract providing for indemnification of any officer, director,
employee or agent of the Company;

  



  

(iv) Contract under which the Company has advanced or loaned any other
Person amounts in the aggregate exceeding $25,000;

  



  

(v) agreement or indenture relating to borrowed money or other
Indebtedness or the mortgaging, pledging or otherwise placing or creating of
a Lien (other than a Permitted Lien) on any asset or group of assets of the
Company;

  



  

(vi) guaranty, pledge, performance or completion bond, surety or
similar agreement or arrangement;

  



    

 | -34-| 
---|---|--- 

 



    



  

(vii) Contract creating or relating to any partnership or joint venture
or any sharing of revenues, profits, losses, costs or liabilities;

  



  

(viii) Lease or agreement under which the Company is lessee of or holds
or operates any tangible property, real or personal, owned by any
other party, except for any lease of real or personal property under which
the aggregate annual rental payments do not exceed $25,000;

  



  

(ix) lease or agreement under which the Company is lessor of or permits
any third party to hold or operate any tangible property, real or personal,
owned or controlled by the Company;

  



  

(x) Contract or group of related Contracts with the same party or group
of affiliated parties, the performance of which involves consideration in the
aggregate in excess of $50,000 in any single fiscal year of the Company, other
than (A) purchase and sales orders incurred in the ordinary course of
business consistent with past practice, (B) contracts disclosed in Section
2.16(a) of the Disclosure Schedule, (C) the Company's standard form at-will
employment agreement in the form provided to Parent, and (D) offer
letters with employees or agreements with consultants in each such case that
involve consideration of less than $50,000 in any single fiscal year of the
Company that are terminable at-will and do not provide for severance or other
separation payments;

  



  

(xi) Contracts relating to the assignment, license, indemnification,
acquisition, transfer, use, development or sharing with respect to any
Company Intellectual Property, except for Assignment Agreements and those
Contracts not material to the business;

  



  

(xii) [Intentionally omitted];

  



  

(xiii) warranty agreement with respect to services rendered by the
Company or products sold or leased by the Company;

  



  

(xiv) Contract relating to the purchase or sale of any product, product
candidate or other asset by or to, or the performance of any services by or
for, any Related Party;

  



  

(xv) Contract under which it has granted any Person any registration
rights (including demand or piggyback registration rights);

  



  

(xvi) sales, distribution, supply or franchise agreement or other
agreement involving an agency relationship;

  



  

(xvii) advertising, vendor rebate or product purchase or sale discount
agreement;

  



    

 | -35-| 
---|---|--- 

 



    



  

(xviii) Contract for capital expenditures or the acquisition or
construction of fixed assets requiring the payment by the Company of an amount
on its face in excess of $25,000;

  



  

(xix) Contract constituting or relating to a Government Contract or
Government Bid;

  



  

(xx) Contract providing for an "earn out", "performance guarantee" or
other similar contingent payments by or to the Company (other than as
contemplated by this Agreement);

  



  

(xxi) Contracts for the cleanup, abatement or other actions in
connection with any Materials of Environmental Concern, the remediation of any
existing environmental condition or relating to the performance of any
environmental audit or study;

  



  

(xxii) Contract granting any Person an option or a right of first
refusal, first-offer or similar preferential right to purchase or acquire
any assets of the Company;

  



  

(xxiii) Contract for the granting or receiving of a license, sublicense
or franchise or under which any Person is obligated to pay or has the
right to receive a royalty, license fee, franchise fee or similar payment of
an amount on its face in excess of $50,000;

  



  

(xxiv) outstanding power of attorney empowering any Person to act on
behalf of the Company;

  



  

(xxv) agreement with a term of more than 60 days which is not
terminable by the Company upon less than 30 days' notice without penalty
and involves a consideration on its face in excess of $50,000 in any single
fiscal year of the Company;

  



  

(xxvi) Contract regarding voting, transfer, issuance or other
arrangements related to the Company's capital stock or warrants, options
or other rights to acquire, or that relates to, the Company's capital stock;

  



  

(xxvii) Contract that (A) limits the ability of the Company or any of
its Affiliates to compete in any line of business or with any Person or in
any geographic area or during any period of time or (B) contains any so called
"most favored nation" provisions or any similar provision requiring the
Company to offer a third party terms or concessions (including levels of
service or content offerings) at least as favorable as offered to one or more
other parties; or

  



  

(xxviii) other Contract that, if terminated, would individually, have
or reasonably be expected to have a Company Material Adverse Effect.

  



    

 | -36-| 
---|---|--- 

 



    



  

(b) All of the Contracts, leases, agreements and instruments set forth
or required to be set forth on Section 2.12(a) of the Disclosure Schedule
(the " _Material Contracts_ ") are in full force and effect and are valid,
binding and enforceable in accordance with their respective terms, except as
such enforceability may be limited by (i) bankruptcy, insolvency,
reorganization, moratorium or other similar laws affecting or relating to
creditors' rights generally, and (ii) the availability of injunctive relief
and other equitable remedies. The Company has performed all material
obligations required to be performed by it and is not in material default
under or in material breach of, nor in receipt of any written claim of
material default or material breach under, any Material Contract. No event
has occurred which (with or without the passage of time or the giving of
notice or both, but allowing for outstanding obligations to be performed)
would, or would reasonably be expected to, (A) result in a material
default or material breach by the Company under any Material Contract, (B)
give any Person the right to declare a material default or exercise any
remedy under any Material Contract, (C) give any Person the right to
accelerate the maturity or performance of any Material Contract or (D) give
any Person the right to cancel, terminate or modify any Material Contract. The
Company has not received any written notice from a Person threatening to
terminate or refuse to perform its obligations under any Material Contract.

  



  

(c) The Company has not received any written notice or, to its
Knowledge, other communication regarding any actual or alleged
material violation or breach of, or default under, any Material Contract.

  



  

(d) The Company has not waived any of its material rights under any
Material Contract.

  



  

(e) There is no term, obligation, understanding or agreement that would
modify any term of a written Material Contract or any right or obligation of
a party thereunder which is not reflected on the face of such written Material
Contract.

  



  

(f) The Company has provided to Parent a true, correct and complete
copy of each of the written Material Contracts and a written
summary description of each of the oral Material Contracts, if any, together
with all amendments, waivers or other changes thereto.

  



  

Section 2.13 _Litigation_.

  



  

(a) There are no Legal Proceedings pending or, to the Knowledge of the
Company, threatened (i) against the Company or any of its
officers, directors, managers or employees (in their capacities as such) or
assets (or, to the Knowledge of the Company, pending or threatened against
any of the Stockholders with respect to the business or proposed business
activities of the Company), or pending or threatened by the Company against
any Person, at law or in equity, or before or by any Governmental Body
(including any Legal Proceedings with respect to the transactions
contemplated by this Agreement), or (ii) that, to the Company's Knowledge,
relate to the ownership of any capital stock of the Company, or any option or
other right to the capital stock of the Company, or any right to receive
consideration as a result of this Agreement.

  



  

(b) The Company is not subject to any Legal Proceedings under
collective bargaining agreements or otherwise or any governmental
investigations or inquiries.

  



    

 | -37-| 
---|---|--- 

 



    



  

(c) The Company is not subject to any judgment, order or decree of any
court or other Governmental Body. There are no actions, suits,
proceedings (including any arbitration proceedings), orders, investigations
or claims pending or, to the Knowledge of the Company, threatened against any
Stockholder in which it is sought to restrain or prohibit or to obtain damages
or other relief in connection with the transactions contemplated by this
Agreement. The Company has provided to Parent true, correct and complete
copies of all pleadings, correspondence and other written materials to which
the Company has access and that relate to any Legal Proceeding set forth
on Section 2.13 of the Disclosure Schedule.

  



  

Section 2.14 _Environmental Matters_.

  



  

(a) The Company is, and has for the past three (3) years has been, in
material compliance with all applicable Environmental Laws.

  



  

(b) The Company is not required to hold any Governmental Authorizations
under Environmental Laws for the conduct of its operations and business.

  



  

(c) The Company has not imported, received, used, manufactured,
produced, processed, labeled, shipped, stored, used, operated,
transported, treated or disposed of any Materials of Environmental Concern
other than in material compliance with all Environmental Laws.

  



  

(d) The Company has not received any notice or other communication (in
writing or otherwise), whether from a Governmental Body, citizens group,
employee or otherwise, that alleges that the Company is not in compliance
with, or has liability under, any Environmental Law.

  



  

(e) The Company has not at any time been subject to any administrative
or judicial proceeding pursuant to, or paid any fines or penalties pursuant
to, applicable Environmental Laws. The Company has not entered into or agreed
to enter into, or has any present intent to enter into, any consent decree or
order, and the Company is not subject to any judgment, decree or judicial or
administrative order relating to compliance with, or the cleanup of Materials
of Environmental Concern under, any applicable Environmental Law.

  



  

(f) To the Knowledge of the Company, there has been no Release of
Materials of Environmental Concern at any plant, facility, site, area or
property at which the Company currently operates or previously operated.

  



  

(g) The Company has provided to Parent true, correct and complete
copies of all environmental reports, investigations and/or audits, if any,
relating to facilities at which the Company currently operates or previously
operated (whether conducted by or on behalf of the Company or a third party)
of which the Company has possession or control.

  



    

 | -38-| 
---|---|--- 

 



    



  

Section 2.15 _Employee Matters_.

  



  

(a) Section 2.15(a)(1) of the Disclosure Schedule sets forth a true,
correct and complete list of all Employees as of the date of this
Agreement, and accurately reflects their wages, salaries or hourly rates of
pay and any other compensation payable to them (including
compensation payable pursuant to bonus, deferred compensation or commission
arrangements, housing allowances, vehicle allowances, and
vacation entitlements), whether such Employees are subject to a written
employment Contract, their dates of employment, their full time, part time or
temporary status, their exempt or non-exempt status, their positions or
titles, their sick pay schemes, a description of the fringe benefits provided
to each such Employee as of the date hereof, and any notice entitlements. The
Company's records accurately reflect the employment or services histories of
its Employees, independent contractors, consultants, contingent workers and
leased employees, including their hours of service. The employment of each of
the Employees is terminable at will. The Company has provided to Parent true,
correct and complete copies of all employee manuals and handbooks, material
disclosure materials, policy statements and other materials relating to the
employment of the current and former Employees of the Company. Section
2.15(a)(2) of the Disclosure Schedule sets forth the citizenship of each
employee and identifies the visa or other similar permit, if
applicable, under which such Employee is working and the dates of issuance
and expiration of such visa or other similar permit.

  



  

(b) Section 2.15(b) of the Disclosure Schedule sets forth each Employee
who is not fully available to perform work because of short-term or long-term
disability, parental leave, maternity leave, compassionate care leave or any
other leave or receiving benefits pursuant to any workers' compensation
legislation and the anticipated date of return to full service.

  



  

(c) Section 2.15(c) of the Disclosure Schedule sets forth a true,
correct and complete list of all consultants and independent contractors used
by the Company as of the date of this Agreement, specifying the name of the
consultant or independent contractor, type of services provided, fees paid to
such consultant or independent contractor for calendar year 2018 and from
January 1, 2019 through February 28, 2019, work location and address. Each
consultant or independent contractor set forth on Section 2.15(c) of the
Disclosure Schedule has the requisite Governmental Authorizations required to
provide the services such consultant or independent contractor provides the
Company, as applicable. The Company has provided to Parent a true, correct and
complete copy of each written agreement with each consultant and independent
contractor set forth on Section 2.15(c) of the Disclosure Schedule. Each of
the consultant and independent contractor relationships with the Persons set
forth on Section 2.15(c) of the Disclosure Schedule is terminable without
notice and without pay.

  



  

(d) Each Person who performs services for or on behalf of the Company
has, at all times, properly been classified and treated as an employee or
non-employee for all purposes including, but not limited to, the Employee
Plans and Tax purposes. Each Employee has at all times properly been
classified as subject to or exempt from overtime requirements. The Company has
never had any temporary or leased employees that were not treated and
accounted for in all respects as Employees.

  



  

(e) The Company is and has been in the last three years in compliance
in all material respects with all applicable Laws, including, but not limited
to, all Labor Laws applicable to the employment of labor. The Company is not
subject to or liable for any arrears of wages, penalties, fines, orders to
pay, assessments, charges, damages or taxes for failure to comply with the
Labor Laws or any other Law applicable to the employment of labor.

  



    

 | -39-| 
---|---|--- 

 



    



  

(f) There are no claims pending, or, to the Knowledge of the Company,
threatened against the Company, by an Employee, in respect of any accident or
injury, which are not fully covered by insurance or under applicable workers
compensation legislation. No levies, assessments or penalties have been made
against the Company pursuant to Applicable Benefit Laws.

  



  

(g) No notice has been received by the Company of any employment
related claims commenced by any Employee or other service provider
against the Company, including claims that the Company has violated Labor
Laws or the common law with respect to an employee's employment, and, to the
Knowledge of the Company, no such claims are threatened.

  



  

(h) The Company has not made any written or verbal commitments to any
officer, employee, former employee, consultant or independent contractor of
the Company with respect to compensation, promotion, retention, termination,
severance or any similar matter in connection with the transactions
contemplated by this Agreement or otherwise.

  



  

(i) The Company is, and has at all times been, in compliance in all
material respects with all applicable Laws and contracts relating to its
independent contractors, consultants and other non-employee service providers.
No independent contractor, consultant or other non-employee service provider
of the Company is eligible to participate in any Employee Plan. There are no
claims pending or to the Knowledge of the Company, threatened against the
Company, by any independent contractor, consultant other non-employee
service provider.

  



  

(j) All amounts due in relation to Employees (whether arising under
common law, statute, equity or otherwise) have been paid, including all
remuneration, expenses, pension contributions, liability to taxation, levies
and other amounts (other than amounts owed to Employees with respect to the
current salary or pay period which are not yet due or have not yet been
earned).

  



  

(k) All amounts due in relation to any independent contractors,
consultants or other non-employee service providers of the Company have been
paid.

  



  

(l) No Employee, since becoming an employee, has been, or currently is,
represented by a labor organization or group that was either certified or
voluntarily recognized by any labor relations board (including the NLRB) or
certified or voluntarily recognized by any other Governmental Body. The
Company is not and has never been a signatory to a collective bargaining
agreement with any trade union, labor organization or group. No
representation election petition or application for certification has been
filed by Employees or is pending with the NLRB or any other Governmental Body
and, to the Knowledge of the Company, no union organizing campaign or
other attempt to organize or establish a labor union, employee organization
or labor organization or group involving Employees has occurred, is in
progress or, to the Knowledge of the Company, is threatened. No labor strike,
work stoppage, slowdown, picketing, lockout or other material labor dispute
has occurred, and none is underway or, to the Knowledge of the Company,
threatened.

  



  

(m) Since January 1, 2013, the Company has not engaged in layoffs,
plant closings, terminations or relocations sufficient in number to
trigger application of any state, local or foreign law or regulation similar
to the WARN Act. None of the Employees has suffered an "employment loss" (as
defined in the WARN Act) in the 90 days prior to the date of this Agreement
and Parent will not incur any liability or obligation under the WARN Act if,
during the 90 day period immediately following the Closing Date, only
terminations in the normal course occur.

  



    

 | -40-| 
---|---|--- 

 



    



  

(n) The Company is not a federal or state contractor.

  



  

(o) No wrongful discharge, retaliation, libel, slander or other claim,
complaint, charge or investigation that arises out of the
employment relationship between the Company and any of its Employees or the
termination of that relationship has been filed or is pending or, to the
Knowledge of the Company, threatened against the Company under any applicable
Law.

  



  

(p) The Company has maintained and currently maintains adequate
insurance as required by applicable Law with respect to workers' compensation
claims and unemployment benefits claims. The Company has provided to Parent a
true, correct and complete copy of the policies of the Company for providing
leaves of absence under the FMLA and their notices thereunder.

  



  

Section 2.16 _Employee Benefit Plans_.

  



  

(a) Section 2.16(a) of the Disclosure Schedule sets forth a true,
correct and complete list, as of the date of this Agreement, of all
bonus, pension, stock option, stock purchase, benefit, welfare, profit-
sharing, retirement, disability, vacation, severance,
hospitalization, insurance, incentive, deferred compensation and any other
similar fringe or employee benefit plan (as such term is defined in
ERISA Section 3(3) whether or not subject to ERISA), fund, program or
arrangement, whether written or oral, in each of the foregoing cases which
cover, are maintained for the benefit of, or relate to any or all current or
former employee, director or natural person service provider of the Company
and any other Entity (" _ERISA Affiliate_ ") related to the Company
under Sections 414(b), (c), (m) and (o) of the Code or a beneficiary,
dependent or family member of any such individual (the " _Employee Plans_ ")
that are material. With respect to each Employee Plan, the Company has
provided to Parent, to the extent applicable, true, correct and complete
copies of (i) all plan documents and amendments thereto (or, in the event the
plan is not written, a written description thereof), (ii) the most recent
determination or opinion letter received from the Internal Revenue Service,
(iii) the most recent application for determination filed with the Internal
Revenue Service, (iv) actuarial valuation reports for the most recent year,
(v) audited financial statements for the most recent year, (vi) the three most
recent Form 5500 Annual Reports filed with the Internal Revenue Service,
including all schedules and attachments thereto, (vii) all related
trust agreements, insurance contracts or other funding arrangements, (viii)
nondiscrimination and coverage tests for the three most recent full plan
years, (ix) all summary plan descriptions, reports or summaries required under
all applicable Laws and summaries of material modifications and each other
material written communication to participants concerning the extent of the
benefits provided under the Employee Plan thereto, and (x) all material
correspondence with any governmental authority within the past six years
relating to such Employee Plan, including all voluntary compliance correction
or other remedial filings.

  



    

 | -41-| 
---|---|--- 

 



    



  

(b) Each of the Employee Plans (and each related trust, insurance
contract, or fund) is, and has been, operated in all material respects in
accordance with its terms and each of the Employee Plans, and administration
thereof, is, and has been, in compliance in all material respects with
respect to form and operation with the requirements provided by any and all
applicable statutes, orders or governmental rules or regulations currently in
effect, including, but not limited to, ERISA and the Code. Each Employee
Plan and its related trust which is intended to qualify under Section 401(a)
and Section 501(a) of the Code is so qualified and has heretofore been
determined by the Internal Revenue Service to so qualify and has received a
favorable determination or opinion letter with respect to all Laws on which
the Internal Revenue Service will issue a favorable determination letter on
its qualification, and nothing has occurred to cause the loss of such
qualification. All required reports and descriptions of the Employee Plans
(including, but not limited to, Form 5500 Annual Reports, Summary Annual
Reports and Summary Plan Descriptions) have been timely filed and distributed
as required by ERISA and the Code. Any notices required by ERISA or the Code
or any other state or federal law or any ruling or regulation of any state or
federal administrative agency with respect to the Employee Plans have been
appropriately given.

  



  

(c) With respect to the Employee Plans, all required contributions,
premiums and other payments for all periods ending before the Closing Date
have been made in full in accordance with all applicable laws and plan terms.

  



  

(d) With respect to each Employee Plan (i) no prohibited transactions
as defined in Section 406 of ERISA or Section 4975 of the Code have occurred
or are expected to occur as a result of the transactions contemplated by this
Agreement, (ii) no action, suit, grievance, arbitration or other manner of
litigation, or claim with respect to the assets thereof of any Employee Plan
(other than routine claims for benefits made in the ordinary course of plan
administration for which plan administrative review procedures have not been
exhausted) is pending, threatened or imminent against or with respect to any
of the Employee Plans, the Company, any ERISA Affiliate or any fiduciary, as
such term is defined in Section 3(21) of ERISA (" _Fiduciary_ "),
including but not limited to any action, suit, grievance, arbitration or
other manner of litigation, or claim regarding conduct that
allegedly interferes with the attainment of rights under any Employee Plan,
and (iii) there are no facts which would give rise to or could give rise to
any such actions, suits, grievances, arbitration or other manner of
litigation, or claims with respect to any Employee Plan. Neither the Company
nor its directors, managers, officers or employees or any Fiduciary has any
liability for failure to comply with ERISA or the Code for any action or
failure to act in connection with the administration or investment of any
Employee Plan.

  



  

(e) The Company and its ERISA Affiliates have not maintained,
established, sponsored, participated in, contributed to or otherwise
incurred any liability with respect to any (i) Employee Plan subject to Title
IV of ERISA, (ii) "multiemployer plan" within the meaning of Section (3)(37)
of ERISA, "multiple employer plan" within the meaning of Code Section 413(c)
or "multiple employer welfare arrangement" within the meaning of ERISA
Section 3(40), (iii) Employee Plan in which stock of the Company or any ERISA
Affiliate is or was held as a plan asset, (iv) plan, program, policy,
practice, agreement or other arrangement that is subject to the laws of a
country other than the United States, or (v) Employee Plan intended to be
exempt under Section 501(c)(9) or 501(c)(17) of the Code.

  



    

 | -42-| 
---|---|--- 

 



    



  

(f) The Company and its ERISA Affiliates do not maintain, contribute
to, or have any liability (fixed, contingent or otherwise) for
medical, health, life insurance or other welfare benefits for terminated
employees or for present employees after termination of their
employment (other than any welfare benefits provided in compliance with
Section 4980B of the Code, Section 601 of ERISA or other applicable law). The
Company does not have any current or projected liability with respect to post-
employment or post-retirement welfare benefits for retired, former or current
employees of the Company.

  



  

(g) Except as set forth in Section 2.16(a) of the Disclosure Schedule,
the Company and its ERISA Affiliates do not have any obligation to or
customary arrangement with employees for bonuses, incentive compensation,
vacations, severance pay, insurance or other benefits. Except as expressly
required or provided by this Agreement or as otherwise required by applicable
laws, the execution of this Agreement and the Stockholder Related Agreements
and the consummation of the transactions contemplated by this Agreement and
the Stockholder Related Agreements will not (either alone or upon the
occurrence of any additional or subsequent events) constitute an event
under any Employee Plan, employment agreement between the Company and any
current or former employee, trust or loan that will or may result (either
alone or in connection with any other circumstance or event) in any payment
(whether of severance pay or otherwise), acceleration, forgiveness of
Indebtedness, vesting, distribution, increase in benefits or obligation to
fund benefits with respect to any current or former employee of the Company.
The transactions contemplated by this Agreement will not cause the Company
to lose a tax deduction pursuant to Section 280G of the Code or cause any
service provider or Stockholder of the Company to be subject to the excise
tax under Section 4999 of the Code.

  



  

(h) The Company and any ERISA Affiliate have, prior to the Closing,
complied in all material respects with the health care
continuation requirements of the Consolidated Omnibus Budget Reconciliation
Act of 1985, as amended, the requirements of the FMLA, the requirements of
the Health Insurance Portability and Accountability Act of 1996, as amended
(Pub. L. 104-191), the requirements of the Patient Protection and Affordable
Care Act, and any similar provisions of state law applicable to the employees
of the Company and its ERISA Affiliates.

  



  

(i) Each Employee Plan that constitutes a "non-qualified deferred
compensation plan" subject to Code Section 409A complies in all material
respects with Code Section 409A with respect to its form and operation, no
amount under any such Employee Plan is or has been subject to the interest
and additional tax set forth under Code Section 409A(a)(1)(B), and there is no
obligation to reimburse or otherwise "gross-up" any Person for the interest
or additional tax set forth under Code Section 409A(a)(1)(B).

  



  

(j) The Company has not announced or entered into any plan or binding
commitment to (i) create or cause to exist any additional Employee Plan, or
(ii) adopt, amend or terminate any Employee Plan, other than any amendment
required by Applicable Benefit Laws. Each Employee Plan may be amended or
terminated in accordance with its terms without liability to the Company or
Parent (other than non-material ordinary termination fees).

  



    

 | -43-| 
---|---|--- 

 



    



  

Section 2.17 _Compliance With Laws; Governmental Authorizations_.

  



  

(a) The Company is, and has at all times been, in material compliance
with all applicable Laws. The Company has never received any written notice
or, to the Knowledge of the Company, other communication from any Governmental
Body or any other Person regarding (i) any actual or alleged material
violation of, or failure to materially comply with, any Law, or (ii) any
actual or alleged obligation on the part of the Company to undertake, or to
bear all or any portion of the cost of, any cleanup or any remedial,
corrective or response action of any nature under any applicable Law. Nothing
in this Section 2.17(a) relates to privacy, data protection, or data security
with respect to Personal Information, which are addressed exclusively in
Section 2.26.

  



  

(b) Section 2.17(b) of the Disclosure Schedule sets forth each
Governmental Authorization held by the Company, and the Company has
provided to Parent true, correct and complete copies of all such Governmental
Authorizations. The Governmental Authorizations held by the Company are valid
and in full force and effect, and collectively constitute all Governmental
Authorizations necessary (i) to enable the Company to conduct its business in
the manner in which its business is currently being conducted, and (ii) to
permit the Company to own and use its assets in the manner in which it is
currently owned and used. The Company is, and at all times since its
incorporation has been, in material compliance with the terms and
requirements of the Governmental Authorizations held by the Company. The
Company has not received any written notice or, to the Knowledge of the
Company, other communication from any Governmental Body regarding (A) any
violation or failure to comply with any term or requirement of any
Governmental Authorization, or (B) any revocation, withdrawal, suspension,
cancellation, or termination of any Governmental Authorization.

  



  

(c) (i) The Company is, and at all times has been, in material
compliance with all of the terms and requirements of each Governmental
Authorization set forth or required to be set forth on Section 2.17(c) of the
Disclosure Schedule; (ii) to the Knowledge of the Company, no event has
occurred, and no condition or circumstance exists, that would reasonably be
expected to (with or without notice or lapse of time or both) (A) constitute
or result in a material violation of or a failure to comply with any term or
requirement of any Governmental Authorization set forth or required to be set
forth on Section 2.17(c) of the Disclosure Schedule, or (B) result in the
revocation, withdrawal, suspension, cancellation, or termination of any
Governmental Authorization set forth or required to be set forth on Section
2.17(c) of the Disclosure Schedule; (iii) the Company has never received, and,
to the Knowledge of the Company, no employee has ever received, any notice or
other communication from any Governmental Body or any other Person regarding
(x) any actual or alleged violation of or failure to materially comply with
any term or requirement of any Governmental Authorization; or (y) any actual
or proposed revocation, withdrawal, suspension, cancellation or termination of
any Governmental Authorization; and (iv) all applications required to have
been filed for the renewal of the Governmental Authorizations required to be
set forth on Section 2.17(c) of the Disclosure Schedule have been duly filed
on a timely basis with the appropriate Governmental Bodies, and each
other notice or filing required to have been given or made with respect to
such Governmental Authorizations has been duly given or made on a timely
basis with the appropriate Governmental Body.

  



    

 | -44-| 
---|---|--- 

 



    



  

Section 2.18 _Insurance_. Section 2.18 of the Disclosure Schedule
sets forth a true, correct and complete list of all insurance policies and
fidelity bonds maintained by, at the expense of or for the benefit of the
Company and its Employees, officers and directors for the current policy year
and the Company has provided to Parent true, correct and complete copies of
the insurance policies set forth on Section 2.18 of the Disclosure Schedule.
The Company has not reached or exceeded its policy limits for any insurance
policy in effect at any time since the date of the Company's incorporation.
Since the date of the Company's incorporation, the Company has not received
any written notice or, to the Knowledge of the Company, other communication
regarding any actual or possible (a) cancellation or invalidation of any
insurance policy, (b) refusal of any coverage or rejection of any material
claim under any insurance policy, or (c) material adjustment in the amount of
the premiums payable with respect to any insurance policy. All such
policies are in full force and effect. All premiums required to be paid with
respect thereto have been paid and there has been no lapse in coverage under
such policies or failure of payment that will cause coverage to lapse during
any period for which the Company has conducted operations. Section 2.18 of
the Disclosure Schedule sets forth all claims by the Company pending under any
of such policies or bonds as to which coverage has been questioned, denied or
disputed by the underwriters of such policies or bonds or in respect of which
such underwriters have reserved their rights.

  



  

Section 2.19 _Brokerage and Finders_. The Company has not
incurred, and will not incur, directly or indirectly, any liability for
brokerage or finders' fees or agents' commissions, fees related to investment
banking or similar financial advisory services in connection with this
Agreement or any transaction contemplated hereby, nor will Parent, the
Surviving Corporation or the Company incur, directly or indirectly, any such
liability based on arrangements made by or on behalf of the Company.

  



  

Section 2.20 _Title to Tangible Assets_.

  



  

(a) The Company owns, and has good, valid, transferable and marketable
title to, or a valid leasehold interest in all tangible properties and assets
used by it or shown on the Interim Balance Sheet or acquired after the date
thereof, free and clear of all Liens (other than properties and assets
disposed of in the ordinary course of business consistent with past practice
since the date of the Interim Balance Sheet and except for Permitted Liens).

  



  

(b) All facilities, machinery, equipment, fixtures, vehicles and other
tangible properties owned, leased or used by the Company that are, in each
case, necessary to the Company's business as presently conducted, are in good
operating condition and repair and are reasonably fit and usable for the
purposes for which they are being used. The Company is in compliance with all
material terms of each lease to which it is a party or is otherwise bound.
For the avoidance of doubt, no representation or warranty is made in this
Section 2.20 with respect to any Intellectual Property Rights, which
representations are addressed solely in, and to the extent, set forth in
Section 2.11.

  



  

Section 2.21 _Bank Accounts_. Section 2.21 of the Disclosure
Schedule sets forth true, correct and complete information with respect to
each account maintained by or for the benefit of the Company at any bank or
other financial institution, including the name of the bank or financial
institution, the account number, the balance as of the date of this Agreement
(and whether any cash comprising such balances is "restricted cash") and the
names of all individuals authorized to draw on or make withdrawals from
such accounts (and no changes to such information shall have occurred as of
the Closing Date).

  



    

 | -45-| 
---|---|--- 

 



    



  

Section 2.22 _Related Party Transactions_. No Related Party has, or
has at any time had, any direct or indirect interest in any material asset
used in or otherwise relating to the business of the Company. No Related
Party is, or has been, indebted to the Company. No Related Party is a party
to, or has a financial interest in, any Material Contract, transaction or
business dealing involving the Company other than Contracts related to their
employment as an officer or service as a director (including employment,
confidentiality, assignment of inventions, stock options, warrants and
similar agreements).To the Knowledge of the Company, no Related Party
is competing, or has at any time competed, directly or indirectly, with the
Company or has any claim or right against the Company (other than claims or
rights to receive compensation for services performed as an employee or a
director).

  



  

Section 2.23 _Customers and Suppliers_. As of the date of this
Agreement, the Company has no customers. Section 2.23 of the Disclosure
Schedule sets forth a true, correct and complete list of the names and
addresses of the Suppliers. The Company maintains good commercial
relations with each of its Suppliers and no event has occurred that could
materially and adversely affect the Company's relations with any such
Supplier. No Supplier (or former Supplier) during the prior twelve (12) months
has canceled, terminated or, to the Knowledge of the Company, made any threat
to cancel or otherwise terminate any of such Supplier's Contracts with the
Company or to decrease such Supplier's supply of services or products to the
Company. The Company has not received any written notice and the Company does
not have any Knowledge to the effect that any current Supplier may withdraw,
terminate or materially alter, amend or modify its business relations with
the Company, either as a result of the transactions contemplated by this
Agreement or otherwise.

  



  

Section 2.24 _Import/Export Control_.

  



  

(a) The Company has obtained all approvals necessary for exporting its
products and services outside of the United States and importing such
products and services into any country in which such products or services are
now sold, provided or licensed for use, and all such export and import
approvals in the United States and throughout the world are valid, current and
in full force and effect.

  



  

(b) The Company has not received notice of any violation of any
applicable export Law, nor, to the Knowledge of the Company, is there
any law, regulation, order, or pending action or proceeding that restricts,
or that could reasonably be expected to restrict, in any manner, the
development, use, export, import, transfer or licensing of any of the products
or services of the Company or the Intellectual Property Rights or that could
reasonably be expected to affect the validity, use, registration or
enforceability of any Intellectual Property Rights.

  



  

Section 2.25 _Certain Payments_. Neither the Company nor any
employee, agent, consultant, or other Person acting for or on behalf of the
Company, has at any time, directly or indirectly: (a) used any corporate
funds (i) to make any unlawful political contribution or gift or for any
other unlawful purpose relating to any political activity, (ii) to make any
unlawful payment to any governmental official or employee, including without
limitation any payments made in violation of the FCPA or the UK Bribery Act,
(iii) to establish or maintain any unlawful or unrecorded fund or account of
any nature; (b) made any unlawful payoff, influence payment, bribe, rebate,
kickback or unlawful payment to any Person; (c) falsified any Company
documents or (d) agreed, committed, offered or attempted to take any of the
actions described in clauses (a) through (c) above.

  



    

 | -46-| 
---|---|--- 

 



    



  

Section 2.26 _Personal Information and Privacy_.

  



  

(a) Section 2.26(a) of the Disclosure Schedule sets forth and describes
each distinct electronic or other database, if any, containing (in whole or
in part) Personal Information maintained by or for the Company at any time
(each, a " _Company Database_ "), the types of Personal Information in each
such database, the means by which the Personal Information was collected, and
the security policies that have been adopted and maintained with respect to
each such database.

  



  

(b) The Company employs commercially reasonable security measures that
comply in all material respects with all applicable Privacy Laws and Privacy
Policies (as defined below) to protect Personal Information within its custody
or control and requires the same of all vendors that Process Personal
Information on its behalf, including without limitation any contract research
organizations conducting pre-clinical and clinical studies on the Company's
behalf (" _Privacy Vendors_ ").

  



  

(c) There is no written complaint or other written communication to or
audit, proceeding, or claim against, or threatened in writing against, and,
to the Knowledge of the Company, no pending investigation of, the Company or
any Privacy Vendor, by any Governmental Body, or by any Person in respect of
applicable Privacy Laws.

  



  

(d) There is (i) no material breach or violation of any privacy policy
of the Company or any other industry privacy code or privacy procedures to
which the Company subscribes or is bound which governs its Processing of
Personal Information (each, a " _Privacy Policy_ "), (ii) there has been no
material unauthorized or illegal Processing or breach of security involving
any of the Personal Information under the Company's custody or control,
including in any of the Company Databases, and (iii) the Company has not
notified or been required to notify any data subjects or Governmental Body of
any information security breach involving Personal Information, or that
otherwise has resulted in, or would reasonably be expected to result in, any
material liability of the Company.

  



  

(e) The Company and, to the Knowledge of the Company, each Privacy
Vendor (in the case of Privacy Vendors, to the extent applicable)
has complied at all times and in all material respects with (i) all of the
Privacy Policies; (ii) all written representations, warranties, covenants and
agreements of any of the Company pursuant to any Contract related to the
Processing of Personal Information; and (iii) all applicable Privacy Laws.

  



  

(f) The Company and, to the Knowledge of the Company, each Privacy
Vendor has, in all material respects, provided all requisite notices and
obtained all required consents, and satisfied all other requirements
(including but not limited to notification to Governmental Bodies), necessary
for the Company's Processing (including international and onward transfer) of
all Personal Information in connection with the conduct of the business as
currently conducted and in connection with the consummation of the
transactions contemplated hereunder.

  



    

 | -47-| 
---|---|--- 

 



    



  

Section 2.27 _Manufacturing_. All of the manufacturing facilities
and operations of the Company are in compliance in all material respects with
applicable Laws and regulations of the FDA or other Governmental Bodies,
including current good manufacturing practices. No event has occurred that
allows, or with or without notice or lapse of time or both, would allow,
revocation or termination of any FDA registration of the Company's
manufacturing facilities. The Company has not received any unresolved FDA Form
483, notice of adverse filing, warning letter, untitled letter or other
written correspondence or notice from the FDA or any other Governmental Body,
alleging or asserting noncompliance with the Federal Food, Drug and Cosmetic
Act (21 U.S.C.  301 et seq.).

  



  

Section 2.28 _Regulatory Filings_. The Company has made all
required registrations and filings with and submissions to all applicable
Governmental Bodies relating to the operation of the business of the Company.
There is no material false or misleading information or material omission in
any product application or other submission to the FDA or any other comparable
Governmental Body. All such registrations, filings and submissions were in
compliance in all material respects with all Laws and other requirements when
filed. No material deficiencies have been asserted by any such applicable
Governmental Bodies with respect to such registrations, filings or
submissions. The Company has delivered to Parent copies of (a) all material
reports of inspection observations, (b) all material establishment inspection
reports, (c) all material warning letters, and (d) any other material
documents received by the Company from the FDA or any other Governmental Body
relating to the business of the Company that assert ongoing material lack of
compliance with any laws (including regulations promulgated by the FDA and
any other Governmental Body) by the Company. The Company has not received any
Negative FDA Letter.

  



  

Section 2.29 _Product Candidates_.

  



  

(a) Each of the Company's products and product candidates is being, and
at all times has been, developed, tested, manufactured, processed, labeled,
stored, transported and distributed, as applicable, in compliance in all
material respects with all applicable Laws, including those requirements
relating to current good manufacturing practices, good laboratory practices
and good clinical practices. Nothing in this Section 2.29 relates to privacy,
data protection, or data security with respect to Personal Information, which
are addressed exclusively in Section 2.26.

  



  

(b) The pre-clinical and clinical trials (including any post-marketing
studies) conducted by or on behalf of the Company were, and if still pending,
are, being conducted in all material respects in accordance with all clinical
protocols, informed consents and applicable Laws. The Company retains
exclusive ownership of all data resulting from pre-clinical and clinical
trials (including any post-marketing studies) conducted by or on behalf of
the Company. The Company has not been notified by the FDA or any other
Governmental Body of any restriction on the pre-clinical or clinical trials
conducted or currently being conducted by or on behalf of the Company. The
descriptions of, protocols for, and data and other results of, the pre-
clinical and clinical trials conducted or currently being conducted by or on
behalf of the Company that have been provided to Parent are true, correct and
complete.

  



    

 | -48-| 
---|---|--- 

 



    



  

(c) The Company has fulfilled and performed its obligations under each
FDA/EMA Registration in all material respects, and no material event has
occurred or condition or state of facts exists which would reasonably
constitute a breach or default or would cause revocation, suspension, or
termination of any such FDA/EMA Registration. No loss or expiration of any
FDA/EMA Registration is pending or, to the Knowledge of the Company,
threatened, other than expiration of any FDA/EMA Registration in accordance
with the terms thereof, and there is no circumstance that would reasonably be
expected to cause such FDA/EMA Registration to not be renewable upon
expiration to the extent permitted by law, as needed. To the Knowledge of the
Company, any third-party that is a supplier, manufacturer, or contractor for
the Company is in material compliance with all FDA/EMA Registrations and the
authorizations, approvals, licenses, permits, certificates, or exemptions
(including, without limitation, pre-market approval applications, pre-market
notifications, investigational new drug applications, new drug applications,
biologic license applications, manufacturing approvals and
authorizations, pricing and reimbursement approvals, labeling approvals or
their foreign equivalent) held by the Company that are required for, among
other things, the research, development, manufacture, processing, labeling,
distribution, marketing, storage, transportation, use, sale and provision of
the products and services of the Company, of any comparable Governmental Body.

  



  

(d) Section 2.29(d) of the Disclosure Schedule sets forth a true,
correct and complete list of all of the Company's products and
product candidates in clinical trial or development as of the date hereof,
noting, where applicable, (i) the phase of clinical trial or development each
product or product candidate is in, and (ii) those products or product
candidates where FDA and/or other regulatory approval, including foreign
approvals, has been applied for and/or received, and listing the application
made and/or the approval or decision thereon obtained. The Company has
provided to Parent true, correct and complete copies of, without limitation,
(A) any investigational new drug applications or new drug applications
submitted to the FDA or any other Governmental Body by or on behalf of the
Company, including any supplements thereto, (B) all final study results and/or
reports relating to products or product candidates, (C) all material
correspondence to or from the FDA or other Governmental Bodies, including
meeting minutes and records of material contacts, (D) all documents in the
Company's possession related to inspections by the FDA or other
Governmental Bodies, and (E) all adverse drug experience reports obtained or
otherwise received by the Company from any source with respect to the
products or product candidates.

  



  

Section 2.30 _OFAC_. Neither the Company nor Representative of the
Company, nor, to the Knowledge of the Company, any other Person acting for or
on behalf of the Company has: (a) been or is currently subject to any United
States sanctions administered by the Office of Foreign Assets Control of the
United States Treasury Department (" _OFAC_ "); or (b) engaged or is currently
engaging in any business or other dealings with, in, involving, or relating
to (i) any country subject to a comprehensive embargo under the sanctions
administered by OFAC, or (ii) any Person subject to sanctions administered by
OFAC.

  



    

 | -49-| 
---|---|--- 

 



    



  

Section 2.31 _Independent Investigations_. The Company acknowledges
(for itself and on behalf of its Affiliates and the Representatives of any of
the foregoing) that, except for the representations and warranties expressly
set forth in Article III, (a) none of the Parent Parties nor any of their
Affiliates (Person or any of its Affiliates) makes, or has made, any
representation or warranty, either express or implied, relating to any Parent
Party or any of their businesses or operations or otherwise in connection with
this Agreement or the transactions contemplated hereby, and neither the
Company nor any of its Affiliates or Representatives is relying on any
representation or warranty except for those expressly set forth in Article
III, (b) no Person has been authorized by any Parent Party or any of their
Affiliates to make any representation or warranty relating to any Parent Party
or any of its businesses or operations or otherwise in connection with this
Agreement or the transactions contemplated hereby, and if made, such
representation or warranty must not be relied upon by the Company or any of
the Affiliates or the Representatives of any of the foregoing as having been
authorized by any Parent Party or any of its Affiliates (or any other Person
on behalf of any Parent Party), and (c) any estimate, projection, prediction,
data, financial information, memorandum, presentation or any other materials
or information provided or addressed to the Company or any of the Affiliates
or the Representatives of any of the foregoing are not and shall not be
deemed to be or include representations or warranties unless and to the
extent any such materials or information is the subject of any express
representation or warranty set forth in Article III; _provided_ , _however_ ,
none of the representations or warranties set forth in this Section 2.31
shall apply to, or otherwise operate to limit the liability of any Parent
Party or any other Person in respect of any claim or cause of action based on
or arising out of fraud.

  



  

Article III 
 Representations and Warranties of PARENT PARTIES

  



  

Parent and Merger Sub (collectively with Sorrento referred to as the "
_Parent Parties_ ") represent and warrant to the Company, as of the date of
this Agreement and as of the Closing Date, as set forth below (other than as
set forth in Section 3.11).

  



  

Section 3.1 _Organization and Good Standing_. Each of Parent and
Merger Sub is a corporation duly organized, validly existing and in good
standing (or equivalent status in the relevant jurisdiction) under the laws
of the jurisdiction of its incorporation, has all requisite and necessary
power and authority to own, lease, use and operate its properties and assets
and to carry on and conduct its business as now being conducted and as
proposed to be conducted as of the Closing Date and is in good standing as a
foreign corporation (or equivalent status in the relevant jurisdiction) in
each jurisdiction in which the character of the properties it owns,
operates or leases or the nature of its activities makes such qualification
necessary or advisable, except for those jurisdictions where the failure to
be so qualified would not reasonably be expected to have, individually or in
the aggregate, a material adverse effect on Parent's or Merger Sub's ability
to consummate the Merger.

  



    

 | -50-| 
---|---|--- 

 



    



  

Section 3.2 _Authority, No Conflict; Required Filings and
Consents; Compliance with Laws_.

  



  

(a) Each of Parent and Merger Sub has all requisite corporate power
and authority to enter into this Agreement and any Parent Related
Agreement to which it is a party, perform its obligations under this
Agreement and any Parent Related Agreement to which either of them is a party
and to consummate the Merger and the other transactions contemplated by this
Agreement and any Parent Related Agreement to which either of them is a
party. The execution and delivery of this Agreement and any Parent Related
Agreement to which Parent and Merger Sub is a party and the consummation of
the Merger and the other transactions contemplated by this Agreement and
any Parent Related Agreement to which Parent and Merger Sub is a party have
been duly authorized by all necessary corporate action on the part of Parent
and Merger Sub, and no other corporate action or proceeding on the part of
Parent or Merger Sub or their respective boards of directors is necessary to
authorize the execution, delivery or performance of this Agreement, any Parent
Related Agreement to which Parent and Merger Sub is a party or the
consummation of the Merger or any of the other transactions contemplated by
this Agreement or any Parent Related Agreement to which Parent and Merger Sub
is a party. This Agreement has been duly executed and delivered by Parent and
Merger Sub and constitutes the legal, valid and binding obligations of Parent
and Merger Sub, enforceable against Parent and Merger Sub in accordance with
its terms, except as such enforceability may be limited by (i) bankruptcy,
insolvency, reorganization, moratorium or other similar laws affecting or
relating to creditors' rights generally, and (ii) the availability of
injunctive relief and other equitable remedies.

  



  

(b) Neither the execution, delivery or performance by the Parent
Parties of this Agreement or any of the Parent Related Agreements, nor
the consummation of the Merger or any of the other transactions contemplated
by this Agreement or any of the Parent Related Agreements, will (with or
without notice or lapse of time, or both): (i) contravene, conflict with, or
result in any violation or breach of, any of the Organizational Documents of
the Parent Parties, (ii) contravene, conflict with, or result in any violation
or breach of, or constitute (with or without notice or lapse of time, or
both) a default (or give rise to a right of modification,
termination, cancellation or acceleration of any obligation or loss of any
material benefit) under, require notice to any Person or a consent or waiver
under, constitute a change in control under, require the payment of a fee or
penalty under or result in the creation or imposition of any Lien upon or
with respect to any asset owned or used by any of the Parent Parties under,
any of the terms, conditions or provisions of any material Contract to which
any Parent Party is a party or by which it or any of its properties or assets
may be bound, (iii) contravene, conflict with or violate, or give any Person
the right to challenge any of the transactions contemplated by this Agreement
or any of the Parent Related Agreements or to exercise any remedy or obtain
any relief under, any Law or any order, writ, injunction, judgment or decree
to which Parent or Merger Sub is subject, or (iv) contravene, conflict
with or result in a violation of any of the terms or requirements of, or give
any Governmental Body the right to revoke, withdraw, suspend, cancel,
terminate or modify, any Governmental Authorization that is held by any Parent
Party or that otherwise relates to the business of any Parent Party or to any
of the assets owned, used or controlled by any Parent Party other than, in the
case of clauses (ii), (iii) and (iv), above, for such contraventions,
conflicts, violations or rights that would not have a material adverse effect
on the applicable Parent Party's ability to consummate the Merger.

  



  

(c) No Governmental Authorization, or registration, declaration,
notice or filing with, any Governmental Body is required by or with
respect to the Parent Parties: (i) in connection with the execution and
delivery of this Agreement or any of the Parent Related Agreements by any
Parent Party or the consummation by the Parent Parties of the Merger or any of
the other transactions contemplated by this Agreement or any of the Parent
Related Agreements, or (ii) is necessary for the Parent Parties to operate
their respective businesses immediately after the Closing in the same manner
as operated immediately prior to the Closing after giving effect to the
consummation of the Merger and the other transactions contemplated by this
Agreement and Parent Related Agreements, except in each case for (a) the
filing of the Charter Amendment and the Certificate of Merger with the
Secretary of State of the State of Delaware, (b) any filings required by
applicable securities Laws and (c) such consents, waivers, approvals, orders,
authorizations, registrations, declarations and filings which, if not
obtained or made, would not reasonably be expected to be, individually or in
the aggregate, material to the Parent Parties.

  



    

 | -51-| 
---|---|--- 

 



    



  

(d) The Governmental Authorizations held by Parent and Merger Sub
are valid and in full force and effect, and collectively constitute
all Governmental Authorizations necessary (i) to enable Parent and Merger Sub
to conduct their respective businesses in the manner in which their
respective businesses are currently being conducted, and (ii) to permit Parent
and Merger Sub to own and use their respective assets in the manner in which
they are currently owned and used. Parent and Merger Sub are, and at all times
since their incorporation have been, in material compliance with the terms
and requirements of the Governmental Authorizations held by Parent and Merger
Sub. Neither Parent nor Merger Sub has received any written notice or, to the
knowledge of Parent or Merger Sub, other communication from any Governmental
Body regarding (A) any violation or failure to comply with any term or
requirement of any Governmental Authorization, or (B) any revocation,
withdrawal, suspension, cancellation, or termination of any
Governmental Authorization.

  



  

(e) Each of Parent and Merger Sub is, and has at all times been, in
material compliance with all applicable Laws. Neither Parent nor Merger Sub
has received any written notice or, to the knowledge of Parent or Merger Sub,
other communication from any Governmental Body or any other Person regarding
(i) any actual or alleged material violation of, or failure to materially
comply with, any Law, or (ii) any actual or alleged obligation on the part of
Parent or Merger Sub to undertake, or to bear all or any portion of the
cost of, any cleanup or any remedial, corrective or response action of any
nature under any applicable Law.

  



  

Section 3.3 [Intentionally omitted].

  



  

Section 3.4 _Capitalization_.

  



  

(a) Immediately prior to the Effective Time, the authorized capital
stock of Parent consists of (i) 350,000,000 Parent Shares, of which
150,270,392 shares are issued and outstanding and (ii) 20,000,000 shares of
Preferred Stock of Parent, none of which are issued and outstanding.
The Parent Shares have the rights, preferences, privileges and restrictions
set forth in the certificate of incorporation of Parent. All issued and
outstanding Parent Shares were issued in compliance with all applicable Laws.
The Parent Shares to be issued pursuant to this Agreement will be, prior to
the issuance, duly authorized, and when issued in accordance with the terms of
this Agreement, will be validly issued, fully paid and nonassessable.

  



  

(b) As of the date hereof and following Contribution and immediately
prior to the Effective Time, other than this Agreement and the
transactions contemplated herein, there is no: (i) outstanding subscription,
option, call, warrant or right (whether or not currently exercisable) to
acquire any Parent Shares or other securities of Parent, (ii) outstanding
security, instrument or obligation that is or may become convertible into or
exchangeable for any Parent Shares or other securities of Parent, or (iii)
Contract under which Parent is or may become obligated to sell or otherwise
issue any Parent Shares or any other securities of Parent, or (iv) condition
or circumstance that may give rise to or provide a basis for the assertion of
a claim by any Person to the effect that such Person is entitled to acquire
or receive any Parent Shares or other securities of Parent from Parent or, to
the knowledge of Parent, any other Person. Parent does not have any
outstanding stock appreciation rights, phantom stock, performance based stock,
restricted stock units or equity rights or similar stock or equity rights or
obligations. Parent has not issued any debt securities which grant the holder
thereof any right to vote on, or veto, any actions by Parent.

  



    

 | -52-| 
---|---|--- 

 



    



  

(c) Following the Contribution and immediately prior to the
Effective Time, Parent will have the same number and class of shares that are
authorized, issued and outstanding, with such shares being held by the same
Persons, as was authorized, issued and outstanding as Scilex prior to the
Contribution.

  



  

Section 3.5 _Cash Resources of Parent_. Following consummation of
the transactions contemplated by the Loan and Contribution Agreement,
Parent will have sufficient immediately available funds to pay the cash
portion of the Merger Consideration when payable in accordance with this
Agreement.

  



  

Section 3.6 _Independent Investigations_. Each of Parent, Sorrento
and Merger Sub acknowledges (for itself and on behalf of its Affiliates and
the Representatives of any of the foregoing) that, except for the
representations and warranties expressly set forth in Article II, (a)
neither the Company nor any of its Affiliates (Person or any of its
Affiliates) makes, or has made, any representation or warranty,
either express or implied, relating to the Company or any of its businesses
or operations or otherwise in connection with this Agreement or the
transactions contemplated hereby, and none of Parent, Sorrento or Merger Sub
nor any of the Affiliates or the Representatives of the foregoing is relying
on any representation or warranty except for those expressly set forth in
Article II, (b) no Person has been authorized by the Company or any of its
Affiliates to make any representation or warranty relating to the Company or
any of its businesses or operations or otherwise in connection with this
Agreement or the transactions contemplated hereby, and if made, such
representation or warranty must not be relied upon by Parent, Sorrento or
Merger Sub or any of the Affiliates or the Representatives of any of the
foregoing as having been authorized by the Company or any of its Affiliates
(or any other Person on behalf of the Company or Affiliates), and (c) any
estimate, projection, prediction, data, financial information,
memorandum, presentation or any other materials or information provided or
addressed to Parent, Sorrento or Merger Sub or any of the Affiliates or the
Representatives of any of the foregoing, including any materials or
information made available in the electronic data room hosted transactions
contemplated hereby or in connection with presentations by the Company's
management, are not and shall not be deemed to be or include representations
or warranties unless and to the extent any such materials or information is
the subject of any express representation or warranty set forth in Article
II; _provided_ , _however_ , none of the representations or warranties set
forth in this Section 3.6 shall apply to, or otherwise operate to limit the
liability of the Company or any other Person in respect of any claim or cause
of action based on or arising out of fraud.

  



  

Section 3.7 _Parent Shares_. The Parent Shares to be issued by
Parent as part of the Merger Consideration has been duly authorized, and upon
consummation of the Merger and the issuance of such shares pursuant to and in
accordance with the terms hereof, will be validly issued, fully paid and non-
assessable.

  



    

 | -53-| 
---|---|--- 

 



    



  

Section 3.8 _Litigation_. There are no Legal Proceedings pending
against Parent or Merger Sub or their respective properties, nor has Parent or
Merger Sub received written notice of any threat thereof, before any
Governmental Body. Neither Parent nor Merger Sub are parties to or subject to
the provisions of any order, writ, injunction, judgment or decree of any
Governmental Body.

  



  

Section 3.9 _Voting Agreement_. Parent is presently not under any
obligation and has not granted any rights to register under the Securities
Act any of its presently outstanding securities or any of its securities that
may hereafter be issued. To Parent's knowledge, except as contemplated in the
Voting Agreement, no stockholder of Parent has entered into any agreements
with respect to the voting of Parent Shares.

  



  

Section 3.10 _Affiliate Transactions_. All transactions pursuant to
which Sorrento or any of its Affiliates (other than Parent and its
Subsidiaries) has purchased any services, products, technology or
Intellectual Property Rights from, or sold or furnished any services,
products, technology or Intellectual Property Rights to, Parent and its
Subsidiaries have been on an arms-length basis on terms materially less
favorable to Parent and its Subsidiaries than would be available from an
unaffiliated party, nor are any Contracts which provide for any such
transactions following the date hereof currently in effect.

  



  

Section 3.11 _Sorrento Representations_. Sorrento represents and
warrants to the Company, as of the date of this Agreement and as of the
Closing Date, as set forth below:

  



  

(a) Sorrento is a corporation duly organized, validly existing and
in good standing (or equivalent status in the relevant jurisdiction)
under the laws of the jurisdiction of its incorporation, has all requisite
and necessary power and authority to perform its obligations hereunder.

  



  

(b) Sorrento has all requisite corporate power and authority to
enter into this Agreement, perform its obligations under this Agreement.
The execution and delivery of this Agreement and the consummation of the
transactions contemplated by this Agreement have been duly authorized by all
necessary corporate action on the part of Sorrento and no other corporate
action or proceeding on the part of Sorrento or its board of directors is
necessary to authorize the execution, delivery or performance of this
Agreement or any of the transactions contemplated by this Agreement. This
Agreement has been duly executed and delivered by Sorrento and
constitutes legal, valid and binding obligations of Sorrento, enforceable
against Sorrento in accordance with its terms, except as such
enforceability may be limited by (i) bankruptcy, insolvency, reorganization,
moratorium or other similar laws affecting or relating to creditors' rights
generally, and (ii) the availability of injunctive relief and other equitable
remedies.

  



  

(c) Neither the execution, delivery or performance by Sorrento of
this Agreement, nor the consummation of the Merger or any of the other
transactions contemplated by this Agreement, will (with or without notice or
lapse of time, or both) contravene, conflict with, or result in any violation
or breach of, any of the Organizational Documents of Sorrento.

  



    

 | -54-| 
---|---|--- 

 



    



  

(d) No Governmental Authorization, or registration, declaration,
notice or filing with, any Governmental Body is required by or with
respect to Sorrento in connection with the execution and delivery of this
Agreement or the consummation of the Merger or any of the other transactions
contemplated by this Agreement, except in each case for (a) any filings
required by applicable securities Laws and (b) such consents, waivers,
approvals, orders, authorizations, registrations, declarations and filings
which, if not obtained or made, would not reasonably be expected to be,
individually or in the aggregate, material to Sorrento.

  



  

Article IV 
 CERTAIN COVENANTS AND AGREEMENTS

  



  

Section 4.1 _Tax Matters_.

  



  

(a) _Tax Returns_. Parent shall prepare or cause to be prepared in
accordance with past practice (unless otherwise required by applicable Law)
and timely file or cause to be timely filed all Tax Returns for the Company
for all Tax periods ending on or prior to the Closing Date (" _Pre-Closing
Tax Periods_ ") that are due after the Closing Date. After the Closing,
Parent shall also prepare or cause to be prepared and timely file or cause to
be timely filed any Tax Returns of the Company for Tax periods that begin on
or before the Closing Date and end after the Closing Date (" _Straddle Tax
Periods_ "). Parent shall provide a draft of such income and other material
Tax Returns described in the two preceding sentences to the
Equityholders' Representative for review and comment at least thirty (30)
days prior to the due date for filing such Tax Returns. Parent shall consider
in good faith any such comments from the Equityholders' Representative, and
with respect to Tax Returns attributable any Pre-Closing Tax Period implement
the reasonable comments of the Equityholders' Representative. To the fullest
extent permitted by applicable Law, any Tax deductions arising from cash
payments made pursuant to Section 1.12 or payment of the Transaction Expenses
shall be treated as arising in Pre-Closing Tax Periods and shall be utilized,
along with any other net operating losses, net capital losses, research and
development, research and experimentation, investment or other Tax credits or
similar Tax assets and attributes of the Company that exist as of the Closing
Date, to reduce the liabilities of the Company for Pre-Closing Taxes.

  



  

(b) _Tax Refunds_. Except to the extent reflected in the
calculation of the Aggregate Closing Cash, any cash Tax refunds that are
actually received by Parent and/or the Surviving Corporation, and any credit
claimed in lieu of a cash Tax refund to which Parent or the Surviving
Corporation become entitled, that relate to a Pre-Closing Tax Period shall be
for the account of the Equityholders, and Parent shall pay over to the Paying
Agent (for further distribution to the Equityholders) any such refund or the
amount of any such credit within 15 days after receipt or entitlement
thereto; provided that payments to the Paying Agent (for further
distribution to the Equityholders) under this Section 4.1(b) shall be net of
(1) any reasonable out-of-pocket costs incurred in obtaining such refund of
Taxes, (2) any Tax required to be withheld on such payment, and (3) any Taxes
actually imposed on Parent and/or the Surviving Corporation as a result of
such refunds.

  



  

(c) _No Amendments_. After the Closing, Parent shall not, and shall
not cause or permit the Company to, (i) amend any Tax Returns filed with
respect to any Pre-Closing Tax Period, (ii) initiate requests for voluntary
disclosure relief with one or more Governmental Body relating to any Pre-
Closing Tax Period or (iii) make any Tax election that has retroactive effect
to any Pre-Closing Tax Period, in each case without the prior written consent
of the Equityholders' Representative, which consent shall not be
unreasonably withheld, conditioned or delayed.

  



    

 | -55-| 
---|---|--- 

 



    



  

(d) _Cooperation on Tax Matters_. The parties shall reasonably
cooperate as and to the extent reasonably requested by the other party, in
connection with the filing of Tax Returns pursuant to this Section 4.1 and
any audit, litigation or other proceeding with respect to Taxes for any Pre-
Closing Tax Periods or Straddle Tax Periods. Such cooperation shall include
the retention and (upon the other party's request, cost and expense) the
provision of records and information that are reasonably relevant to any such
audit, litigation or other proceeding and making employees or agents
available on a mutually convenient basis to provide additional information
and explanation of any material provided under this Section 4.1(d).

  



  

(e) _Tax Contests_. After the Closing, Parent and the Company shall
promptly inform the Equityholders Representative in writing of
the commencement of any claim, audit, investigation, examination, or other
proceeding relating in whole or in part to Taxes for a Pre-Closing Tax Period
for which any Indemnified Party may be entitled to indemnification from the
Equityholders under this Agreement (" _Tax Contest_ "). After the Closing
Date, Parent shall have the exclusive right to represent the interests of
Company in any and all Tax Contests; _provided, however_ , that the
Equityholders Representative shall have the right to participate in any such
Tax Contest and to employ counsel (at the expense of the Equityholders) of its
choice (which counsel shall be reasonably acceptable to Parent) for purposes
of such participation. In the event that Parent proposes to compromise or
settle any Tax Contest, or consent or agree to any Tax liability in
connection with a Tax Contest, relating to the Company that would result in an
indemnification obligation by the Equityholders, the Equityholders
Representative shall have the right to review such proposed compromise,
settlement, consent or agreement. Parent shall not agree or consent to
compromise or settle any Tax Contest on a basis that would result in a Tax
liability of the Company for a Pre-Closing Tax Period or liability of the
Equityholders for indemnification under this Agreement unless the
Equityholders Representative consents to such settlement, compromise or
concession, which consent shall not be unreasonably withheld, conditioned or
delayed.

  



  

(f) _Transfer Taxes_. Any Taxes or recording fees payable as a
result of the purchase and sale of the Company Common Shares or any other
action contemplated by this Agreement (other than any federal, state, local
or foreign Taxes measured by or based upon income or gains imposed upon
Parent) shall be borne equally by (i) the Stockholders on the one hand, and
(ii) Parent, on the other. The parties shall reasonably cooperate in the
preparation, execution and filing of all returns, questionnaires, applications
and other documents regarding Taxes and all transfer, recording, registration
and other fees that become payable in connection with the
transactions contemplated by this Agreement that are required or permitted to
be filed at or prior to the Closing.

  



  

(g) _Termination of Tax Allocation, Indemnity or Sharing
Agreements_. Before or in connection with the Closing, any Tax allocation,
indemnity or sharing agreement between the Company and any other Person shall
be terminated as to the Company on or prior to the Closing Date, and after
the Closing Date neither the Company nor Parent shall have any liability
thereunder.

  



    

 | -56-| 
---|---|--- 

 



    



  

(h) _Taxes for a Straddle Tax Period_. In the case of any Taxes
that are imposed for a Straddle Tax Period, the portion of such Tax
that relates to the portion of such taxable period ending on the Closing Date
shall (i) in the case of any Taxes other than Taxes based upon or related to
income or receipts, be deemed to be the amount of such Tax for the entire Tax
period multiplied by a fraction the number of which is the number of days in
the Tax period ending on and including the Closing Date and the denominator of
which is the number of days in the entire Tax period and (ii) in the case of
any Tax based upon or related to income or receipts be deemed equal to the
amount that would be payable if the relevant Tax period ended at the end of
the Closing Date.

  



  

(i) _Closing of the Company Tax Year_. The parties acknowledge that
the taxable year of the Company will end for U.S. federal income tax purposes
at the end of the day on the Closing Date pursuant to Treasury Regulations
Section 1.1502-76(b) by reason of Parent including the Company on Parent's
U.S. federal consolidated income Tax Return beginning on the day after the
Closing Date.

  



  

(j) _Closing of the Company Tax Year_. The parties acknowledge that
the taxable year of the Company will end for U.S. federal income tax purposes
at the end of the day on the Closing Date pursuant to Treasury Regulations
Section 1.1502-76(b) by reason of Parent including the Company on Parent's
U.S. federal consolidated income Tax Return beginning on the day after the
Closing Date.

  



  

(k) _Tax Treatment_. The parties intend that the Merger will be in
connection with, and pursuant to the same plan as, the contribution of shares
of capital stock of Scilex to Parent such that one hundred percent (100%) of
such shares of Scilex have been contributed to Parent (the " _Contribution_
") by the stockholders of Scilex. Parent, Merger Sub, Sorrento and the
Company intend that the Contribution, together with the Merger contemplated
herein, will qualify as a transaction governed by Section 351 of the Code.

  



  

Section 4.2 _Legends_. Each book-entry security entitlement
representing any Parent Shares (or any other securities issued in respect of
such shares upon any stock split, stock dividend, recapitalization, merger,
consolidation or similar event) issued to or held by any Equityholder in
accordance with the terms hereof or the Escrow Agreement shall bear the
following legends (in addition to any other legends required by law, Parent's
certificate of incorporation, Parent's bylaws or any other agreement to which
such Equityholder is a party):

  



  

THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE
SECURITIES ACT OF 1933, AS AMENDED (THE " _ACT_ "), OR UNDER THE
SECURITIES LAWS OF ANY STATE. THESE SECURITIES ARE SUBJECT TO RESTRICTIONS ON
TRANSFERABILITY AND RESALE AND MAY NOT BE TRANSFERRED OR RESOLD EXCEPT AS
PERMITTED UNDER THE ACT AND APPLICABLE STATE SECURITIES LAWS, PURSUANT TO
REGISTRATION OR EXEMPTION THEREFROM. INVESTORS SHOULD BE AWARE THAT THEY MAY
BE REQUIRED TO BEAR THE FINANCIAL RISKS OF THIS INVESTMENT FOR AN INDEFINITE
PERIOD OF TIME. THE ISSUER OF THESE SECURITIES MAY REQUIRE AN OPINION OF
COUNSEL IN FORM AND SUBSTANCE SATISFACTORY TO THE ISSUER TO THE EFFECT
THAT ANY PROPOSED TRANSFER OR RESALE IS IN COMPLIANCE WITH THE ACT AND ANY
APPLICABLE STATE SECURITIES LAWS.

  



    

 | -57-| 
---|---|--- 

 



    



  

This legend shall be removed by Parent from any book-entry security
entitlement evidencing Parent Shares upon delivery by the holder thereof to
Parent of a written request to that effect if at the time of such written
request (a) a registration statement under the Securities Act is at that time
in effect with respect to the legended security or (b) the legended security
can be transferred in a transaction in compliance with Rule 144 under the
Securities Act, and, in the case of (b), upon the request of Parent, the
holder of such Parent Shares (x) executes and delivers a representation
letter that includes customary representations regarding the holding
requirements and whether such holder is an "affiliate" for purposes of Rule
144 under the Securities Act, and/or (y) secures the delivery to Parent of an
opinion by counsel, in form and substance reasonably satisfactory to Parent,
that such security can be freely transferred in a public sale without
registration pursuant to an available exemption from the registration
requirements of the Securities Act and that such transfer will not jeopardize
the exemption or exemptions from registration pursuant to which Parent issued
the Parent Shares.

  



  

Section 4.3 _Stockholder Approvals; Notice to Stockholders_.

  



  

(a) Within two (2) hours after the execution of this Agreement, the
Company shall deliver to Parent duly executed Stockholder Written
Consents from Stockholders pursuant to such solicitation that are sufficient
to fully and irrevocably deliver the Required Company Stockholder Vote. The
Company shall ensure that the Stockholder Written Consents are obtained in
compliance with, and are valid and effective under, Section 228 of the DGCL
and the Organizational Documents of the Company.

  



  

(b) Contemporaneously with the Closing, the Company shall deliver to
each Stockholder that did not execute and deliver a Stockholder Written
Consent the notice required by Section 228(e) of the DGCL, which notice shall
include the notice to stockholders required by Section 262 of the DGCL (and
under any other applicable Law regarding appraisal rights of stockholders) of
the approval of the Merger and that appraisal rights are available.

  



  

Section 4.4 _Director and Officer Indemnification_.

  



  

(a) From and after the Effective Time, and until the sixth (6th)
anniversary of the Effective Time, Parent shall cause the Surviving
Corporation to fulfill and honor in all respects the obligations of the
Company to Persons who on or prior to the Effective Time are or
were directors and/or officers of the Company (the " _Company Indemnified
Parties_ ") pursuant to any indemnification, exculpation and advancement
provisions under the Organizational Documents of the Company as in effect on
the date hereof and pursuant to any indemnification agreements between the
Company and such Company Indemnified Parties existing as of the date hereof,
in each case, to the extent true and complete copies of which have been made
available to Parent prior to the date hereof, with respect to claims arising
out of matters occurring at or prior to the Effective Time; _provided,
however_ , the foregoing obligations shall be subject to any limitation
imposed by applicable Law. In addition, during the period commencing at the
Effective Time and ending on the sixth (6th) anniversary of the Effective
Time, the Surviving Corporation shall (and Parent shall cause the
Surviving Corporation to) cause the Organizational Documents of the Surviving
Corporation to contain provisions with respect to
indemnification, exculpation and the advancement of expenses that are at
least as favorable as the indemnification, exculpation and advancement of
expenses provisions contained in the Organizational Documents of the Company
as of the date hereof, and during such six (6)-year period, such provisions
shall not be repealed, amended or otherwise modified in any manner except as
required by applicable Law.

  



    

 | -58-| 
---|---|--- 

 



    



  

(b) The Company has purchased a six (6)-year "tail" fully prepaid
directors' and officers' liability insurance policy which covers only those
persons who are currently covered by the Company's existing directors' and
officers' liability insurance policy in effect as of the date hereof and only
for matters occurring at or prior to the Effective Time (a " _D andO Tail
Policy_"). The Surviving Corporation shall (and Parent shall cause the
Surviving Corporation to) maintain such DandO Tail Policy in full force and
effect and continue to honor their respective obligations thereunder. To the
extent doing so would not conflict with the DandO Tail Policy, the Company
Indemnified Parties shall seek recovery from the DandO Tail Policy (if and to
the extent such recovery is available at such time) prior to seeking recourse
from Parent or the Surviving Corporation.

  



  

(c) If Parent or the Surviving Corporation or any of its successors
or assigns shall (i) consolidate with or merge into any other Person and
shall not be the continuing or surviving corporation or entity of such
consolidation or merger, or (ii) transfer all or substantially all of its
properties and assets to any Person, then, and in each such case, proper
provisions shall be made so that the successors and assigns of the Surviving
Corporation shall assume all of the obligations of Parent and the Surviving
Corporation set forth in this Section 4.4.

  



  

(d) Each of the Company Indemnified Parties (and their heirs and
representatives) are intended to be third party beneficiaries of this
Section 4.4, with full rights of enforcement as if a party thereto. The
rights of the Company Indemnified Parties (and their heirs
and representatives) under this Section 4.4 shall be in addition to, and not
in substitution for, any other rights that such persons may have under the
certificates of incorporation, bylaws or other equivalent organizational
documents, any and all indemnification agreements of or entered into by the
Company disclosed in the Disclosure Schedule, or applicable Law (whether at
law or in equity).

  



  

(e) Nothing in this Agreement is intended to, shall be construed to
or shall release, waive or impair any rights to insurance claims under any
policy that is or has been in existence with respect to the Company for any of
their respective directors, officers or other employees, it being understood
and agreed that the obligations provided for in this Section 4.4 is not prior
to or in substitution for any such claims.

  



  

Section 4.5 _Spreadsheets_. The parties hereto agree that the "
_Closing Spreadsheet_ " shall be a spreadsheet in a form reasonably
acceptable to Parent, which shall include the following information as of the
Closing:

  



    

 | -59-| 
---|---|--- 

 



    



  

(a) the calculation of (A) the Initial Merger Consideration
(including the components thereof), (B) the Aggregate Available Parent
Shares, (C) the Initial Cash Amount, (D) the Initial Stock Amount, (E) the
Preference Cash Amount, (F) the Preference Stock Amount, (G) the
Participation Cash Amount, (H) the Participation Stock Amount, (I) the Fully
Diluted Capital Number, (J) the Fully Diluted Common Number, (K) the Per
Share Cash Preference, (L) the Per Share Stock Preference, (M) the Per Share
Cash Participation, (N) the Per Share Stock Participation, (O) the Initial
Escrow Shares, (P) the number of Initial Escrow Shares be deposited in the
General Escrow Fund in accordance with Section 1.10(a), and (Q) the amount of
cash to be deposited in the Expense Fund;

  



  

(b) (A) with respect to each Equityholder (x) the name, address,
email address (if available) and tax identification number (if available) of
such Equityholder, and (y) indication whether such Equityholder is, to the
Company's Knowledge, an "accredited investor" as defined in Rule 501(a) of
Regulation D promulgated under the Securities Act, (B) with respect to each
Stockholder, the number, class and series of shares of Company Shares held by
such Stockholder (listed on a certificate-by-certificate basis),
the respective certificate numbers and the date of acquisition of such shares
and (C) with respect to each Company Optionholder, the number of Company
Options (including whether vested or unvested) held by such Company
Optionholder and the exercise price of each such Company Option;

  



  

(c) with respect to each Equityholder, the aggregate portion of the
Initial Cash Amount such Equityholder is entitled to receive pursuant to each
of, as applicable, (A) Section 1.5(c)(i), (B) Section 1.5(c)(iii), (C) Section
1.5(d)(i) and (D) Section 1.12(a)(ii); and

  



  

(d) with respect to each Equityholder, the aggregate portion of the
Initial Stock Amount expressed in Parent Shares such Equityholder is entitled
to receive pursuant to each of, as applicable, (A) Section 1.5(c)(ii), (B)
Section 1.5(c)(iv), (C) Section 1.5(d)(ii) and (D) Section 1.12(a)(i).

  



  

Article V 
 COMPANY CLOSING DELIVERABLES

  



  

Section 5.1 _Ancillary Agreements and Deliveries_. At the Closing,
the Company shall deliver, or cause to be delivered, to Parent the following
agreements and documents:

  



  

(a) a certificate, dated as of the Closing Date, signed by the
Secretary of the Company, (i) attaching copies of the Organizational
Documents of the Company, and any amendments thereto, of the Company, (ii)
certifying that attached thereto are true, correct and complete copies of
actions by written consent or resolutions duly adopted by the board of
directors of the Company which adopt this Agreement and authorize and approve
the execution, delivery and performance of this Agreement and the consummation
of the Merger and the other transactions contemplated by this Agreement and
(iii) certifying that attached thereto are true, correct and complete
copies of actions by written consent or resolutions duly adopted by the
Stockholders constituting the Required Company Stockholder Vote which adopt
this Agreement and authorize and approve the execution, delivery and
performance of this Agreement and the consummation of the Merger and the
other transactions contemplated by this Agreement;

  



    

 | -60-| 
---|---|--- 

 



    



  

(b) a long-form certificate of good standing from the Secretary of
State of the State of Delaware which is dated within two (2) Business Days
prior to Closing with respect to the Company;

  



  

(c) a certificate in such form as may be reasonably requested by
counsel to Parent that complies with Treasury Regulation Section
1.1445-2(c)(3), accompanied by any appropriate notice to be delivered to the
Internal Revenue Service pursuant to Treasury Regulations Section 1.897-2(h);

  



  

(d) evidence, in form and substance reasonably satisfactory to
Parent, that each consent, approval or waiver set forth on Schedule 5.1(d)
has been obtained or made and is in full force and effect;

  



  

(e) a true, correct and complete copy of resolutions adopted by the
board of directors of the Company authorizing the termination of each of the
Company Options in order to give effect to the transactions contemplated by
this Agreement;

  



  

(f) the Charter Amendment, duly executed by the Company;

  



  

(g) the Certificate of Merger, duly executed by the Company;

  



  

(h) an Investor Questionnaire executed by each Equityholder that is
indicated as an "accredited investor" in the Closing Spreadsheet;

  



  

(i) a Disqualification Questionnaire executed by each Equityholder
that is, or is contemplated by the transactions hereby to become, a director,
officer, promoter of Parent or beneficial owner of 20% or more of the Parent
Shares;

  



  

(j) a Joinder Agreement duly executed by each Stockholder holding
greater than one-fourth of one percent (0.25%) of the Fully Diluted Capital
Number and Equityholders holding in the aggregate not less than ninety-five
percent (95%) of the Fully Diluted Capital Number (collectively, the "
_Joinder Agreements_ ");

  



  

(k) the Escrow Agreement, signed by the Equityholders'
Representative;

  



  

(l) the Closing Spreadsheet;

  



  

(m) evidence reasonably satisfactory to Parent that all amounts owed
to the Company by any Stockholder, any holder of a Company Option, any holder
of Company Rights or any Related Party at and as of the Closing Date, any
debts of the Company owed to any Stockholder, any holder of a Company Option,
any holder of Company Rights (in each case other than as provided for in
Article I) or any Related Party, have been paid and canceled;

  



  

(n) a statement, reasonably detailed, including wire instructions,
and separated by lender, setting forth the Closing Indebtedness (the "
_Closing Indebtedness Statement_ ");

  



    

 | -61-| 
---|---|--- 

 



    



  

(o) a statement, reasonably detailed, including wire instructions,
and separated by lender, setting forth the Closing Transaction Expenses (the
" _Closing Transaction Expenses Statement_ ");

  



  

(p) evidence reasonably satisfactory to Parent that all Liens (other
than Permitted Liens) set forth on Schedule 5.1(p) have been released or will
be released upon Closing;

  



  

(q) a true, correct and complete copy of resolutions adopted by the
board of directors of the Company authorizing the termination of each of the
Employee Plans set forth on Schedule 5.1(o), which termination shall be
effective as of one day prior to the Closing;

  



  

(r) evidence satisfactory to Parent that all agreements and
arrangements set forth on Schedule 5.1(r) have been terminated effective as of
the Closing Date without any further obligation of, or liability to, the
Company, Parent or their affiliates;

  



  

(s) an Exchange and Registration Rights Agreement in the form
attached hereto as Exhibit H (the " _Exchange Agreement_ ") duly executed by
each Equityholder that is receiving Parent Shares pursuant to Section 1.5 and
Section 1.12; and

  



  

  

(t) an executed payoff letter in form and substance reasonably
satisfactory to Parent from each Person receiving payment in respect
of Closing Indebtedness pursuant to Section 1.8(i).

    

  



  

Article VI 
 Parent Closing Deliverables

  



  

Section 6.1 _Ancillary Agreements and Deliveries_. Parent shall
have delivered, or caused to be delivered, to the Company or the
Equityholders' Representative:

  



  

(a)  the Escrow Agreement, duly executed by Parent and the Escrow
Agent;

  



  

(b) the voting agreement, in the form attached hereto as Exhibit H
(the " _Voting Agreement_ "), duly executed by parties thereto, and evidence
reasonably satisfactory to the Company that Parent has taken all actions
necessary to appoint the designees set forth in Section 2.2 thereof as
members of the directors of Parent as of immediately following the Closing;

  



  

(c) evidence to the Company that the transactions contemplated by
the Contribution and Loan Agreement have been, or concurrently with the
Closing will be, effected; and

  



  

  

  

(d) The Exchange Agreement duly executed by Parent and Sorrento.

  



    

    

 | -62-| 
---|---|--- 

 



    



  

Article VII 
 TERMINATION

  



  

Section 7.1 _Termination Events_.

  



  

(a) This Agreement may be terminated prior to the Closing:

  



  

(i) by mutual written consent of Parent and the Company; or

  



  

(ii) by written notice from Parent to the Company, if no later than
twenty-four (24) hours following the execution and delivery of this Agreement
by all of the parties hereto the Company shall not have delivered to Parent
evidence that this Agreement has been adopted by Stockholders constituting
the Required Company Stockholder Vote; _provided_ , that this termination
right shall terminate if this Agreement has not been terminated prior to the
time that the Required Company Stockholder Vote is obtained.

  



  

(b) In the event of termination of this Agreement pursuant to this
Article VIII, this Agreement shall forthwith become void and there shall be
no liability on the part of any party to this Agreement or its partners,
officers, directors, stockholders, members or other equity holders, except
for obligations under Section 10.1 (Fees and Expenses), Section 10.2 (Waiver;
Amendment), Section 10.3 (Entire Agreement), Section 10.4 (Execution of
Agreement; Counterparts; Electronic Signatures), Section 10.5 (Governing
Law; Arbitration; Venue), Section 10.6 (WAIVER OF JURY TRIAL), Section 10.7
(Assignment and Successors), Section 10.9 (Notices), Section 10.10
(Construction; Usage), Section 10.11 (Enforcement of Agreement), Section 10.12
(Severability) and this Section 7.1, and the definitions used in each of the
foregoing sections, including those set forth in Exhibit A hereto, all of
which shall survive such termination; _provided, however_ , that nothing
contained in this Section 7.1(b) shall relieve any party from liability for
fraud or any willful and knowing breach of this Agreement. Upon termination
of this Agreement, each of the parties to this Agreement shall, in all
events, be bound by and be subject to the Confidentiality Agreements.

  



  

Article VIII 
 Indemnification

  



  

Section 8.1 _Indemnification Obligations of the Equityholders_.

  



  

(a) The Equityholders (collectively, the " _Indemnifying Parties_
"), severally and not jointly in accordance with their Indemnification Pro
Rata Shares, shall indemnify Parent and its Affiliates (including the Company
after the Closing) and each of their stockholders, partners, Representatives,
successors and assigns (collectively, the " _Indemnified Parties_ ") and save
and hold each of them harmless against and pay on behalf of or reimburse such
Indemnified Parties as and when incurred for any loss, liability, cost,
damage, deficiency, Tax, penalty, fine or expense, whether or not arising out
of a third-party demand, claim, action or cause of action (including (A)
interest, penalties, reasonable attorneys' fees and expenses and (B)
all settlement amounts and reasonable amounts paid in investigation or
defense of any of the foregoing, in each case, that have been incurred in
accordance with Section 8.3 (and for the avoidance of doubt, subject to the
limitations on settlements set forth in Section 8.3)) (collectively, subject
to the limitations in Section 8.2(h), " _Losses_ "), which any
such Indemnified Party may suffer, sustain or become subject to, as a result
of, in connection with, arising out of, relating or incidental to or by
virtue of:

  



    

 | -63-| 
---|---|--- 

 



    



  

(i) any inaccuracy in or breach of any representation or warranty of
the Company set forth in this Agreement (it being agreed that materiality and
"Material Adverse Effect" qualifications in any representation or warranty
shall be taken into account in determining whether an inaccuracy in such
representation or warranty exists, but once it is determined that any such
inaccuracy or breach exists, shall not be taken into account in determining
the amount of any Losses with respect to such inaccuracy or breach);

  



  

(ii) [Intentionally omitted];

  



  

(iii) any and all claims (A) by any Stockholder or Company
Optionholder relating to or arising out of the transactions contemplated
hereby, including the allocation of the Merger Consideration relating to or
(B) by any Person asserting, alleging or seeking to assert any right arising
at or prior to the Closing with respect to Company Shares, Company Options or
Company Indebtedness (together, " _Company Securities_ "), including any
claim asserted, based upon or related to the following with respect to
matters occurring at or prior to the Closing: (1) the ownership or rights to
ownership of any Company Securities, (2) any rights of a securityholder or
creditor of the Company, including any rights to securities, preemptive
rights, rights to notice or to vote securities, (3) any rights under the
Organizational Documents of the Company and (4) any claim that any Person's
equity securities were wrongfully repurchased by the Company, in each case
(without limiting the indemnity under Section 8.1(a)(iv)), other than the
right of any Equityholder to receive the consideration set forth in this
Agreement;

  



  

(iv) any inaccuracy in the Closing Spreadsheet or allocation of a
Milestone Payment by (or on behalf of) the Equityholders'
Representative, including any inconsistency of such spreadsheet or payment
with respect to the certificate of incorporation of the Company;

  



  

(v) any fraud on the part of the Company, any Equityholder or any
Representative of the foregoing, in each case, in connection with
the transactions contemplated in this Agreement;

  



  

(vi) any Pre-Closing Taxes; and

  



  

(vii) the exercise by any stockholder of the Company of such
stockholder's appraisal rights under the DGCL or the CCC (or under any other
any applicable Law) for any amount in excess of what is payable by Parent in
accordance with Section 1.5.

  



  

Section 8.2 _Limitations on Indemnification_.

  



  

(a) Notwithstanding any provisions of this Agreement to the
contrary, other than with respect to the Fundamental Representations and the
Specified IP Representations, the Indemnifying Parties shall not have any
liability or obligation under Section 8.1(a)(i) unless the
aggregate liability for Losses suffered by the Indemnified Parties thereunder
exceeds $300,000, in which case the Indemnified Parties shall be entitled to
recover all Losses (subject to the other limitations herein).

  



    

 | -64-| 
---|---|--- 

 



    



  

(b) Notwithstanding any provisions in this Agreement to the
contrary, other than as provided for in clause (ii) of the proviso in Section
8.2(d), (i) the Indemnifying Parties' aggregate liability and obligations
under Section 8.1(a)(i), other than with respect to any inaccuracy or breach
of a Fundamental Representation or the Specified IP Representations (such
matters described in this clause (i) are referred to collectively as the "
_General Indemnification Matters_ "), shall be limited to recovery by the
Indemnified Parties against the amount then available in the General Escrow
Fund plus, to the extent claims for Fundamental Indemnification Matters that
have been satisfied in accordance with this Agreement by reducing the General
Escrow Fund on or prior to the Final Escrow Release Date (such reduction in
the aggregate, the " _Fundamental Matter Escrow Amount_ "), an
additional amount equal to the Fundamental Matter Escrow Amount (it being
understood, for the avoidance of doubt, that (x) all indemnification claims
for General Indemnification Matters that are satisfied outside the General
Escrow Fund (whether directly by the Equityholders or pursuant to the setoff
rights in Section 8.6) shall be counted towards and reduce the Fundamental
Matter Escrow Amount, and (y) claims for General Indemnification Matters
shall still be subject, when viewed in the aggregate, to a cap equal to the
aggregate amount of General Escrow Property placed in the General Escrow Fund
prior to the expiration of the Final Escrow Period and prior to any reduction
thereof, valuing the Parent Shares at the Parent Stock Price) and (ii) each
Indemnifying Party's aggregate liability and obligations under this Article
VIII shall not exceed the portion of the Merger Consideration actually
received by such Indemnifying Party (in addition to the forfeiture of the
portion of the Merger Consideration paid to the Indemnified Parties from the
General Escrow Fund, the Designated Escrow Fund or through the exercise of the
setoff rights set forth in Section 8.6) (with the Parent Shares being valued
at the Parent Stock Price). All indemnification obligations under Section
8.1(a) that are not General Indemnification Matters or Specified IP Matters
are referred to herein as " _Fundamental Indemnification Matters_ ". The
Specified IP Matters and the Fundamental Indemnification Matters are
collectively referred to herein as the " _Designated Indemnification
Matters_."

  



  

(c) Notwithstanding any provisions in this Agreement to the
contrary, other than as provided for in clause (ii) of the proviso in Section
8.2(d), the Indemnifying Parties' aggregate liability and obligations under
Section 8.1(a)(i) with respect to the Specified IP Matters, shall be limited
to the setoff rights of the Indemnified Parties set forth in Section 8.6 and
recovery from amounts held in the Designated Escrow Fund.

  



  

(d) Notwithstanding any provisions of this Agreement to the
contrary, the indemnification for Losses pursuant to this Article VIII
(subject to the limitations set forth herein) shall be the sole and exclusive
remedy of the Indemnified Parties from and after the Effective Time for any
claims or Losses arising under this Agreement or in connection with the
transactions contemplated by this Agreement, including claims of any
inaccuracy in or breach of any representation, warranty or covenant in this
Agreement; _provided_ ,  _however_ , that (i) this Section 8.2(d) shall not
be deemed a waiver by any party of any right to specific performance
or injunctive relief and (ii) nothing in this Agreement shall limit any
Indemnifying Party's liability for fraud committed by such Indemnifying Party
in connection with this Agreement or the transactions contemplated by this
Agreement.

  



    

 | -65-| 
---|---|--- 

 



    



  

(e) Notwithstanding any provisions of this Agreement to the
contrary, from and after the Effective Time, the Indemnified Parties shall not
be entitled to double recovery pursuant to this Article VIII for any
adjustments to the Merger Consideration provided for hereunder or for any
prior indemnifiable matter pursuant to this Article VIII to the extent they
have been previously satisfied.

  



  

(f) Notwithstanding anything to the contrary contained herein, the
Company is not making and shall not be construed to have made, and the
Equityholders shall not have any liability or obligation (i) with respect to,
any representation or warranty as to the amount of, or any
Indemnified Party's ability to use after the Closing Date, any net operating
losses, Tax credits, Tax basis or other Tax attribute, (ii) for any Taxes
resulting from any election made under Section 338 of the Code (or any similar
or analogous provision of Tax law) with respect to the Merger, or (iii) for
any Taxes resulting from any action outside the ordinary course of business
and not specifically contemplated by this Agreement taken by the Company or
Parent after the Closing on the Closing Date.

  



  

(g) All Losses for which any Indemnified Party would otherwise be
entitled to indemnification under this Article VIII shall be reduced by the
net amount of insurance proceeds or other third party recoveries to which any
Indemnified Party actually recovers in respect of any Losses incurred by such
Indemnified Party (net of any costs of recovery and any increased premiums
resulting therefrom). In the event that any such insurance proceeds or other
third party recoveries are actually recovered by an Indemnified Party
subsequent to receipt by such Indemnified Party of any indemnification
payment hereunder in respect of the claims to which such insurance proceeds
or other third-party recoveries relate, then such amounts recovered (net of
any costs of recovery and any increased premiums resulting therefrom and up
to the amount first recovered by the Indemnified Parties) shall be paid
promptly by the relevant Indemnified Parties to the Indemnifying Parties (or,
if such indemnification payments were paid from the General Escrow Fund or the
Designated Escrow Fund and such refund becomes payable pursuant to this
Section 8.2(g) prior to the release of such fund, to the General Escrow Fund
or the Designated Escrow Fund).

  



  

(h) Under no circumstances shall any Indemnified Party be entitled
to indemnification or set-off pursuant to this Article VIII, and "Losses"
shall not include, any special, punitive, exemplary, consequential, or similar
damages, unless such special, punitive, exemplary, consequential or similar
damages are owed to a non-Affiliated third party.

  



  

(i) To the extent required by applicable Law, Parent shall (and
shall cause each Indemnified Party to) use its commercially
reasonable efforts to mitigate all Losses after becoming aware of any event
which may give rise to any Losses in respect of which the Indemnified Party
may be entitled to indemnification pursuant to this Article VIII.

  



    

 | -66-| 
---|---|--- 

 



    



  

Section 8.3 _Indemnification Procedure_.

  



  

(a) Promptly following receipt by an Indemnified Party of notice by
a third party that is not an Indemnified Party (including any
Governmental Body) of any complaint, dispute or claim or the commencement of
any audit, investigation, action or proceeding with respect to which such
Indemnified Party may be entitled to indemnification pursuant to this Article
VIII (a " _Third-Party Claim_ "), such Indemnified Party shall provide
written notice thereof to the Equityholders' Representative (a " _Notice of
Third-Party Claim_ "), describing in reasonable detail the facts and
circumstances with respect to the subject matter of such complaint, dispute,
claim, audit, investigation action or proceeding; _provided, however_ ,
that the failure to so provide a Notice of Third-Party Claim to the
Equityholders' Representative shall relieve the Indemnifying Party from
liability under this Article VIII with respect to such Third-Party Claim only
if, and only to the extent that, such failure to so provide a Notice of
Third-Party Claim to the Equityholders' Representative materially prejudices
the rights and defenses otherwise available to the Indemnifying Party with
respect to such Third-Party Claim. The Indemnified Party shall provide
reasonable cooperation with the Equityholders' Representative in connection
with such the Third-Party Claim, including, in cases in which Parent or the
Surviving Corporation is the Indemnified Party, by providing the
Equityholders' Representative with reasonable access to books, records,
employees and officers (including as witnesses) of Parent or the Surviving
Corporation.

  



  

(b) The Indemnifying Party shall have the right, upon written notice
from the Equityholders' Representative delivered to the Indemnified Party
within thirty (30) days of receipt of the applicable Notice of Third-Party
Claim acknowledging and agreeing to the Indemnifying Party's obligation to
indemnify the Indemnified Parties under this Article VIII in respect of such
Third-Party Claim, to assume the defense of such Third-Party Claim, including
the employment of counsel reasonably satisfactory to the Indemnified
Party and the payment of the fees and disbursements of such counsel;
_provided_ , _however_ , that the Indemnifying Party shall not have the right
to assume the defense of any Third-Party Claim that (i) affects any
Intellectual Property Rights that the Company owns or has a right to use in
the conduct of its business as currently conducted and as proposed to be
conducted by the Company as of the Closing and by Parent after the Closing,
(ii) is asserted directly by or on behalf of any Person that is a supplier
or a customer of the Company, the Indemnified Party or their Affiliates,
(iii) seeks an injunction or other equitable relief against the Indemnified
Party or its Affiliates, (iv) involves a finding of any violation of Law or
other wrongdoing by the Indemnified Party, the Company or their Affiliates,
(v) relates to or arises in connection with any criminal proceeding, action,
indictment, allegation or investigation, or (vi) does not seek only monetary
damages and, in the case of this clause (vi), the Indemnified Party
reasonably believes an adverse determination with respect to the Third-
Party Claim would be detrimental to or materially injure the reputation or
future business prospects of the Indemnified Party. In the event, however,
that the Indemnifying Party declines or fails to assume the defense of such
Third-Party Claim on the terms of this Section 8.3(b) or to employ counsel
reasonably satisfactory to the Indemnified Party, in either case within such
thirty (30) day period, or thereafter defaults in continuing to defend the
Indemnified Party, then the Indemnified Party shall thereafter have the right
to assume the defense of such Third-Party Claim.

  



  

(c) In any Third-Party Claim for which indemnification is being
sought under this Article VIII, the Indemnified Party or the
Indemnifying Party, whichever is not assuming the defense of such Third-Party
Claim, shall have the right to participate in such matter and to retain its
own counsel at such party's own expense. Notwithstanding anything to the
contrary herein, if the Indemnifying Party is assuming the defense of such
Third-Party Claim and there are one or more legal or equitable defenses
available to the Indemnified Party that are different from or in addition to
those available to the Indemnifying Party or if the Indemnified Party is
advised by counsel that a reasonable likelihood exists of a conflict of
interest between the Indemnified Party and the Indemnifying Party with
respect to the subject matter of such Third-Party Claim, then the Indemnified
Party may employ separate counsel. The Indemnifying Party or the Indemnified
Party (as the case may be) shall at all times use reasonable efforts to keep
the Equityholders' Representative or Indemnified Party (as the case may be)
reasonably apprised of the status of the defense of any matter, the
defense of which it is maintaining, and to cooperate in good faith with the
other party with respect to the defense of any such matter.

  



    

 | -67-| 
---|---|--- 

 



    



  

(d) Subject to the limitations set forth in Schedule 8.3(d), any
settlement or compromise of any Third-Party Claim or consent to the entry of
any judgment with respect to which indemnification is being sought under this
Article VIII by the Indemnified Party without the prior written consent of
the Equityholders' Representative (or, in the event indemnification is being
sought hereunder directly from an Equityholder, such Equityholder), which
consent shall not be unreasonably withheld, conditioned or delayed, shall not
be determinative of whether the Indemnified Party has the right to be
indemnified pursuant to this Article VIII, or the amount of Losses
recoverable in respect of such matter. An Indemnifying Party may not, without
the prior written consent of the Indemnified Party, settle or compromise any
Third-Party Claim or consent to the entry of any judgment with respect to
which indemnification is being sought under this Article VIII unless such
settlement, compromise or consent (i) includes an unconditional release of
the Indemnified Party and its officers, directors, employees and Affiliates
from all liability arising out of, or related to, such Third-Party Claim,
(ii) does not contain any admission or statement suggesting any wrongdoing or
liability on behalf of the Indemnified Party, and (iii) does not contain any
equitable order, judgment or term that in any manner affects, restrains or
interferes with the business of the Indemnified Party or any of the
Indemnified Party's Affiliates.

  



  

(e) In the event an Indemnified Party claims a right to payment
pursuant to this Article VIII with respect to any Loss not involving a Third-
Party Claim (a " _Direct Claim_ "), such Indemnified Party shall send written
notice of such claim to the Equityholders' Representative (and in the event
that recourse is being sought hereunder directly from an Indemnifying Party,
such Indemnifying Party) (a " _Notice of Direct Claim_ "). Such Notice of
Direct Claim shall specify the basis for such Direct Claim. In the event the
Equityholders' Representative does not notify the Indemnified Party
within thirty (30) days following its receipt of such Notice of Direct Claim
that the Equityholders' Representative disputes the Indemnifying Parties'
liability to the Indemnified Party under this Article VIII and, if stated in
such Notice of Direct Claim, the amount thereof, the Equityholders'
Representative shall be deemed to have consented to the Direct Claim
solely to the extent that such claim is made against the amounts held in the
General Escrow Fund, the Designated Escrow Fund or satisfied through the
exercise of the setoff rights set forth in Section 8.6. In the event the
Equityholders' Representative (or in the event that recourse is being sought
hereunder directly from an Indemnifying Party, such Indemnifying Party) has
disputed its liability with respect to such Direct Claim as provided in this
Section 8.3(e), as promptly as reasonably practicable, such Indemnified Party
and the Equityholders' Representative or Indemnifying Party, as applicable
shall establish the merits and amount of such Direct Claim (by mutual
agreement, litigation or otherwise) and, within five (5) Business Days
following the final determination of the merits and amount of such Direct
Claim, the Indemnifying Party shall, subject to the limitations set forth in
this Article VIII, pay to the Indemnified Party in immediately available
funds an amount equal to such Direct Claim as determined pursuant to
this Section 8.3(e); _provided_ that any such foregoing payments (i) if
settled (or deemed consented to) by the Equityholders' Representative, shall
be made exclusively from, and shall not exceed the amount then available in,
the General Escrow Fund, the Designated Escrow Fund or otherwise satisfied
through the exercise of the setoff rights set forth in Section 8.6 and (ii) if
settled by an Indemnifying Parties, any such foregoing payments shall be paid
exclusively by such consenting Indemnifying Parties. If any such dispute
cannot be resolved within thirty (30) days of the date the Indemnifying Party
disputes or is deemed to have disputed such Direct Claim, then any
Indemnifying Party or Indemnified Party may commence an arbitration proceeding
for the purposes of resolving such dispute pursuant to Section 10.5. If a
dispute exists as to the amount of any Direct Claim, the prevailing
party shall be entitled to reasonable legal and other fees paid in asserting
or defending such Direct Claim, as the case may be. This Section 8.3 shall
not apply to any claim with respect to Taxes.

  



    

 | -68-| 
---|---|--- 

 



    



  

Section 8.4 _Satisfaction of Losses_. In the event any Indemnified
Party shall suffer any Losses for which such Indemnified Party is finally
determined pursuant to the terms of this Agreement to be entitled to
indemnification under this Article VIII (subject to the limitations set forth
herein), such Indemnified Party shall be entitled to recover such Losses (a)
first, by the reduction of the number of Parent Shares (with each such
Initial Escrow Share being valued at the Parent Stock Price) and amount of
cash being held as General Escrow Property pursuant to Section 1.10 and the
Escrow Agreement until no General Escrow Property remains, (b) second, with
respect to (i) Designated Indemnification Matters, and (ii) the General
Indemnification Matters (to the extent permitted pursuant to clause (i) of
Section 8.2(b) (if and to the extent applicable)), by the reduction of
Retained Milestone Amounts in accordance with Section 8.6 and (c) third, with
respect to the Designated Indemnification Matters, recovery against the
amounts then held in the Designated Escrow Fund and (d) fourth, with respect
to (i) Fundamental Indemnification Matters and (ii) General Indemnification
Matters, to the extent permitted pursuant to clause (i) of Section 8.2(b) (if
and to the extent applicable), directly from each Indemnifying Party in
accordance with such Indemnifying Party's Indemnification Pro Rata Share.

  



  

Section 8.5 _Survival and Claims Periods_. The representations,
warranties and covenants made by the Company in this Agreement shall not be
extinguished by the Closing, but shall survive the Closing for, and all
claims for indemnification in connection therewith may not be asserted later
than, twelve (12) months following the Closing Date; _provided_ , however,
that (a) each of the representations and warranties contained in Section
2.1(a) (Organization and Good Standing), Section 2.2 (Capitalization), Section
2.3(a) (Subsidiaries), Section 2.4(a) (Authority) and Section 2.19 (Brokerage
and Finders), shall survive the Closing without limitation as to time, and the
period during which a claim for indemnification may be asserted in connection
therewith shall be indefinite; (b) each of the representations contained in
Section 2.8 (Taxes) shall survive the closing for, and all claims for
indemnification in connection therewith shall be asserted not later than the
90th day following the end of the period, if any, during which an assessment,
reassessment or other form of document assessing liability for Taxes in
respect of any taxation year to which these representations and warranties
extend could be issued to the Company (together with the representations and
warranties in the preceding clause (a), the " _Fundamental Representations_
") and (c) each of the Specified IP Representations shall survive the Closing
for, and all claims for indemnification in connection therewith shall be
asserted not later than, five (5) years following the Closing Date (such
date, the " _Designated Survival Date_ "). Notwithstanding the foregoing, if,
prior to the close of business on the last day a claim for indemnification
may be asserted under this Article VIII the Equityholders' Representative
and the Indemnifying Parties (with respect to direct claims against the
Indemnifying Parties, if applicable) shall have been properly notified of a
claim for indemnity pursuant to Section 8.3 that is an Unresolved Claim, such
claim shall continue to survive and shall remain a basis for indemnity under
this Article VIII until such claim is finally resolved or disposed of in
accordance with the terms of this Agreement. All representations and
warranties made by Parent and Merger Sub shall terminate and expire as of the
Closing, and any liability of Parent and Merger Sub with respect to cease.

  



    

 | -69-| 
---|---|--- 

 



    



  

Section 8.6 _Set-Off_.

  



  

(a) If at the time a Milestone Payment becomes due and payable (but
has not been paid) (i) an Indemnified Party has duly delivered pursuant to
Section 8.3 a Notice of Direct Claim or Notice of Third-Party Claim with
respect to any Fundamental Indemnification Matter or a Specified IP Matter,
in each case, that constitutes an Unresolved Claim and (ii) the amount of
Losses that the Indemnified Parties reasonably anticipates to be entitled to
in satisfaction of the claims set forth therein (subject to the limitations in
this Article VIII) with respect to such Fundamental Indemnification Matter or
Specified IP Matters (the " _Anticipated Fundamental Losses_ ") exceeds the
amount then available to satisfy indemnification claims in the General Escrow
Fund and the Designated Escrow Fund (after taking into account all other
Unresolved Claims for indemnification from the General Escrow Fund and/or the
Designated Escrow Fund made by Indemnified Parties delivered pursuant to
Section 8.3), then (A) the amount of the Milestone Payment to be paid at
such time shall be reduced by the amount such Anticipated Fundamental Losses
are greater than the amount then available to satisfy indemnification claims
in the General Escrow Fund and the Designated Escrow Fund (the aggregate
amount of all Anticipated Fundamental Losses withheld from a Milestone
Payment, the " _Retained Milestone Amount_ ")) pending the resolution of such
Unresolved Claim in accordance with this Agreement, (B) Parent shall, subject
to the deposit of the applicable Milestone General Escrow Property or
Designated Escrow Property with the Escrow Agent pursuant to Section 1.10,
distribute the remaining portion of such Milestone Payment in accordance with
Section 1.13 and (C) Parent shall promptly (and in any event within two (2)
Business Days) provide the Equityholders' Representative with written notice
of the reduction of any Milestone Payments pursuant to this Section 8.6(a).

  



  

(b) Subject to Section 8.4, following the final resolution pursuant
to this Agreement of such claim for indemnification with respect to
the applicable Fundamental Indemnification Matter or Specified IP Matters for
which a Retained Milestone Amount was retained, (A) if Parent has been
finally determined pursuant to such resolution to have suffered aggregate
indemnifiable Losses under this Article VIII with respect to such claim
(subject to the limitations set forth herein) in an amount less than such
Retained Milestone Amount after taking into account the amount of such Losses
to be satisfied from the General Escrow Fund or the Designated Escrow Fund in
accordance with Section 8.4, then Parent shall, within ten (10) days after
such final resolution, pay (or shall cause to be paid) the portion of the
Retained Milestone Amount not used to satisfy such indemnifiable Losses to the
Paying Agent, for further distribution to the Equityholders in accordance
with Section 1.13 in the respective amounts they would have been entitled to
receive had such amount not been so retained.

  



    

 | -70-| 
---|---|--- 

 



    



  

Section 8.7 _Characterization of Indemnification Payments_. Parent
and the Equityholders agree to treat any payment made under this Article VIII
as an adjustment to the Merger Consideration to the fullest extent permitted
by applicable Law.

  



  

Article IX 
 EquityHOLDERS' REPRESENTATIVE

  



  

Section 9.1 _Equityholders ' Representative_.

  



  

(a) The Equityholders, by the approval and adoption of this
Agreement and without any further action of any of the Equityholders or
the Company, hereby appoint the Equityholders' Representative as agent and
attorney in fact for the Company and each Equityholder, and authorize the
Equityholders' Representative (i) to take all action necessary to consummate
the Merger and the other transactions contemplated by this Agreement and the
Escrow Agreement, or the defense and/or settlement of any claims for which the
Equityholders may be required to indemnify Parent or any other Indemnified
Party pursuant to Article VIII, (ii) to give and receive all notices required
to be given to the Equityholders' Representative under this Agreement, the
Escrow Agreement or the Stockholder Related Agreements, (iii) to review,
negotiate and authorize delivery to Parent of the General Escrow Property and
the Designated Escrow Property in satisfaction of claims by Parent and set
off of Milestone Payments pursuant to Section 8.6, (iv) object to such claims
pursuant to this Agreement, (v) consent or agree to, negotiate, enter into,
or, if applicable, contest, prosecute or defend, settlements and compromises
of, and demand arbitration and comply with Orders of courts and awards of
arbitrators with respect to, such claims, resolve any such claims, take any
actions in connection with the resolution of any dispute relating to this
Agreement, or the transactions contemplated by this Agreement, by
arbitration, settlement or otherwise, and take or forego any or all
actions permitted or required of any Equityholder or necessary in the
judgment of the Equityholders' Representative for the accomplishment of the
foregoing and all of the other terms, conditions and limitations of this
Agreement, (vi) consult with legal counsel, independent public accountants
and other experts selected by it, solely at the cost and expense of the
Equityholders and (vii) to make decisions on behalf of the Equityholders and
take any and all additional action as is contemplated to be taken by or on
behalf of the Equityholders by the terms of this Agreement or the Escrow
Agreement, including, without limitation regarding (A)
indemnification claims, Direct Claims, Third-Party Claims, Notices of Third-
Party Claims and Notices of Direct Claims and (B) amendments to
this Agreement, the Escrow Agreement or the Stockholder Related Agreements
(other than the Non-Competition Agreements), provided that the Equityholders'
Representative shall not be authorized to (1) receive notice of, or take
action on behalf of the applicable Indemnifying Party in the event that
recourse is being sought hereunder directly from such Indemnifying Party, (2)
agree to make any Indemnifying Party directly liable for any Losses in
respect of a claim for indemnification that is being sought
hereunder directly from such Indemnifying Party or (3) treat any of the
Equityholders in a manner that is different or disproportionate from one
another (the " _Limits on Authority_ "). Notwithstanding the foregoing, the
Equityholders' Representative shall have no obligation to act on behalf of
the Equityholders, except as expressly provided herein and in the Escrow
Agreement, the Engagement Agreement, and for purposes of clarity, there are
no obligations of the Equityholders' Representative in any ancillary
agreement, schedule, exhibit or the Disclosure Schedule. The Person serving as
the Equityholders' Representative may be removed or replaced from time to
time, or if such Person resigns from its position as the Equityholders'
Representative, then a successor may be appointed, by the holders of a
majority in interest of the aggregate value of property then held in
the General Escrow Fund upon not less than thirty (30) days' prior written
notice to Parent. The immunities and rights to indemnification shall survive
the resignation or removal of the Equityholders' Representative or any member
of the Advisory Group and the Closing and/or any termination of this
Agreement and the Escrow Agreement.

  



    

 | -71-| 
---|---|--- 

 



    



  

(b) Subject to the Limits on Authority, all decisions and actions
taken by the Equityholders' Representative in accordance with this Article
IX, including without limitation (i) agreements between the Equityholders'
Representative and Parent relating to the defense or settlement of claims for
which the Equityholders may be required to indemnify Parent pursuant to
Article VIII and (ii) agreements between the Equityholders' Representative
and Parent relating to the Escrow Agreement or the determination of Parent's
payment obligations under Section 1.5 or Section 1.13 or any other matter
relating to Article I, shall be binding upon all of the Equityholders and
each such Equityholder's successors as if expressly confirmed and ratified in
writing by such Equityholder, and no Equityholder shall have the right to
object, dissent, protest or otherwise contest the same.

  



  

(c) Certain Equityholders have entered into an engagement agreement
(the " _Engagement Agreement_ ") with the Equityholders' Representative to
provide direction to the Equityholders' Representative in connection with its
services under this Agreement, the Escrow Agreement and the Engagement
Agreement (such Equityholders, including their individual representatives,
collectively hereinafter referred to as the " _Advisory Group_ "). Neither
the Equityholders' Representative nor its members, managers, directors,
officers, contractors, agents and employees nor any member of the Advisory
Group (collectively, the " _Equityholders ' Representative Group_") shall
have any liability or obligation to any of the parties to this Agreement or
to the Equityholders for any act done or omitted pursuant to this Agreement,
the Escrow Agreement or the Engagement Agreement as the Equityholders'
Representative while acting in good faith, without gross negligence
or willful misconduct, and in the exercise of reasonable judgment, and any
act done or omitted pursuant to the advice of counsel shall be conclusive
evidence of such good faith. The Equityholders shall severally and not jointly
indemnify and defend the Equityholders' Representative Group and hold the
Equityholders' Representative Group harmless against any damage, loss, cost,
liability, fees or expenses (including fees, disbursements and costs of
counsel and other skilled professionals and in connection with
seeking recovery from insurers, judgments, fines or amounts paid in
settlement) incurred by the Equityholders' Representative and arising out of
or in connection with the acceptance or administration of the Equityholders'
Representative's duties under this Agreement, the Escrow Agreement and the
Engagement Agreement (collectively, the " _Representative Losses_ "), in each
case as such Representative Loss is suffered or incurred, _provided_ , that in
the event that any such Representative Loss is finally adjudicated to have
been directly caused by the gross negligence, willful misconduct or bad faith
of the Equityholders' Representative, the Equityholders' Representative will
reimburse the Equityholders the amount of such indemnified
Representative Loss to the extent attributable to such gross negligence,
willful misconduct or bad faith. If not paid directly to the
Equityholders' Representative by the Equityholders, any such Representative
Losses may be recovered by the Equityholders' Representative first from the
Expense Fund, and second, from any distribution of the General Escrow Fund,
Designated Escrow Fund or Milestone Payment otherwise distributable to the
Equityholders at the time of distribution; _provided_ , that while this
section allows the Equityholders' Representative to be paid from the Expense
Fund, General Escrow Fund, Designated Escrow Fund or Milestone Payment, as
the case may be, this does not relieve the Equityholders from their obligation
to promptly pay such Representative Losses as they are suffered or incurred,
nor does it prevent the Equityholders' Representative from seeking any
remedies available to it at law or otherwise. The Equityholders acknowledge
that the Equityholders' Representative shall not be required to expend or
risk its own funds or otherwise incur any financial liability in the exercise
or performance of any of its powers, rights, duties or privileges or pursuant
to this Agreement, the Escrow Agreement or the transactions contemplated
hereby or thereby. Furthermore, the Equityholders' Representative shall not
be required to take any action unless the Equityholders' Representative has
been provided with funds, security or indemnities which, in its determination,
are sufficient to protect the Equityholders' Representative against the
costs, expenses and liabilities which may be incurred by the
Equityholders' Representative in performing such actions.

  



    

 | -72-| 
---|---|--- 

 



    



  

(d) Subject to the Limits on Authority, the Equityholders'
Representative shall have full power and authority on behalf of each
Equityholder to take any and all actions on behalf of, execute any and all
instruments on behalf of, and execute or waive any and all rights of, the
Equityholders under this Agreement, the Escrow Agreement and the Stockholder
Related Agreements (other than the Non-Competition Agreements).

  



  

(e) The Equityholders, by approval and adoption of this Agreement,
agree, in addition to the foregoing, and solely to the extent consistent with
Section 9.1(a), that:

  



  

(i) Parent shall be entitled to rely conclusively on the
instructions and decisions of the Equityholders' Representative as to (A)
the settlement of any claims for indemnification by Parent pursuant to
Article VIII, (B) actions taken in respect of indemnification claims, Direct
Claims, Third-Party Claims and Notices of Claims, and (C) any other actions
required or permitted to be taken by the Equityholders' Representative under
this Agreement, the Escrow Agreement and any Stockholder Related Agreement
(other than the Non-Competition Agreements), and no Equityholder shall have
any cause of action against Parent for any action taken by Parent in reliance
upon the instructions or decisions of the Equityholders' Representative;

  



  

(ii) all actions, decisions and instructions of the Equityholders'
Representative taken in accordance with this Article IX shall be conclusive
and binding upon the Company and all of the Equityholders and no Equityholder
shall have any cause of action against the Equityholders' Representative for
any action taken, decision made or instruction given by the Equityholders'
Representative under this Agreement or the Escrow Agreement except for fraud,
gross negligence, willful misconduct or bad faith by the
Equityholders' Representative in connection with the matters described in
this Article IX;

  



  

(iii) the provisions of this Article IX are independent and severable,
are irrevocable and coupled with an interest and shall be
enforceable notwithstanding any rights or remedies that any Equityholder may
have in connection with the transactions contemplated by this Agreement, the
Escrow Agreement and the Stockholder Related Agreements; and

  



    

 | -73-| 
---|---|--- 

 



    



  

(iv) the provisions of this Article IX and all actions taken by the
Equityholders' Representative under this Agreement, the Escrow Agreement or
the Engagement Agreement shall be binding upon the executors, heirs, legal
Representatives, personal Representatives, successor trustees and successors
of each Equityholder as if expressly confirmed and ratified in writing by such
Equityholder, and any reference in this Agreement or the Escrow Agreement to
an Equityholder or the Equityholders shall mean and include the successors to
the rights of the Equityholders under this Agreement, whether pursuant to
testamentary disposition, the laws of descent and distribution or otherwise.

  



  

(f) The powers, immunities and rights to indemnification granted to
the Equityholders' Representative Group hereunder: (i) are coupled with an
interest and shall be irrevocable and survive the death, incompetence,
bankruptcy or liquidation of any Equityholder and shall be binding on any
successor thereto, and (ii) shall survive the delivery of an assignment by any
Equityholder of the whole or any fraction of his, her or its interest in the
General Escrow Fund.

  



  

(g) The Equityholders' Representative shall be entitled to: (i) rely
upon the Closing Spreadsheet, (ii) rely upon any signature believed by it to
be genuine, and (iii) reasonably assume that a signatory has proper
authorization to sign on behalf of the applicable Equityholder or other
party.

  



  

  

(h) The Expense Fund will be used for the purposes of (i) paying
directly or reimbursing the Equityholders' Representative for any third-party
expenses pursuant to this Agreement, the Escrow Agreement, the Engagement
Agreement and any agreement ancillary hereto and (ii) as otherwise determined
by the Advisory Group. The Equityholders will not receive any interest or
earnings on the Expense Fund and irrevocably transfer and assign to the
Equityholders' Representative any ownership right that they may
otherwise have had in any such interest or earnings. The Equityholders'
Representative is not providing any investment supervision, recommendations
or advice and will not be liable for any loss of principal of the Expense Fund
other than as a result of its negligence, willful misconduct or bad faith.
The Equityholders' Representative will hold these funds separate from its
corporate funds and will not voluntarily make these funds available to its
creditors in the event of bankruptcy. The Equityholders' Representative is
not acting as a withholding agent or in any similar capacity in connection
with the Expense Fund, and has no tax reporting or income distribution
obligations. As promptly as reasonably practicable (and in any event within
three (3) Business Days) following the reasonable determination by the
Equityholders' Representative that the Expense Fund is no longer required to
be withheld, the Equityholders' Representative shall deliver, or cause to be
delivered, the amount remaining in the Expense Fund to the Paying Agent, for
further distribution to the Equityholders in accordance with the allocations
provided in Section 1.13(b), _provided_ , that Parent shall reasonably
cooperate with the Equityholders' Representative to facilitate the payment of
any portion of such payment that is payable to Company Optionholders who are
current or former employees and subject to Tax withholding through Parent's
or its Affiliate's payroll system.

    

  



    

 | -74-| 
---|---|--- 

 



    



  

Article X 
 Miscellaneous Provisions

  



  

Section 10.1 _Fees and Expenses_. Each party to this Agreement shall
bear and pay all fees, costs and expenses (including legal fees and
accounting fees) that have been incurred or that are incurred by such party
in connection with the transactions contemplated by this Agreement; 
_provided_ , _however_ , that Parent shall pay the costs and expenses of the
audit and review of the Company Financial Statements by an independent
registered public accounting firm on behalf of Parent and Sorrento (the "
_Financial Statement Costs_ ").

  



  

Section 10.2 _Waiver; Amendment_. Any agreement on the part of a
party to this Agreement to any extension or waiver of any provision of this
Agreement shall be valid only if set forth in an instrument in writing signed
on behalf of such party. A waiver by a party to this Agreement of the
performance of any covenant, agreement, obligation, condition, representation
or warranty shall not be construed as a waiver of any other covenant,
agreement, obligation, condition, representation or warranty. A waiver by any
party to this Agreement of the performance of any act shall not constitute a
waiver of the performance of any other act or an identical act required to
be performed at a later time. Following the Closing, this Agreement may not
be amended, modified, altered or supplemented except by written agreement
between Parent and the Equityholders' Representative.

  



  

Section 10.3 _Entire Agreement_. This Agreement and the other
agreements referred to in this Agreement constitute the entire agreement among
the parties to this Agreement and supersede all other prior agreements and
understandings (including that certain non-binding term sheet between the
Company, Parent and Sorrento, entered into on January 3, 2019), both written
and oral, among or between any of the parties with respect to the subject
matter of this Agreement and thereof; _provided_ , _however_ , that the
Confidentiality Agreements shall not be superseded by this Agreement and
shall remain in effect in accordance with their respective terms until the
earlier of: (a) the Closing Date, or (b) the date on which the applicable
Confidentiality Agreement is terminated in accordance with its terms.

  



  

Section 10.4 _Execution of Agreement; Counterparts; Electronic
Signatures_.

  



  

(a) This Agreement may be executed in several counterparts, each of
which shall be deemed an original and all of which, when taken
together, shall constitute one and the same instrument, and shall become
effective when counterparts have been signed by each of the parties to this
Agreement and delivered to the other parties to this Agreement; it being
understood that all parties to this Agreement need not sign the same
counterparts.

  



  

(b) This Agreement and any amendments to this Agreement may be
executed in one or more counterparts, each of which shall be
enforceable against the parties to this Agreement that execute such
counterparts, and all of which together shall constitute one and the
same instrument. Facsimile and ".pdf" copies of signed signature pages shall
be deemed binding originals and no party to this Agreement shall raise the
use of facsimile machine or electronic transmission in ".pdf" as a defense to
the formation of a contract.

  



    

 | -75-| 
---|---|--- 

 



    



  

Section 10.5 _Governing Law; Arbitration; Venue_.

  



  

(a) This Agreement shall be governed by and construed in accordance
with the internal laws (and not the law of conflicts) of the State
of Delaware.

  



  

(b) Any claim or dispute arising under or relating to this
Agreement, including disputes related to the validity, interpretation or
enforcement of any provision this Agreement, shall be finally settled under
the JAMS Comprehensive Arbitration Rules and Procedures by a panel of three
arbitrators (the " _Panel_ "). Parent and the Company shall each select one
arbitrator to represent them, and such two arbitrators together shall select
a third arbitrator for the proceedings. The place of arbitration shall be San
Diego, California. The arbitration shall be conducted in the English language.

  



  

(c) The Panel shall render an award within six months from the date
of the appointment of the Panel, unless the parties to this
Agreement otherwise agree in writing or the Panel determines that an
extension is necessary. The arbitral award shall be in writing, state the
reasons for the award, and be final and binding upon, and non-appealable by,
the parties to this Agreement. The award may include an award of costs,
including, without limitation, reasonable attorneys' fees and disbursements.
In addition to monetary damages, the Panel shall be empowered to award
equitable relief, including, but not limited to, an injunction and specific
performance of any obligation under this Agreement. Notwithstanding the
foregoing, the parties to this Agreement agree that any of them may
seek equitable relief, including, but not limited to, an injunction and
specific performance of any obligation under this Agreement from any court of
competent jurisdiction, but that the final resolution of any disputes will be
settled solely by the Panel.

  



  

(d) The Panel shall not be empowered to award damages in excess of
compensatory damages, and each party to this Agreement hereby
irrevocably waives any right to recover special, punitive, exemplary,
consequential or similar damages with respect to any dispute, except insofar
as a claim for such award arises out of indemnification against a party in an
action brought against it by an independent third party in which such an
award for special, punitive, exemplary, consequential or similar damages was
awarded. The Panel shall be authorized in its discretion to grant pre-award
and post-award interest at commercial rates. Judgment upon the award may
be entered by any court having jurisdiction thereof or having jurisdiction
over the relevant party or its assets.

  



  

(e) The Panel, in its discretion, may consolidate two or more
arbitrations or claims between any of the parties to this Agreement
arising under this Agreement or any other agreement among the parties to this
Agreement into one arbitration, or terminate any such consolidation and/or
establish other arbitration proceedings for different claims that may arise in
any one arbitration. Notwithstanding the foregoing, the Panel shall
consolidate arbitrations and/or claims, if it determines that it would be more
efficient to consolidate such arbitrations and/or claims than to continue
them separately and (i) there are matters of fact or law that are common to
the arbitrations and/or claims to be consolidated, (ii) there are related
payment and performance obligations considered in the arbitrations and/or
claims to be consolidated, or (iii) there is a danger of inconsistent awards.

  



  

(f) The Panel shall render any monetary award and interest related
to such award in U.S. Dollars.

  



    

 | -76-| 
---|---|--- 

 



    



  

(g) The parties to this Agreement agree that the arbitration shall
be kept confidential and that the existence of the proceeding and any element
of it (including but not limited to any pleadings, briefs or other documents
submitted or exchanged, any testimony or other oral submissions, and any
awards) shall not be disclosed beyond the Panel, the parties, their counsel
and any person necessary to the conduct of the proceeding, except as may be
lawfully required in judicial proceedings relating to the arbitration or
otherwise, or as required by the rules of any other quotation system or
exchange on which the disclosing party's securities are listed or applicable
Laws, _provided_ that the Equityholders' Representative shall not be
prohibited from making any disclosures to the Equityholders.

  



  

(h) The costs of arbitration shall be borne by the losing party
unless otherwise determined by the arbitration award.

  



  

(i) Each party to this Agreement agrees not to assert (by way of
motion, as a defense or otherwise), in any such dispute that any
claim arising out of, relating to, or in connection with the interpretation
or performance of this Agreement is not subject to the jurisdiction of the
Panel or that this Agreement may not be enforced by the Panel.

  



  

Section 10.6 _WAIVER OF JURY TRIAL_. EACH OF THE PARTIES OF THIS
AGREEMENT HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY LAW,
ALL RIGHTS TO A TRIAL BY JURY IN ANY ACTION, PROCEEDINGS OR COUNTERCLAIM
(WHETHER BASED ON CONTRACT, TORT OR OTHERWISE) ARISING OUT OF OR RELATING TO
THIS AGREEMENT OR ANY OF THE TRANSACTIONS CONTEMPLATED HEREBY.

  



  

Section 10.7 _Assignment and Successors_. Subject to Section
1.13(h), no party to this Agreement may assign any of its rights or delegate
any of its obligations under this Agreement without the prior written consent
of the other parties to this Agreement, except that Parent and Merger Sub may
assign any of its rights and delegate any of its obligations under this
Agreement to any Affiliate of Parent, _provided_  that notwithstanding any
such assignment or delegation, Parent and/or Merger Sub, as applicable, shall
remain liable for all of its obligations under this Agreement. Subject to the
preceding sentence, this Agreement shall apply to, be binding in all
respects upon and inure to the benefit of the successors and permitted
assigns of the parties to this Agreement.

  



  

Section 10.8 _Parties in Interest_. This Agreement is not intended
to, and shall not, confer upon any other Person any rights or remedies
hereunder, except for the provisions of Section 4.4 (which shall be for the
benefit of (among the other parties hereto) the Company Indemnified Parties,
and the Company Indemnified Parties (among the other parties hereto) will have
the rights provided for therein) and the provisions of Section 10.14 (which
shall be for the benefit of (among the other parties hereto) WSGR and Cooley,
and WSGR and Cooley (among the other parties hereto) will have the rights
provided for therein. Notwithstanding the foregoing, following the
Closing, the Equityholders' Representative (on behalf of the Equityholders)
shall, subject to the terms set forth herein, have the right to bring claims
against Parent, Sorrento and Merger Sub based on Parent's, Sorrento's or
Merger Sub's breach or failure to perform any of the terms or obligations in
this Agreement that would benefit the Equityholders, including claims for
equitable relief, damages and other remedies, (including by bringing a claim
to recover damages, if any, suffered by the Equityholders, which claim may
seek recovery in an amount equal to the Milestone Payments that were not
achieved, as a result of such breach or failure to perform any of the terms
or obligations set forth in Section 1.13) and that such amounts shall be
deemed to be damages of the Equityholders' Representative. The Equityholders'
Representative agrees that if it obtains any amounts from Sorrento, Parent or
Merger Sub, that it shall deliver, or cause to be delivered, such amounts to
the Paying Agent, for further distribution to the Equityholders, as if they
constituted Milestone Payments hereunder and the parties shall treat any such
payment as a Milestone Payment for tax reporting purposes, _provided_ , that
Parent shall reasonably cooperate with the Equityholders' Representative to
facilitate the payment of any portion of such payment that constitutes an
Option Contingent Payment payable to Company Optionholders who are current or
former employees and subject to Tax withholding through Parent's or its
Affiliate's payroll system.

  



    

 | -77-| 
---|---|--- 

 



    



  

Section 10.9 _Notices_. All notices, requests, claims, demands,
consents, waivers and other communications required or permitted by this
Agreement shall be in writing and shall be deemed given to a party to this
Agreement when (a) other than with respect to the
Equityholders' Representative, delivered to the appropriate address by hand
or by nationally recognized overnight courier service (costs prepaid), or (b)
if sent by e-mail, upon confirmation of delivery when directed to the relevant
e-mail mail address, if sent during normal business hours of the recipient,
or if not sent during normal business hours of the recipient, then on the
recipient's next business day, in each case to the following addresses,
facsimile numbers or e-mail addresses and marked to the attention of
the Person (by name or title) designated below (or to such other address,
facsimile number, e-mail address or Person as a party may designate by notice
to the other parties to this Agreement):

  

 _ _

  

 _If to the Company (before the Closing):_

  



  

Semnur Pharmaceuticals, Inc. 
 4970 El Camino Real, Suite 205 
 Los Altos, CA 94022 
 Attention: Mahendra Shah 
 Email: mshah@vivocapital.com

  

 _ _

  

 _with a mandatory copy (which copy shall not constitute notice) to_ :

  



  

Wilson Sonsini Goodrich and Rosati, P.C. 
 650 Page Mill Road 
 Palo Alto, CA 94304 
 Attention: Kenneth A. Clark, Esq. and Brian Keyes, Esq. 
 Email: KClark@wsgr.com

  

Email: BKeyes@wsgr.com

  

 _ _

  

 _If to the Equityholders ' Representative (on its own behalf and for the
benefit of the Equityholders):_

  



  

Fortis Advisors LLC 
 Attention: Notice Department 
 Email: notices@fortisrep.com

  

Facsimile No.: (858) 408-1843

  

 _ _

    

 | -78-| 
---|---|--- 

 



    

 _ _

  

 _If to Sorrento, Parent or Merger Sub_ :

  

Scilex Pharmaceuticals Inc. 
 c/o Sorrento Therapeutics, Inc. 
 4955 Directors Place 
 San Diego, CA 92121

  

     Attention:  | Henry Ji, PhD., President and Chief Executive Officer 
---|--- 
     | Deborah Telman, Esq., Senior Vice President and General Counsel 
    

Email: hji@sorrentotherapeutics.com

  

Email: dtelman@sorrentotherapeutics.com

  

 _ _

  

 _with a mandatory copy (which copy shall not constitute notice) to_ :

  



  

Paul Hastings LLP 
 1117 S. California Avenue 
 Palo Alto, CA 94304 
 Attention: Jeffrey T. Hartlin, Esq. 
 Email: jeffhartlin@paulhastings.com

  



  

Section 10.10 _Construction; Usage_.

  



  

(a) _Interpretation_. In this Agreement, unless a clear contrary
intention appears:

  



  

(i) the Annexes, Schedules and Exhibits attached to this Agreement
(including the Disclosure Schedule) are hereby incorporated into
this Agreement and are hereby made a part of this Agreement as if set out in
full in this Agreement;

  



  

(ii) the singular number includes the plural number and vice versa;

  



  

(iii) reference to any Person includes such Person's successors and
assigns but, if applicable, only if such successors and assigns are
not prohibited by this Agreement, and reference to a Person in a particular
capacity excludes such Person in any other capacity or individually;

  



  

(iv) reference to any gender includes each other gender and neutral
forms of such words;

  



  

(v) reference to any agreement, document or instrument means such
agreement, document or instrument as amended or modified and in effect
from time to time in accordance with the terms thereof;

  



  

(vi) reference to any Law means such Law as amended, modified,
codified, replaced or reenacted, in whole or in part, and in effect from time
to time, including rules and regulations promulgated thereunder, and
reference to any section or other provision of any Law means that provision
of such Law from time to time in effect and constituting the substantive
amendment, modification, codification, replacement or reenactment of such
section or other provision;

  



    

 | -79-| 
---|---|--- 

 



    



  

(vii) "hereunder," "hereof," "hereto" and words of similar import shall
be deemed references to this Agreement as a whole and not to any particular
Article, Section or other provision of this Agreement;

  



  

(viii) "including" means including without limiting the generality of
any description preceding such term;

  



  

(ix) references to documents, instruments or agreements shall be
deemed to refer as well to all addenda, exhibits, schedules or amendments
thereto;

  



  

(x) all references to "days" shall be to calendar days unless
otherwise indicated as a "Business Day";

  



  

(xi) references to clauses without a cross-reference to a Section or
subsection are references to clauses within the same Section or, if more
specific, subsection;

  



  

(xii) reference to a "Section" or "Article" in this Agreement shall
mean a Section or Article, respectively, of this Agreement unless otherwise
provided;

  



  

(xiii) references to "fraud" shall be deemed to have the meaning set
forth in Schedule 10.10(xiii); and

  



  

(xiv) for purposes of this agreement, "party", "parties" and words of
similar import (A) in the Specified Sections, shall constitute a reference to
a party, or the parties, to this Agreement (including Sorrento) and (B) for
sections of this Agreement other than the Specified Sections, shall
constitute a reference to a party, or the parties, to this Agreement, but
shall not include Sorrento.

  



  

(b) _Legal Representation of the Parties_. This Agreement was
negotiated by the parties to this Agreement with the benefit of legal
representation and any rule of construction or interpretation otherwise
requiring this Agreement to be construed or interpreted against any party to
this Agreement shall not apply to any construction or interpretation of this
Agreement.

  



  

(c) _Headings_. The headings contained in this Agreement are for
the convenience of reference only, shall not be deemed to be a part of this
Agreement and shall not be referred to in connection with the construction or
interpretation of this Agreement.

  



  

(d) _Dollar Amounts_. All references to "$" contained in this
Agreement shall refer to United States Dollars unless otherwise stated.

  



    

 | -80-| 
---|---|--- 

 



    



  

Section 10.11 _Enforcement of Agreement_. The parties to this
Agreement acknowledge and agree that irreparable damage would occur if any of
the provisions of this Agreement are not performed in accordance with their
specific terms and that any breach of this Agreement may not be
adequately compensated in all cases by monetary damages alone. Accordingly,
in addition to any other right or remedy to which the parties shall be
entitled, at law or in equity, they shall each be entitled to enforce any
provision of this Agreement by a decree of specific performance and
temporary, preliminary and permanent injunctive relief to prevent breaches or
threatened breaches of any of the provisions of this Agreement, without
posting any bond or other undertaking. The rights and remedies of the parties
to this Agreement shall be cumulative (and not alternative).

  



  

Section 10.12 _Severability_. If any provision of this Agreement is
held invalid or unenforceable by any court of competent jurisdiction, the
other provisions of this Agreement shall remain in full force and effect. Any
provision of this Agreement held invalid or unenforceable only in part or
degree shall remain in full force and effect to the extent not held invalid or
unenforceable. The parties hereto shall use all reasonable efforts to replace
any such invalid or unenforceable provision of this Agreement with a valid and
enforceable provision that shall achieve, to the greatest extent possible,
the economic, business and other purposes of such invalid or
unenforceable provision.

  



  

Section 10.13 _Time of Essence_. With regard to all dates and time
periods set forth or referred to in this Agreement, time is of the essence.

  



  

Section 10.14 _Privileged Communications_. To the extent that
communications between a Company Party, on the one hand, and either Wilson
Sonsini Goodrich and Rosati (" _WSGR_ ") or Cooley LLP (" _Cooley_ "), on the
other hand, that constitute advice or counsel regarding the interpretation of
this Agreement and that would be subject to the attorney-client privilege
or attorney work product privilege or any other legal privilege or protection
if they were sought by an unrelated third party in a legal proceeding as of
immediately prior to the Closing (such communication, the " _Acquisition
Communications_ "), such Acquisition Communications shall be deemed to be
attorney-client confidences that belong solely to the
Equityholders' Representative for and on behalf of the Equityholders. Without
limiting the generality of the foregoing, Parent acknowledges and agrees, for
itself and on behalf of its Affiliates, including the Surviving Corporation,
upon and after the Closing: (i) the Equityholders' Representative, for and on
behalf of the Company, its Representatives, the Equityholders and the
Equityholders' Representative (collectively, the " _Company Parties_ "),
shall be the sole holders of the attorney-client privilege of the Company
Parties with respect to the Acquisition Communications, and neither Parent nor
any of its Affiliates, including the Surviving Corporation, shall be a holder
thereof; and (ii) neither WSGR nor Cooley shall have any duty whatsoever to
reveal or disclose any such Acquisition Communications; _provided_ that, to
the extent any communication contains both Acquisition Communications and
communications that are not Acquisition Communications, Parent may request
WSGR and Cooley, as the case may be, to provide (and the Equityholders'
Representative, for and on behalf of the other Company Parties, shall instruct
WSGR or Cooley, as the case may be, to provide) appropriately redacted
versions of such communications, files or work product to Parent or its
Affiliates, including the Surviving Corporation, such that such
communications do not disclose any Acquisition Communications.
Notwithstanding the foregoing, in the event that a dispute arises between any
of Parent or the Surviving Corporation or their Affiliates, on one hand, and
any of the Company Parties, on the other hand, concerning this Agreement or
the transactions contemplated in this Agreement, Parent, for itself and on
behalf of its Affiliates and the Surviving Corporation and its Affiliates,
agrees that Parent, the Surviving Corporation and their Affiliates shall not
offer into evidence or assert to the applicable arbitrator or Governmental
Body the Acquisition Communications against the Company Parties.

       

 | -81-| 
---|---|--- 

 



    



  

IN WITNESS WHEREOF, the parties hereto have caused this Agreement and Plan of
Merger to be duly executed, as of the date first above written.

  



       | Scilex Holding Company 
---|--- 
     | 
     | By:  | /s/ Henry Ji, Ph.D. 
     |   | Name: Henry Ji, Ph.D. 
     |   | Title: Secretary and Treasurer 
  



       | Sigma Merger Sub, Inc. 
---|--- 
     | 
     | By:   | /s/ Henry Ji, Ph.D. 
     |   | Name: Henry Ji, Ph.D. 
     |   | Title: Secretary and Treasurer 
  



       | Sorrento Therapeutics, Inc., solely with respect to the
Specified Sections 
---|--- 
     | 
     | By:   | /s/ Henry Ji, Ph.D. 
     |   | Name: Henry Ji, Ph.D. 
     |   | Title: President and Chief Executive Officer 
  



  

[ _Signature Page to the Agreement and Plan of Merger_ ]

  



    



 



    



  

IN WITNESS WHEREOF, the parties hereto have caused this Agreement and Plan of
Merger to be duly executed, as of the date first above written.

  



       | Semnur Pharmaceuticals, Inc. 
---|--- 
     | 
     | By:   | /s/ Jaisim Shah 
     |   | Name: Jaisim Shah 
     |   | Title: Chief Executive Officer 
  



       | Fortis Advisors, LLC, as the Equityholders' Representative 
---|--- 
     | 
     | By:   | /s/ Richard Fink 
     |   | Name: Richard Fink 
     |   | Title: Managing Director 
  



  

[ _Signature Page to the Agreement and Plan of Merger_ ]

  



    



 



    



  

INDEX OF DEFINED TERMS

  



     Term  |   | Section 
---|---|--- 
   Acquisition Communications  |   | 10.14 
   Act  |   | 4.2 
   Anticipated Fundamental Losses  |   | 8.6(a) 
   Assignment Agreement  |   | 2.11(j) 
   Assumption Agreement  |   | 1.13(h)(i)(1) 
   Audited Party  |   | 1.13(g) 
   CCC  |   | Recitals 
   Certificate of Merger  |   | 1.3 
   Charter Amendment  |   | 1.3 
   Closing  |   | 1.3 
   Closing Date  |   | 1.3 
   Closing Spreadsheet  |   | 4.14 
   Common Catch-Up  |   | 1.13(b)(ii) 
   Company  |   | Preamble 
   Company Constituent Documents  |   | 2.1(d) 
   Company Database  |   | 2.26(a) 
   Company Financial Statements  |   | 2.5(a) 
   Company Indemnified Parties  |   | 4.4(a) 
   Company Parties  |   | 10.14 
   Company Rights  |   | 2.2(c) 
   Company Securities  |   | 8.1(a)(iii) 
   Company Share Certificate  |   | 1.7 
   Cooley  |   | 10.14 
   DandO Tail Policy  |   | 4.4(b) 
   DGCL  |   | Recitals 
   Diligent Efforts  |   | 1.13(c) 
   Direct Claim  |   | 8.3(e) 
   Disqualification Questionnaire  |   | Recitals 
   Dissenting Shares  |   | 1.11(a) 
   Effective Time  |   | 1.3 
   Employee Plans  |   | 2.16(a) 
   Equityholders' Representative  |   | Preamble 
   ERISA Affiliate  |   | 2.16(a) 
   Escrow Agent  |   | 1.10(a) 
   Escrow Agreement  |   | 1.10(d) 
   Exchange Act  |   | 2.4(d) 
   Expense Fund  |   | 1.10(b) 
     |   | 
   Fiduciary  |   | 2.16(d) 
   Final Escrow Period  |   | 1.10(f) 
   Final Escrow Release Date  |   | 1.10(f) 
   Financial Statement Costs  |   | 10.1 
  



    

 | -i-| 
---|---|--- 

 



    



     First Escrow Period  |   | 1.10(e) 
---|---|--- 
   First Escrow Release Date  |   | 1.10(e) 
   First-Half Escrow Property  |   | 1.10(e) 
   Fundamental Indemnification Matters  |   | 8.2(b) 
   Fundamental Matter Escrow Amount  |   | 8.2(b) 
   Fundamental Representations  |   | 8.5 
   General Escrow Fund  |   | 1.10(a) 
   General Escrow Property  |   | 1.10(a) 
   General Indemnification Matters  |   | 8.2(b) 
   Indemnified Parties  |   | 8.1(a) 
   Indemnifying Parties  |   | 8.1(a) 
   Information Statement  |   | 4.3(b) 
   Interim Balance Sheet  |   | 2.5(a)(ii) 
   Investor Questionnaire  |   | Recitals 
   Joinder Agreements  |   | 5.1(j) 
   Leases  |   | 2.9(b) 
   Letters of Transmittal  |   | 1.8(b) 
   Limits on Authority  |   | 9.1(a) 
   Losses  |   | 8.1(a) 
   Material Contracts  |   | 2.12(b) 
   Maximum Share Amount  |   | 1.14 
   Merger  |   | Recitals 
   Merger Sub  |   | Preamble 
   Milestone  |   | 1.13(a) 
   Milestone Escrow Period  |   | 1.10(d) 
   Milestone General Escrow Property  |   | 1.10(a) 
   Milestone Payment  |   | 1.13(a) 
   Milestone Provisions  |   | 1.13(i) 
   Milestone Right  |   | 1.13(h) 
   Non-Competition Agreement  |   | Recitals 
   Non-Dissenting Stockholder  |   | 1.8(c) 
   Notice of Direct Claim  |   | 8.3(e) 
   Notice of Third-Party Claim  |   | 8.3(a) 
   OFAC  |   | 2.30 
   Option Contingent Payment  |   | 1.12(a)(iii) 
   Option Exercise Price  |   | 1.12(a)(i) 
   Panel  |   | 10.5(b) 
   Parent  |   | Preamble 
   Parent Parties  |   | Article III 
   Parent Stock Issuance  |   | 1.14 
   Permitted Repurchases  |   | 2.2(g) 
   Pre-Closing Tax Periods  |   | 4.1(a) 
   Preferred Cap  |   | 1.13(b)(i) 
   Privacy Contract  |   | 2.26(d) 
  



    

 | -ii-| 
---|---|--- 

 



    



     Privacy Policy  |   | 2.26(d) 
---|---|--- 
   Privacy Vendors  |   | 2.26(b) 
   Remaining Exercise Price  |   | 1.12(a)(i) 
   Representative Losses  |   | 9.1(c) 
   Required Company Stockholder Vote  |   | 2.4(a) 
   Restricted Shares  |   | 2.2(d) 
   Retained Milestone Amount  |   | 8.6(a) 
   SEC  |   | 2.4(d) 
   Selling Stockholder Questionnaire  |   | Recitals 
   Specified IP Matters  |   | 8.5 
   Specified IP Representations  |   | 8.5 
   Specified Sections  |   | Preamble 
   Stock Reduction Amount  |   | 1.14 
   Stockholder Written Consent  |   | Recitals 
   Straddle Tax Periods  |   | 4.1(a) 
   Surviving Corporation  |   | 1.1 
   Tax Contest  |   | 4.1(e) 
   Third-Party Claim  |   | 8.3(a) 
   Total Milestone Rights  |   | 1.13(h)(i)(1) 
   Underlying Company Shares  |   | 1.12(a)(i) 
   Unresolved Claim  |   | 1.10(e) 
   Update Report  |   | 1.13(f) 
   WSGR  |   | 10.14 
  



    

 | -iii-| 
---|---|--- 

 



    



  

Annex A

  



     Milestone Event|   | Milestone Payment| 
---|---|---|--- 
   Receipt of the first U.S. FDA Approval of a Company Product.|   | $|
40,000,000| 
   Achievement of $100,000,000 in Net Sales of a Company Product.|   | $|
20,000,000| 
   Achievement of $250,000,000 in Net Sales of a Company Product.|   | $|
20,000,000| 
   Achievement of $500,000,000 in Net Sales of a Company Product.|   | $|
50,000,000| 
   Achievement of $750,000,000 in Net Sales of a Company Product.|   | $|
150,000,000| 
   



  

For purposes of this Annex A and elsewhere in the Agreement:

  



  

" _Company Patent_ " means (a) any Patent Right owned, or otherwise
controlled, by the Company as of immediately prior to the Effective Time; (b)
any Patent Right filed after the Effective Time that claims priority to any
Patent Right described in the foregoing clause (a); or (c) any Patent Right
issued or granted based upon any Patent Right described in the foregoing
clauses (a) or (b).

  



  

" _Company Product_ " means any preparation or formulation, in any dosage
form (a) that contains an active pharmaceutical ingredient the composition of
matter, use or manufacture of which is covered by a Company Patent, alone or
in combination with one or more other active ingredients; (b) that has
undergone, or is undergoing, as of immediately prior to the Effective Time, a
human clinical study performed by or on behalf of the Company; or (c) for
which an NDA or MAA is filed with the applicable Competent
Authority containing or referencing any data generated in a human clinical
study referenced in the foregoing clause (b).

  



  

" _Compassionate Use_ " means the use of a Company Product as an
investigational drug in accordance with applicable Law outside of a clinical
trial to treat a patient with a serious or life-threatening disease or
condition who has no comparable or satisfactory alternative treatment options
prior to the receipt of the first Marketing Approval of such Company Product
in the country where the patient is treated.

  



  

" _Competent Authority_ " means any federal, national or multinational
governmental health regulatory agency or authority within a regulatory
jurisdiction, with the authority to grant approvals, licenses, registrations
or authorizations necessary for the development, manufacture, use, sale or
other exploitation of a pharmaceutical product. For clarity, references in
this Agreement to Competent Authority shall be deemed to include the FDA and
the EMA.

  



  

" _Development_ " means with respect to a Company Product, the activities
performed to obtain and maintain the Marketing Approval for the
relevant Company Product, including without limitation: research, test method
development and stability testing, assay development,
toxicology, pharmacology, formulation, quality assurance, quality
development, statistical analysis, process development, and scale-up,
pharmacokinetic studies, data collection and management, clinical studies
(including research to design clinical studies and specifically
excluding activities directed to obtaining pricing and reimbursement
approvals), regulatory affairs (including submission of data or
other materials to a Competent Authority to obtain, maintain and/or expand
Marketing Approval of a Company Product), project management, drug safety
surveillance activities related to clinical studies, validation of methods and
tests.

  



    

 | -1-| 
---|---|--- 

 



    



  

" _MAA_ " means a Marketing Authorization Application, in relation to any
Company Product, filed or to be filed (a) with the EMA (if Marketing Approval
in Europe is to be obtained based upon the centralized evaluation process of
the EMA) or (b) with the applicable Competent Authority in the United
Kingdom, Germany, France, Italy or Spain (if Marketing Approval in Europe has
not been obtained based upon the centralized evaluation process of the EMA),
in each case for authorization to place a medicinal product on the market in
the European Union or the applicable country in Europe.

  



  

" _Marketing Approval_ " means all approvals, licenses, registrations or
authorizations of the Competent Authorities in a country, necessary for the
marketing and sale of the Company Product in such country, including the
approval of an MAA or an NDA, and excluding pricing and reimbursement
approvals.

  



  

" _NDA_ " means a new drug application for the approval of a Company Product
as a new drug by the FDA.

  



  

" _Net Sales_ " means in the case of sales by or for the benefit of Parent,
its Affiliates, its Sublicensees or any Milestone Obligor (in each case, "
_Seller_ ") to a Third Party, the cumulative, gross amount of monies or cash
equivalents or other consideration billed or invoiced or received (without
duplication) by all Sellers (combined) with respect to the Company
Products from and after the Closing Date, less the following deductions
(which may not be deducted more than once with respect to any sale), in each
case only to the extent the same are (a) actually paid, granted or accrued by
such Seller (each as recognized by GAAP applied consistently throughout the
calculation), (b) not otherwise recovered by or reimbursed to a Seller in
connection with such Company Product and (c) allocated to the Company
Product, separately billed or specifically charged and clearly disclosed on
the sale by the Seller to the Third Party (" _Permitted Deductions_ "):

  



  

(i) trade, cash, promotional, prompt payment or quantity discounts;

  



  

(ii) returns, refunds, allowances, rebates and chargebacks but only
to the extent actually recognized against the gross revenues;

  



  

(iii) customs or excise duties, excise, sales or use taxes,
consumption tax, value added tax or other taxes (except income taxes) or
duties relating to sales taxes on sales (such as excise, sales or use taxes
or value added tax);

  



  

(iv) taxes on sales of pharmaceutical specialties reimbursed pursuant
to a government health service, health insurance, social insurance or similar
social services program;

  



  

(v) freight, insurance, packing costs and other transportation
charges to the extent added to the sales price;

  



    

 | -2-| 
---|---|--- 

 



    



  

(vi) amounts repaid or credits taken by reason of rejections, defects
or returns or because of retroactive price reductions, or due to recalls or
Laws requiring rebates;

  



  

(vii) rebates taken by or fees paid to Third Party distributors,
wholesalers, group purchasing organizations, pharmacy benefit management
companies and managed care entities and charge-backs;

  



  

(viii) rebates and/or discounts on sales of Company Products given to
health insurance and other types of payers due to specific agreements ("claw-
back" type of agreements) involving the Company Products; and

  



  

(ix) any other specifically identifiable amounts included in gross
amounts invoiced for the Company Products, to the extent such amounts are
customary deductions from net sales calculations in the pharmaceutical or
biotechnology industries in the applicable country for reasons substantially
equivalent to those listed above.

  



  

" _Net Sales_ " shall not include any consideration received with respect to
a sale, use or other disposition of any Company Product in a country for
Development purposes or as samples or for Compassionate Use, at a price no
greater than the manufacturing costs of the quantities so sold, used or
disposed of. Notwithstanding the foregoing, the amounts invoiced for the sale
of Company Products by (a) Parent, its Affiliates, or their Sublicensees
among Parent, its Affiliates or their respective Sublicensees or (b) any
Milestone Obligor or its Affiliates among such Milestone Obligor or its
Affiliates, as applicable, for resale shall not be included in the
computation of Net Sales hereunder and Net Sales shall be the gross invoice
or contract price charged to the Third Party customer for that Company
Product in an arms' length transaction, less the Permitted Deductions. With
respect to any sale of a Company Product in a given country other than in an
arm's length transaction, for purposes of calculating Net Sales under this
Agreement, such Company Product will be deemed to have been sold at the
average Net Sales price charged to Third Parties for sales in such country in
arms' length transactions during the applicable calendar quarter (or if there
were no such sales in such country during such calendar quarter, at the fair
market value as determined by comparable markets). All of the foregoing
elements of Net Sales calculations shall be determined in accordance with
GAAP applied consistently throughout the calculation. In the event that a
Company Product is sold as a fixed dose or co-packaged combination with other
therapeutically active pharmaceutical compound(s) at a single price (a "
_Combination Product_ "), Net Sales from the sale of such Combination Product
will be calculated for each applicable calendar quarter by multiplying the
Net Sales (as determined without reference to this paragraph) of such
Combination Product by the fraction A/(A+B), where (i) A is the average gross
selling price in the applicable country of the Company Product and (ii) B is
the average gross selling price in the applicable country of the other
therapeutically active pharmaceutical compound(s) included in such
Combination Product, each when sold separately in finished form, during the
applicable calendar quarter or, if sales of the Combination Product and the
separate product(s) did not occur during such calendar quarter, the most
recent calendar quarter in which sales of such products occurred. In the event
that the average gross selling price(s) cannot be determined for A or B, the
Net Sales attributable to the Company Product shall be reasonably allocated
between A and B based on their relative fair market values.

  



    

 | -3-| 
---|---|--- 

 



    



  

" _Sublicensees_ " means a Third Party which is a licensee or sublicensee of
some or all of the rights with respect to a Company Product; provided that,
for sake of clarity, Sublicensees do not include (a) wholesalers, distributors
or similar entities performing similar functions, in each case who do not
promote the Company Product sold to it and (b) Parent's or Sorrento's
Affiliates.

  



  

" _Third Party_ " means any person or entity other than Sorrento, Parent and
their respective Affiliates.

  



  

" _U.S. FDA Approval_ " means the approval an NDA by the FDA.

  



  



    

 | -4-| 
---|---|--- 

 



    



  

Exhibit A

  



  

Certain Definitions

  



  

For purposes of this Agreement:

  



  

" _Acquisition Transaction_ " means any transaction or series of transactions
involving:

  



  

(a) any merger, consolidation, share exchange, business combination,
issuance of securities (other than in respect of the exercise or
conversion of equity awards in existence as of the date of this Agreement),
direct or indirect acquisition of securities, recapitalization, tender offer,
exchange offer or other similar transaction involving the Company;

  



  

(b) any direct or indirect sale, lease, exchange, transfer, license,
acquisition or disposition of a material portion of the business or assets of
the Company; or

  



  

(c) any liquidation, dissolution or winding up of the Company.

  



  

" _Affiliate_ " means, with respect to any specified Person, any other Person
who or which, directly or indirectly, controls, is controlled by, or is under
common control with such specified Person, including, without limitation, any
general partner, limited partner, member, officer, director or manager of
such Person and any venture capital or private equity fund now or hereafter
existing that is controlled by one or more general partners or managing
members of, or shares the same management company with, such Person. For
purposes of this definition, the terms " _controls_ ," " _controlled by_ ,"
or " _under common control with_ " means the possession, direct or indirect,
of power to direct or cause the direction of management or policies (whether
through ownership of voting securities, by contract or otherwise).

  



  

" _Agreement_ " means the Agreement and Plan of Merger of which this Exhibit
A is a part, as amended or restated from time to time.

  



  

" _Applicable Benefit Laws_ " means all Laws, including those of a
jurisdiction outside of the United States, applicable to any Employee Plan.

  



  

" _Business Day_ " means a weekday on which banks are open for general
banking business in San Diego, California.

  



  

" _Cash_ " means the cash and cash equivalents of the Company net of costs to
make readily available, calculated in accordance with GAAP.

  



  

" _Code_ " means the United States Internal Revenue Code of 1986, as amended,
and the rules and regulations promulgated thereunder.

  



  

" _Company Common Shares_ " means the shares of common stock, par value
$0.00001 per share, of the Company.

  



    

 | A-1| 
---|---|--- 

 



    



  

" _Company Intellectual Property_ " means the Company Owned Intellectual
Property and the Company Licensed Intellectual Property.

  



  

" _Company Licensed Intellectual Property_ " means all Intellectual Property
Rights that are licensed to the Company by any other third-party.

  



  

" _Company Material Adverse Effect_ " means any state of facts, change,
event, effect, occurrence or circumstance that, individually or in the
aggregate (considered together with all other state of facts, change, event,
effect, occurrence or circumstance) has, has had or would reasonably be
expected to have or give rise to a material adverse effect on (a) the
business, condition (financial or otherwise), results of operations, assets,
liabilities, operations or financial performance of the Company taken as a
whole, or (b) the ability of the Company to consummate the Merger; _provided_
, _however_ , with respect to clause (a), that none of the following shall be
deemed in themselves, either alone or in combination, to constitute, and none
of the following shall be taken into account in determining whether there has
been or will be, a Company Material Adverse Effect unless, in the case
of (i), (ii), (iii), (iv), (v) or (vi) the Company is adversely affected in a
disproportionate manner thereby as compared to other Persons or businesses
that operate in the industry in which the Company operates: (i) any change
generally affecting the economy, financial markets or political, economic or
regulatory conditions in the United States or any other geographic region in
which the Company's business is conducted; (ii) general financial, credit or
capital market conditions or any changes therein; (iii) acts of war (whether
or not declared), the commencement, continuation or escalation of a war, acts
of armed hostility, sabotage or terrorism or other international or national
calamity or any material worsening of such conditions threatened or existing
as of the date hereof; (iv) change in the general conditions in the
industries in which the Company conducts business; (v)
earthquakes, hurricanes, tsunamis, tornadoes, floods, mudslides, wild fires
or other natural disasters, in the United States or any other country or
region in the world; (vi) changes in applicable Law or changes in GAAP after
the date hereof; (vii) the announcement of this Agreement or the pendency or
consummation of the transactions contemplated hereby; and (viii) any failure
by the Company to meet any internal budgets, plans or forecasts of its
revenues, earnings or other financial performance or results of
operations, in and of itself (but not, in each case, any facts, changes,
events, effects, occurrences or circumstances giving rise to or
contributing to such failure, unless such facts, changes, events, effects,
occurrences or circumstances would otherwise be excepted from
this definition).

  



  

" _Company Options_ " means all options to purchase Company Common Shares
(whether or not vested).

  



  

" _Company Optionholder_ " means any holder of Company Options.

  



  

" _Company Owned Intellectual Property_ " means all Intellectual Property
Rights that are owned by the Company.

  



  

" _Company Owned Registrations_ " means all Company Registrations that are
owned by the Company.

  



    

 | A-2| 
---|---|--- 

 



    



  

" _Company Preferred Shares_ " means the shares of Series A Preferred stock,
par value $0.00001 per share, of the Company.

  



  

" _Company Registrations_ " means Patent Rights, registered trademarks and
service marks, registered copyrights and designs, domain name registrations
and applications (including intent to use applications) for each of the
foregoing that are registered or filed or recorded with any Person in the
name of or exclusively licensed by the Company, alone or jointly with others.

  



  

" _Company Shares_ " means the Company Common Shares and the Company
Preferred Shares.

  



  

" _Company Stock Option Plan_ " means the Company's 2013 Equity Incentive
Plan.

  



  

" _Confidential Information_ " means any data or information concerning the
Company (including trade secrets), without regard to form, regarding (for
example and including) (a) business process models, (b) proprietary software,
(c) research, development, products, services, marketing, selling, business
plans, budgets, unpublished financial statements, licenses, prices, costs,
contracts, suppliers, customers, and customer lists, (d) the identity, skills
and compensation of employees, contractors, independent contractors and
consultants, (e) specialized training, or (f) discoveries, developments, trade
secrets, processes, formulas, data, lists, and all other works of authorship,
mask works, ideas, concepts, know-how, designs, and techniques, whether or not
any of the foregoing is or are patentable, copyrightable, or registrable
under any intellectual property Laws or industrial property Laws in the
United States or elsewhere. Notwithstanding the foregoing, no data or
information constitutes "Confidential Information" if such data or
information is publicly known and in the public domain through means that do
not involve a breach by the Company or a Stockholder of any covenant or
obligation set forth in the Agreement.

  



  

" _Confidentiality Agreements_ " means the Parent Confidentiality Agreement
and the Sorrento Confidentiality Agreement.

  



  

" _Contract_ " means any written, oral or other agreement, contract,
subcontract, lease, understanding, instrument, note, warranty, license,
sublicense, insurance policy, benefit plan or legally binding commitment of
any nature.

  



  

" _Disclosure Schedule_ " means the disclosure schedule (dated as of the date
of the Agreement) delivered to Parent on behalf of the Company on the date of
the Agreement.

  



  

" _EMA_ " means the European Medicines Agency or any successor thereto.

  



  

" _Employee_ " means each of the employees of the Company.

  



  

" _Entity_ " means any corporation (including any non-profit corporation),
general partnership, limited partnership, limited liability
partnership, joint venture, estate, trust, company (including any limited
liability company or joint stock company), firm or other
enterprise, association, organization or entity.

  



    

 | A-3| 
---|---|--- 

 



    



  

" _Environmental Law_ " means any national, provincial, territorial, federal,
state, local or foreign Law relating to pollution or protection of human
health or the environment (including ambient air, surface water, ground water,
land surface or subsurface strata), including any law, regulation, permit or
certificate of approval relating to emissions, discharges, releases or
threatened releases of Materials of Environmental Concern, or otherwise
relating to the manufacture, processing, distribution, use, treatment,
storage, disposal, transport or handling of Materials of Environmental
Concern.

  



  

" _Equityholders_ " means the Stockholders and Company Optionholders as of
immediately prior to the Effective Time.

  



  

" _ERISA_ " means the United States Employee Retirement Income Security Act
of 1974, as amended, and the rules and regulations promulgated thereunder.

  



  

" _Excluded Agreements_ " means (i) any non-exclusive Contract concerning
"off-the-shelf" or similar software that is available on commercially
reasonable terms for less than $10,000, (ii) standard non-disclosure,
confidentiality and material transfer Contracts granting non-exclusive
Intellectual Property Rights and entered into in the ordinary course of
business, (iii) Contracts that are not material to the business and that have
expired on their own terms or were terminated or can be cancelled in whole
(including with respect to any licenses, covenants, or other rights to
Intellectual Property Rights granted thereunder) by the Company without
penalty or with thirty (30) days' notice or less, (iv) Contracts that have
expired on their own terms or were terminated and wherein all licenses,
covenants, and other rights to Intellectual Property Rights granted thereunder
have expired or terminated, and (v) standard purchase orders and associated
terms and conditions entered into in the ordinary course of business for
which the underlying goods or services have been delivered or received.

  



  

" _FCPA_ " means the Foreign Corrupt Practices Act of 1977, as amended.

  



  

" _FDA_ " means the United States Food and Drug Administration or any
successor thereto.

  



  

" _FDA/EMA Registrations_ " means authorizations, approvals, licenses,
permits, certificates, or exemptions issued by the FDA or EMA (including,
without limitation, pre-market approval applications, pre-market
notifications, investigational new drug applications, new drug applications,
biologic license applications, manufacturing approvals and authorizations,
pricing and reimbursement approvals, labeling approvals or their foreign
equivalent) held by the Company that are required for, among other things, the
research, development, manufacture, processing, labeling, distribution,
marketing, storage, transportation, use, sale and provision of the products
and services of the Company.

  



  

" _GAAP_ " means United States generally accepted accounting principles as in
effect from time to time.

  



  

" _Government Bid_ " means any quotation, bid or proposal submitted to any
Governmental Body or any proposed prime contractor or higher-tier
subcontractor of any Governmental Body.

  



  

" _Government Contract_ " means any prime contract, subcontract, letter
contract, purchase order or delivery order executed or submitted to or on
behalf of any Governmental Body or any prime contractor or higher-tier
subcontractor, or under which any Governmental Body or any such prime
contractor or subcontractor otherwise has or may acquire any right or
interest.

  



    

 | A-4| 
---|---|--- 

 



    



  

" _Governmental Authorization_ " means any (a) approval, permit, license,
certificate, certificate of approval, franchise, permission, clearance,
registration, qualification or other authorization issued, granted, given or
otherwise made available by or under the authority of any Governmental Body
or pursuant to any Law, or (b) right under any Contract with any Governmental
Body.

  



  

" _Governmental Body_ " means any domestic or foreign multinational, federal,
state, provincial, municipal or local government (or any political
subdivision thereof) or any domestic or foreign governmental, regulatory or
administrative authority or any department, commission, board, agency, court,
tribunal, judicial body or instrumentality thereof, or any other body
exercising, or entitled to exercise, any administrative, executive, judicial,
legislative, police, regulatory or taxing authority or power of any
nature (including any arbitral body).

  



  

" _Indebtedness_ " means, without duplication, the aggregate of the
following: (a) all obligations for borrowed money, whether or not
contingent, or issued or incurred in substitution or exchange for any such
liability for borrowed money, or extensions of credit (including under credit
cards, bank overdrafts and advances), (b) all obligations evidenced by bonds,
debentures, notes or other similar instruments, (c) all obligations to pay
the deferred purchase price of property or services, except trade accounts
payable arising in the ordinary course of business consistent with past
practice, (d) all obligations of others secured by a Lien on any asset of the
Company (including accounts and contract rights), whether or not such
obligations are assumed, (e) all obligations, contingent or otherwise,
directly or indirectly guaranteeing any obligations of any other Person, all
obligations to reimburse the issuer in respect of letters of credit or under
performance or surety bonds, or other similar obligations; all obligations
under which the Company has agreed (contingently or otherwise) to purchase or
otherwise acquire the liability of any other Person or in respect of which
the Company has otherwise assured a creditor against loss, (f) all obligations
in respect of bankers' acceptances, note purchases or similar facilities and
under reverse repurchase agreements and (g) all obligations in respect of
futures contracts, other financial contracts and other similar obligations
(determined on a net basis as if such contract or obligation was being
terminated early on such date). For purposes of the Agreement, "
_Indebtedness_ " includes (i) any and all accrued interest, fees, change of
control payments, prepayment premiums, make whole premiums or penalties and
fees or expenses actually incurred (including attorneys' fees) associated with
the repayment of any Indebtedness, and (ii) any and all amounts of the nature
described in clauses (a) through (g) above owed by the Company to any of its
Affiliates, including any of the Stockholders; _provided, however_ , that "
_Indebtedness_ " shall not include, without limitation (i) Permitted Costs
set forth on Section 4.2 of the Disclosure Schedule, (ii) any operating or
lease obligations, and (iii) any installment payments.

  



  

" _Indemnification Pro Rata Share_ " with respect to any Equityholder, means
a fraction, rounded to four decimal places, equal to (x) the aggregate amount
of cash and the cash value of the Parent Shares (as determined based on the
Parent Stock Price) paid or payable to such Equityholder pursuant to Section
1.5(c), Section 1.5(d) and Section 1.12 (which, for the avoidance of doubt,
excludes any payments in respect of Dissenting Shares) _divided by_ (y) the
aggregate amount of cash and the cash value of the Parent Shares (as
determined based on the Parent Stock Price) paid or payable to all
Equityholders pursuant to Section 1.5(c), Section 1.5(d) and Section 1.12
(which, for the avoidance of doubt, excludes any payments in respect of
Dissenting Shares).

  



    

 | A-5| 
---|---|--- 

 



    



  

" _Intellectual Property Rights_ " means all (a) foreign and domestic
patents, patent applications, patent disclosures and inventions, (b) Internet
domain names, trademarks, service marks, trade dress, trade names, logos and
corporate or company names (both foreign and domestic) and registrations and
applications for registration thereof together with all of the goodwill
associated therewith, (c) copyrights (registered or unregistered) and
copyrightable works (both foreign and domestic) and registrations and
applications for registration thereof, (d) mask works and registrations and
applications for registration thereof, (e) computer software, data, data
bases and documentation thereof, including rights to third party software used
in the business, (f) trade secrets and other Confidential Information
(including ideas, formulas, compositions, inventions (whether patentable or
unpatentable and whether or not reduced to practice), know-how, manufacturing
and production processes and techniques, research and development
information, drawings, specifications, designs, plans, proposals, technical
data, copyrightable works, financial and marketing plans and customer and
supplier lists and information), (g) other intellectual property rights, and
(h) copies and tangible embodiments thereof (in whatever form or medium).

  



  

" _Knowledge_ " An individual shall be deemed to have "Knowledge" of a
particular fact or other matter if such individual is actually aware of such
fact or other matter after due inquiry and investigation of the matter. The
Company shall be deemed to have "Knowledge" of a particular fact or other
matter if any of the Specified Individuals has Knowledge of such fact or other
matter. With respect to matters involving Intellectual Property Rights,
Knowledge does not require the Company, or any of the Specified
Individuals, to have conducted or have obtained any freedom-to-operate
opinions of counsel or any patent, trademark or other Intellectual
Property Rights clearance searches.

  



  

" _Labor Laws_ " means all Laws governing or concerning labor relations,
unions and collective bargaining, conditions of employment, termination of
employment, employee classification, background checks, employment
discrimination and harassment, wages, hours, meal and rest periods, accrual
and payment of vacation pay and paid time off, or occupational safety and
health and the payment and withholding of Taxes and other sums as required by
the appropriate Governmental Body.

  



  

" _Law_ " means any federal, national, state, provincial, territorial, local,
municipal, foreign or international, multinational law,
statute, constitution, principle of common law, resolution, ordinance, code,
edict, decree, rule, regulation, ruling or other legal requirement issued,
enacted, adopted, promulgated, implemented or otherwise put into effect by or
under the authority of any Governmental Body.

  



  

" _Leased Real Property_ " means the parcels of real property of which the
Company is the lessee or sublessee (together with all fixtures and
improvements thereon).

  



    

 | A-6| 
---|---|--- 

 



    



  

" _Legal Proceeding_ " means any ongoing action, suit, litigation,
arbitration, proceeding (including any civil, criminal,
administrative, investigative or appellate proceeding), hearing, order,
inquiry, audit, examination or investigation commenced, brought, conducted or
heard before, or otherwise involving, any court or other Governmental Body or
any arbitrator or arbitration panel.

  



  

" _Lien_ " means any lien, pledge, hypothecation, charge, mortgage, security
interest, encumbrance, claim, infringement, interference, option, right of
first refusal, preemptive right, community property interest or restriction of
any nature affecting property, real or personal, tangible or intangible,
including any restriction on the voting of any security, any restriction on
the transfer of any security or other asset, any restriction on the receipt
of any income derived from any asset, any restriction on the use of
any asset, any restriction on the possession, exercise or transfer of any
other attribute of ownership of any asset, any lease in the nature thereof
and any filing of or agreement to give any financing statement under the
Uniform Commercial Code (or equivalent statute of any jurisdiction).

  



  

" _Materials of Environmental Concern_ " means any chemicals, pollutants,
contaminants, wastes, toxic substances, petroleum, petroleum products,
petroleum by-products, asbestos-containing material, lead-containing paint,
pipes or plumbing, polychlorinated biphenyls, radioactive materials or radon,
infectious, biological or medical waste, including biohazards, radioactive
materials and blood-borne pathogens and any other substances that are now or
hereafter: (a) listed, classified, regulated or fall within the definition
of a "hazardous substance," "hazardous waste" or "hazardous material"
pursuant to any Environmental Law or (b) the subject of regulatory action by
any Governmental Body pursuant to any Environmental Law.

  



  

" _Merger Consideration_ " means the Initial Cash Amount and Aggregate
Available Parent Shares together with the Milestone Payments that become
payable to the Equityholders, if at all, following the Effective Time pursuant
to and in accordance with Section 1.13(a).

  



  

" _Milestone Obligor_ " means any Person (including any Sublicensee) that
acquires, directly or indirectly, from Parent or an Affiliate of Parent (or
from another Milestone Obligor) any rights to develop, seek Marketing Approval
for and/or commercialize a Company Product, through one or more transactions
or series of transactions, whether by sale, assignment, license or any other
direct grant or transfer of rights, but excluding, for the avoidance of
doubt, acquisitions resulting from sales of units of any Company Product in
the ordinary course of business.

  



  

" _Negative FDA Letter_ " means any FDA Form 483, notice of adverse filing,
warning letter, untitled letter or other correspondence or notice from the
FDA or any other Governmental Body, alleging or asserting noncompliance with
the Federal Food, Drug and Cosmetic Act (21 U.S.C.  301 et seq.).

  



  

" _NLRB_ " means the United States National Labor Relations Board.

  



  

" _Order_ " means any order, judgment, writ, decree, stipulation,
determination, decision, award, ruling, injunction, restraining order,
settlement or similar assessment of a Governmental Body (whether temporary,
preliminary or permanent).

  



    

 | A-7| 
---|---|--- 

 



    



  

" _Organizational Documents_ " means, with respect to any Entity, the
constitution, certificate of incorporation, articles of incorporation, by-
laws, articles of organization, articles of association, partnership
agreement, limited liability company agreement, trust deed, formation
agreement, joint venture agreement or other similar organizational documents
of such Entity (in each case, as amended through the date of the Agreement).

  



  

" _Parent Confidentiality Agreement_ " means that certain Mutual
Confidentiality Agreement, dated October 19, 2016, by and between the Company
and Parent.

  



  

" _Parent Related Agreement_ " means any certificate, agreement, document or
other instrument, other than the Agreement, to be executed and delivered by
Parent or Merger Sub in connection with the transactions contemplated by the
Agreement.

  



  

" _Parent Shares_ " means the shares of common stock of Parent, par value of
$0.0001 per share.

  



  

" _Parent Stock Price_ " means $1.16.

  



  

" _Patent Rights_ " means all patents, patent applications, utility models,
design registrations and certificates of invention and other governmental
grants for the protection of inventions or industrial designs (including all
related continuations, continuations-in-part, divisionals, reissues and
reexaminations).

  



  

" _Permitted Lien_ " means any (a) Lien for Taxes not yet due and payable or
which are being contested in good faith and for which adequate accruals or
reserves have been established in accordance with GAAP as historically applied
by the Company (excluding Liens arising under ERISA or the Code), (b) Liens
of carriers, warehousemen, mechanics, materialmen and repairmen incurred in
the ordinary course of business consistent with past practice and not yet
delinquent or that are being contested in good faith and by
appropriate proceedings and for which adequate accruals or reserves have been
established in accordance with GAAP as historically applied by the Company,
(c) in the case of real property, zoning, building, occupancy or other
restrictions, variances, covenants, rights of way, encumbrances, easements
and other minor irregularities in title, none of which, individually or in the
aggregate, (i) interfere in any material respect with the present use of or
occupancy of the affected parcel by the Company, (ii) have more than an
immaterial effect on the value thereof or its use, or (iii) would impair the
ability of such parcel to be sold for its present use; (d) Liens imposed by
applicable Law (excluding Liens arising under ERISA or the Code) involving
amounts that are not yet delinquent or that are being contested in good faith
and by appropriate proceedings and for which adequate accruals or reserves
have been established in accordance with GAAP as historically applied by the
Company; (e) pledges or deposits to secure obligations under
workers' compensation Laws or similar legislation or to secure public or
statutory obligations; (f) pledges and deposits to secure the performance of
bids, trade contracts, leases, surety and appeal bonds, performance bonds and
other obligations of a similar nature, in each case in the ordinary course of
business consistent with past practice; or (g) non-exclusive licenses of
Intellectual Property Rights granted in the ordinary course of business
consistent with past practice.

  



  

" _Person_ " means any individual, Entity, trust, Governmental Body or other
organization.

  



    

 | A-8| 
---|---|--- 

 



    



  

" _Personal Information_ " means any information that identifies or that, in
combination with other information, can be used to identify or locate a
natural person, including without limitation name, street address, telephone
number, e-mail address, photograph, social security number, driver's license
number, passport number or customer or account number, IP address, and any
persistent identifier or any other information that is otherwise considered
personal information, personal data, protected health information, or other
personally identifiable information under applicable Privacy Laws.

  



  

" _Pre-Closing Taxes_ " means (i) all Taxes imposed on or incurred by the
Company with respect to any Pre-Closing Tax Period or the portion of any
Straddle Tax Period that relates to the portion of such Straddle Tax Period
ending on and including the Closing Date as determined in accordance with
Section 4.1(h), (ii) Taxes of any member of an affiliated, consolidated,
combined or unitary group of which the Company was a member prior to the
Closing, including pursuant to Treasury Regulation Section 1.1502-6 (or
similar provision of state, local or foreign law), or (iii) Taxes of any
Person (other than the Company) imposed on the Company as a transferee or
successor, by contract or pursuant to any law, rule or regulation, which Taxes
relate to an event or transaction occurring prior to the Closing Date, in
each case whether or not disclosed to Parent in any Exhibits or Schedules
attached to this Agreement, the Company Financial Statements or otherwise.

  



  

" _Privacy Laws_ " means any national, provincial, territorial, state, local
or foreign Law and self-regulatory programs now in force governing the
Processing of Personal Information, including without limitation, the Health
Insurance Portability and Accountability Act of 1996, as amended, the Health
Information Technology for Economic and Clinical Health Act, state data breach
notification Laws, state social security number protection Laws, the Federal
Trade Commission Act, the Financial Services Modernization Act of 1999, the
Fair Credit Reporting Act, the Fair and Accurate Credit Transactions Act, the
EU General Data Protection Regulation, and state consumer protection and data
security Laws.

  



  

" _Process_ " or " _Processing_ " means the collection, use, storage,
recording, distribution, processing, transfer, import, export, protection
(including security measures), disposal, destruction, disclosure or other
activity regarding data (whether electronically or in any other form or
medium).

  



  

" _Related Party_ " means (a) each individual who is, or who has at any time
been, an officer or director of the Company; (b) each member of the immediate
family of each of the individuals referred to in clause (a) above; and (c) any
trust or other Entity (other than the Company) in which any one of the
individuals referred to in clauses (a) and (b) above holds (or in which more
than one of such individuals collectively hold), beneficially or otherwise, a
material voting, proprietary, equity or other financial interest.

  



  

" _Release_ " or " _Released_ " means with respect to any Materials of
Environmental Concern, any spilling, leaking, pumping, pouring, emitting,
emptying, discharging, injecting, escaping, leaching, migrating, dumping or
disposing into any surface or ground water, drinking water supply, soil,
surface or subsurface strata or medium or the ambient air. For purposes of the
Agreement, the term "Release" shall also mean any threatened release.

  



    

 | A-9| 
---|---|--- 

 



    



  

" _Representatives_ " means, with respect to a Person, the officers,
directors, employees, agents, attorneys, accountants, advisors and
representatives of such Person.

  



  

" _Securities Act_ " means the Securities Act of 1933, as amended, and the
rules and regulations promulgated thereunder.

  



  

" _Significant Pharmaceutical Company_ " means any company whose market
capitalization of equity securities at the time of any transfer contemplated
by Section 1.13(h) is an amount equal to at least $2,000,000,000.

  



  

" _Sorrento Confidentiality Agreement_ " means that certain Mutual
Confidentiality Agreement, dated June 8, 2015, by and between the Company and
Sorrento.

  



  

" _Specified Individuals_ " means the individuals named on Schedule A.

  



  

" _Specified IP Matters_ " means the indemnification obligations under
Section 8.1(a) with respect to the Specified IP Representations.

  



  

" _Specified IP Representations_ " means the representations and warranties
of the Company set forth in (i) the first two sentences of Section 2.11(a),
(ii) the last sentence of Section 2.11(a), (iii) the first sentence of Section
2.11(c), (iv) Section 2.11(j) and (v) Section 2.11(k).

  



  

" _Stockholders_ " means the holders of Company Shares.

  



  

" _Stockholder Related Agreement_ " means any certificate, agreement,
document or other instrument, other than the Agreement, to be executed and
delivered by the Company or a Stockholder in connection with the transactions
contemplated the Agreement, including without limitation the Non-Competition
Agreements and Joinder Agreements.

  



  

" _Subsidiary_ " means, with respect to any party, any corporation,
partnership, trust, limited liability company or other non-corporate
business enterprise in which such party (or another Subsidiary of such party)
holds stock or other ownership interests representing (a) 25% or more of the
voting power of all outstanding stock or ownership interests of such Entity,
or (b) the right to receive 25% or more of the net assets of such Entity
available for distribution to the holders of outstanding stock or ownership
interests upon a liquidation or dissolution of such Entity.

  



  

" _Supplier_ " means any supplier of goods or services to which the Company
paid more than $25,000 in the aggregate during the 6-month period ended
December 31, 2018, or expects to pay more than $50,000 in the aggregate during
the 12-month period ending June 30, 2019.

  



  

" _Tax Returns_ " means any and all reports, returns, or declarations
relating to Taxes filed or required to be filed with any Governmental
Body, including any schedule or attachment thereto, including any amendment
thereof.

  



    

 | A-10| 
---|---|--- 

 



    



  

" _Taxes_ " means (i) any and all taxes, charges, fees, levies or other
similar assessments or liabilities in the nature of a tax, including income,
gross receipts, ad valorem, premium, value-added, net worth, capital stock,
capital gains, documentary, recapture, alternative or add-on minimum,
disability, estimated, registration, recording, excise, escheat, real
property, personal property, sales, use, license, lease, service, service
use, transfer, withholding, employment, unemployment, insurance, employment
insurance, social security, business license, business organization,
environmental, worker's compensation, pension, payroll, profits,
severance, stamp, occupation, windfall profits, customs, franchise and other
taxes of any kind whatsoever imposed by the United States, or any state,
provincial, local or foreign government, or any agency or political
subdivision thereof, (ii) any interest, penalties or additions to tax imposed
with respect to such items or any contest or dispute thereof or in connection
with the failure to timely or properly file any Tax Return; (iii) any
liability for payment of amounts described in clause (i) or (ii) whether as a
result of successor or transferee liability, of being a member of an
affiliated, consolidated, combined or unitary group for any period or
otherwise through operation of law; and (iv) any liability for the payment of
amounts described in clauses (i), (ii) or (iii) as a result of any tax
sharing, tax indemnity or tax allocation agreement or any other express or
implied agreement to indemnify any other Person.

  



  

" _Transaction Expenses_ " means the sum of all fees, costs and expenses
(including legal fees and accounting fees and including the amount of all
special or other bonuses payable by the Company to any officers of the Company
or other Persons in connection with the consummation of the transactions
contemplated by the Agreement), other than the Financial Statement Costs, in
each case, that are incurred by the Company for the benefit of the Company or
an Equityholder in connection with the transactions contemplated by the
Agreement based on arrangements entered into, or agreed to, by the Company
prior to the Closing.

  



  

" _Treasury Regulations_ " means the temporary and final income Tax
regulations promulgated under the Code.

  



  

" _UK Bribery Act_ " means the United Kingdom Bribery Act 2010.

  



    

 | A-11| 
---|---|--- 

    



          '

